Cancer evidence library
Lung Cancer
PubMed-indexed evidence for non-small-cell and small-cell lung cancer, including treatment and emerging research.
PubMed only
Research ranked
Conflicts shown
Data downloadable
Living evidence synopsis
What the current PubMed collection shows.
Alexandria currently organizes 827 non-retracted PubMed-indexed records for Lung Cancer. The structured collection includes 13 guideline or consensus records, 110 evidence syntheses/systematic reviews/meta-analyses, and 95 randomized or phase III studies. 310 records were identified by the configured last-24-month search. Conflict-of-interest statements are available in the PubMed record for 646 of 827 included records.
Evidence data
Research landscape
Charts are generated from Alexandria’s structured PubMed records, not copied from journal figures.
Publication activity
Latest 12 represented yearsRecords by publication year
2
2014
3
2016
1
2017
7
2019
3
2020
5
2021
8
2022
6
2023
25
2024
45
2025
717
2026
3
2027
Evidence composition
Study designs
Transparency
Conflict-of-interest reporting
Absence of a conflict-of-interest statement in PubMed does not establish that no conflict existed.
Abstract result signals
Extracted result direction
Reported outcomes
Numerical results extracted from PubMed abstracts
Each value remains attached to its original PMID. Alexandria does not pool these results or imply that unlike populations and endpoints are directly comparable.
Non-pooled ratio measures
Reference = 1.0
Hazard, risk, and odds ratios reported in abstracts
0.250.51.02.04.0
View extracted numerical results 60
| Publication | Outcome | Measure | Reported value | Source |
|---|---|---|---|---|
| Increasing hydrophobicity in poly(amino acid) adjuvants elicits potent and durable anti-tumor immunity via coordinated cellular and humoral responses.Bioactive materials · 2027 | not_reported | Odds Ratio | 15.0 | PMID 42662463 |
| First-line serplulimab plus chemotherapy with or without HLX04 versus chemotherapy in locally advanced or metastatic non-squamous non-small-cell lung cancer (ASTRUM-002): a randomised, double-blind, multicentre phase 3 trial.The Lancet. Respiratory medicine · 2026 | progression-free survival | Hazard Ratio | 0.0 | PMID 41354044 |
| Clinical outcomes with perioperative nivolumab by nodal status in patients with stage III resectable NSCLC: phase 3 CheckMate 77T exploratory analysis.Nature cancer · 2026 | event-free survival | Percentage Comparison | 70.0percent vs 45.0percent | PMID 41507539 |
| Clinical outcomes with perioperative nivolumab by nodal status in patients with stage III resectable NSCLC: phase 3 CheckMate 77T exploratory analysis.Nature cancer · 2026 | event-free survival | Percentage Comparison | 22.0percent vs 5.6percent | PMID 41507539 |
| Clinical outcomes with perioperative nivolumab by nodal status in patients with stage III resectable NSCLC: phase 3 CheckMate 77T exploratory analysis.Nature cancer · 2026 | event-free survival | Percentage Comparison | 77.0percent vs 73.0percent | PMID 41507539 |
| Clinical outcomes with perioperative nivolumab by nodal status in patients with stage III resectable NSCLC: phase 3 CheckMate 77T exploratory analysis.Nature cancer · 2026 | event-free survival | Percentage Comparison | 84.0percent vs 74.0percent | PMID 41507539 |
| Clinical outcomes with perioperative nivolumab by nodal status in patients with stage III resectable NSCLC: phase 3 CheckMate 77T exploratory analysis.Nature cancer · 2026 | event-free survival | Percentage Comparison | 71.0percent vs 46.0percent | PMID 41507539 |
| Clinical outcomes with perioperative nivolumab by nodal status in patients with stage III resectable NSCLC: phase 3 CheckMate 77T exploratory analysis.Nature cancer · 2026 | event-free survival | Percentage Comparison | 29.0percent vs 2.7percent | PMID 41507539 |
| Clinical outcomes with perioperative nivolumab by nodal status in patients with stage III resectable NSCLC: phase 3 CheckMate 77T exploratory analysis.Nature cancer · 2026 | not_reported | Percentage Comparison | 57.0percent vs 44.0percent | PMID 41507539 |
| Clinical outcomes with perioperative nivolumab by nodal status in patients with stage III resectable NSCLC: phase 3 CheckMate 77T exploratory analysis.Nature cancer · 2026 | not_reported | Percentage Comparison | 74.0percent vs 62.0percent | PMID 41507539 |
| Endobronchial ultrasound-guided mediastinal biopsies for the diagnosis of mediastinal diseases: A network meta-analysis.Pulmonology · 2026 | not_reported | Odds Ratio | 4.01 | PMID 41560513 |
| Endobronchial ultrasound-guided mediastinal biopsies for the diagnosis of mediastinal diseases: A network meta-analysis.Pulmonology · 2026 | not_reported | Odds Ratio | 2.75 | PMID 41560513 |
| Endobronchial ultrasound-guided mediastinal biopsies for the diagnosis of mediastinal diseases: A network meta-analysis.Pulmonology · 2026 | not_reported | Odds Ratio | 1.8 | PMID 41560513 |
| Endobronchial ultrasound-guided mediastinal biopsies for the diagnosis of mediastinal diseases: A network meta-analysis.Pulmonology · 2026 | not_reported | Odds Ratio | 1.81 | PMID 41560513 |
| Persistent homology analysis of longitudinal computed tomography fibrotic features in COPD.The European respiratory journal · 2026 | mortality | Hazard Ratio | 1.94 | PMID 41748284 |
| Persistent homology analysis of longitudinal computed tomography fibrotic features in COPD.The European respiratory journal · 2026 | mortality | Hazard Ratio | 1.86 | PMID 41748284 |
| Datopotamab Deruxtecan Plus Pembrolizumab With or Without Platinum-Based Chemotherapy for Advanced or Metastatic NSCLC: The Phase Ib TROPION-Lung02 Trial.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2026 | not_reported | Odds Ratio | 6.0 | PMID 41871716 |
| ESTRO-EORTC expert guideline on target delineation and radiotherapy details for stage I-III small cell lung cancer.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2026 | not_reported | Odds Ratio | 66.0 | PMID 41932500 |
| Extrapleural Saline Hydrodissection Before CT-Guided Lung Biopsy to Reduce Pneumothorax: A Prospective Comparative Study in Pleura-Adjacent Lesions.Academic radiology · 2026 | not_reported | Odds Ratio | 4.68 95% CI 1.24–17.65 p = 0.023 | PMID 42070962 |
| Expanded detection of early fibrotic phenotypes using lobar traction bronchiolectasis in lung cancer screening.American journal of respiratory and critical care medicine · 2026 | not_reported | Odds Ratio | 1.1 95% CI 1.0–1.1 P = .02 | PMID 42085205 |
| Final overall survival analysis of the APPLE study: atezolizumab and platinum-pemetrexed with or without bevacizumab for metastatic nonsquamous non-small cell lung cancer.Lung cancer (Amsterdam, Netherlands) · 2026 | not_reported | Hazard Ratio | 0.96 | PMID 42127535 |
| Final overall survival analysis of the APPLE study: atezolizumab and platinum-pemetrexed with or without bevacizumab for metastatic nonsquamous non-small cell lung cancer.Lung cancer (Amsterdam, Netherlands) · 2026 | not_reported | Hazard Ratio | 0.71 | PMID 42127535 |
| Real-life management and outcomes of octogenarians with non-small-cell lung cancer: A 10-year evolution.European journal of cancer (Oxford, England : 1990) · 2026 | not_reported | Percentage Comparison | 26.0percent vs 46.4percent | PMID 42235466 |
| Real-life management and outcomes of octogenarians with non-small-cell lung cancer: A 10-year evolution.European journal of cancer (Oxford, England : 1990) · 2026 | not_reported | Percentage Comparison | 10.6percent vs 19.1percent | PMID 42235466 |
| Impact of Smoking Cessation Duration on Postoperative Complications in Lung Cancer Surgery.The Journal of surgical research · 2026 | not_reported | Odds Ratio | 0.42 95% CI 0.17–0.99 | PMID 42241832 |
| Efficacy of alectinib for ALK-positive NSCLC according to tumor burden and body mass index: A pooled analysis of the randomized phase III trials ALEX and J-ALEX.European journal of cancer (Oxford, England : 1990) · 2026 | not_reported | Hazard Ratio | 0.41 95% CI 0.31–0.55 p < 0.001 | PMID 42269244 |
| Efficacy of alectinib for ALK-positive NSCLC according to tumor burden and body mass index: A pooled analysis of the randomized phase III trials ALEX and J-ALEX.European journal of cancer (Oxford, England : 1990) · 2026 | not_reported | Hazard Ratio | 0.8 95% CI 0.5–1.28 p < 0.001 | PMID 42269244 |
| Efficacy of alectinib for ALK-positive NSCLC according to tumor burden and body mass index: A pooled analysis of the randomized phase III trials ALEX and J-ALEX.European journal of cancer (Oxford, England : 1990) · 2026 | not_reported | Hazard Ratio | 1.88 95% CI 1.44–2.45 p < 0.001 | PMID 42269244 |
| Efficacy of alectinib for ALK-positive NSCLC according to tumor burden and body mass index: A pooled analysis of the randomized phase III trials ALEX and J-ALEX.European journal of cancer (Oxford, England : 1990) · 2026 | not_reported | Hazard Ratio | 2.24 95% CI 1.4–3.58 p < 0.001 | PMID 42269244 |
| Efficacy of alectinib for ALK-positive NSCLC according to tumor burden and body mass index: A pooled analysis of the randomized phase III trials ALEX and J-ALEX.European journal of cancer (Oxford, England : 1990) · 2026 | not_reported | Hazard Ratio | 1.66 95% CI 1.26–2.2 p < 0.001 | PMID 42269244 |
| Efficacy of alectinib for ALK-positive NSCLC according to tumor burden and body mass index: A pooled analysis of the randomized phase III trials ALEX and J-ALEX.European journal of cancer (Oxford, England : 1990) · 2026 | not_reported | Hazard Ratio | 0.25 95% CI 0.16–0.41 p < 0.001 | PMID 42269244 |
| Efficacy of alectinib for ALK-positive NSCLC according to tumor burden and body mass index: A pooled analysis of the randomized phase III trials ALEX and J-ALEX.European journal of cancer (Oxford, England : 1990) · 2026 | not_reported | Hazard Ratio | 0.52 95% CI 0.36–0.76 p < 0.001 | PMID 42269244 |
| Efficacy of alectinib for ALK-positive NSCLC according to tumor burden and body mass index: A pooled analysis of the randomized phase III trials ALEX and J-ALEX.European journal of cancer (Oxford, England : 1990) · 2026 | not_reported | Hazard Ratio | 0.92 95% CI 0.68–1.25 p = 0.375 | PMID 42269244 |
| Efficacy of alectinib for ALK-positive NSCLC according to tumor burden and body mass index: A pooled analysis of the randomized phase III trials ALEX and J-ALEX.European journal of cancer (Oxford, England : 1990) · 2026 | not_reported | Hazard Ratio | 0.5 95% CI 0.29–0.88 p = 0.375 | PMID 42269244 |
| Association of inflammation-related composite indices with lung cancer risk in US adults and all-cause mortality among lung cancer patients: evidence from the 1999-2018 NHANES.Annals of human biology · 2026 | mortality | Odds Ratio | 1.5 | PMID 42446284 |
| Association of inflammation-related composite indices with lung cancer risk in US adults and all-cause mortality among lung cancer patients: evidence from the 1999-2018 NHANES.Annals of human biology · 2026 | not_reported | Hazard Ratio | 1.4 | PMID 42446284 |
| Association of inflammation-related composite indices with lung cancer risk in US adults and all-cause mortality among lung cancer patients: evidence from the 1999-2018 NHANES.Annals of human biology · 2026 | mortality | Hazard Ratio | 0.53 | PMID 42446284 |
| Association of inflammation-related composite indices with lung cancer risk in US adults and all-cause mortality among lung cancer patients: evidence from the 1999-2018 NHANES.Annals of human biology · 2026 | mortality | Odds Ratio | 0.58 | PMID 42446284 |
| Prognosis of Patients with Lung Cancer Admitted to the Intensive Care Unit: A Systematic Review and Meta-Analysis.Journal of intensive care medicine · 2026 | mortality | Risk Ratio | 1.3 95% CI 1.06–1.59 | PMID 40370214 |
| Prognosis of Patients with Lung Cancer Admitted to the Intensive Care Unit: A Systematic Review and Meta-Analysis.Journal of intensive care medicine · 2026 | mortality | Risk Ratio | 1.33 95% CI 1.12–1.57 | PMID 40370214 |
Research transparency
Funding and conflicts of interest
Conflict and funding fields reproduce what is available in PubMed records. Missing disclosure data does not establish that no conflict or funding existed.
NCI NIH HHS128
National Natural Science Foundation of China24
NHLBI NIH HHS19
NIH HHS12
U.S. Department of Health & Human Services | National Institutes of Health (NIH)10
National Natural Science Foundation of China (NSFC)9
National Cancer Institute (NCI)9
NIGMS NIH HHS8
View records with declared financial or industry relationships 12
Pharmacological, psychosocial, and brain stimulation interventions in oncologic populations with mental disorders: An umbrella review.
Declaration of competing interest MS has received honoraria/has been a consultant for AbbVie, Angelini, Bausch Health, Boehringer Ingelheim, Pharmascience, Lundbeck, Otsuka, Teva. MS holds shares of MESAS, S2M. Other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
PMID 42184575 · 2026Development of a clinical prediction model using digital device data for interstitial lung disease in patients with unresectable stage III non-small cell lung cancer treated with durvalumab.
Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Satoshi Ikeda has received grants or contracts for his institution from AstraZeneca K.K. and Chugai Pharmaceutical Co., Ltd., and personal fees from AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., and Bristol-Myers Squibb K.K. in the past 36 months. Hirotsugu Kenmotsu has received grants or contracts for his institution from AstraZeneca K.K., Eli Lilly Japan K.K., Novartis Pharma K.K., Ono Pharmaceutical Co., Ltd., and LOXO Oncology in the past 36 months. Hiroshi Kitagawa, Chikako Iwao, Yoshinori Sato, Mizue Ogi, Ryo Koto, and Takehiro Hirai own stocks and stock options of AstraZeneca in the past 36 months. Nobuyuki Yamamoto has received support to his institution for the present manuscript from Chugai Pharmaceutical Co., Ltd. and Daiichi Sankyo Co., Ltd. since the initial planning of the work; grants or contracts for his institution from AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd., MSD K.K., Nippon Boehringer Ingelheim Co., Ltd., Eli Lilly Japan K.K., Mebix, Inc., and IQVIA Solutions Japan K.K.; and personal fees from AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., MSD K.K., Daiichi Sankyo Co., Ltd., Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Amgen K.K., Novartis Pharma K.K., and Merck Biopharma Co., Ltd. in the past 36 months..
PMID 42235163 · 2026De Novo Cancer in Liver Transplant Patients With HIV Infection: A Multicenter Nationwide Cohort Study.
Potential conflicts of interest . J. M. M. has received consulting honoraria and/or research grants from Angelini, Basilea, Bristol-Myers Squibb, Genentech, Gilead Sciences, Jansen, Merck, Pfizer, Novartis, and ViiV Healthcare, outside the submitted work. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
PMID 41989878 · 2026Persistent homology analysis of longitudinal computed tomography fibrotic features in COPD.
Conflict of interest: N. Tanabe reports grants from FUJIFILM Co., Ltd and Daiichi Sankyo Company, Ltd, and payment or honoraria for lectures, presentations, manuscript writing or educational events from Sanofi, GSK and AstraZeneca. T. Oguma reports payment or honoraria for lectures, presentations, manuscript writing or educational events from GSK, AstraZeneca, Boehringer Ingelheim, Kyowa Kirin and Tanabe Mitsubishi. T. Handa reports grants from FUJIFILM Co., Ltd, and is in the employment of the Collaborative Research Laboratory, funded by Teijin Pharma Co., Ltd. S. Sato reports grants from FUJIFILM Co., Ltd, Nippon Boehringer Ingelheim, Philips Japan, Fukuda Denshi, Fukuda Lifetec Keiji and ResMed. T. Hiari reports grants from FUJIFILM Co., Ltd and Daiichi Sankyo Company, Ltd. The remaining authors have no potential conflicts of interest to declare.
PMID 41748284 · 2026A mixed inflammatory peripheral signature defines clinical outcomes in a phase II trial combining pembrolizumab with paclitaxel and carboplatin in melanoma.
In accordance with Taylor & Francis policy and ethical obligation of researchers, WM is reporting having received research funding and honoraria from BMS, Novartis, GSK, Roche, AstraZeneca, MethylGene, MedImmune, Bayer, Amgen, Merck, Incyte, Sanofi, Array, Ocellaris Pharma, Astellas, Alkermes, Exelixis, VelosBio, Genentech, Seagen, Zymeworks and consulting fees for Mylan, EMD Serono, Sanofi. CLe has received honoraria for advisory boards from Ipsen, BMS, Regeneron, Sanofi, Novartis, Pfizer, and Astra-Zeneca. RJ Honoraria from Pfizer, BMS GmbH & Co. KG, Merck KGaA, Novartis and consulting Role to BMS, Medison pharma, Pfizer, Merck KGaA and Novartis. JFC is reporting having received funding, honoraria from Merck, Astra-Zeneca, Novartis. RL is reporting having received funding, honoraria and research contract from BMS, Pfizer, Merck, PREVENT/Folia Biotech and Fondation Famille Diane et Léon Gosselin. RL and JFC are founders and CSO/CMO, respectively, of Cell-Immune Pharma, Inc. Other authors did not report any potential conflict of interest.
PMID 41732954 · 2026Cost-effectiveness analysis of tepotinib vs capmatinib as subsequent therapy in MET exon 14-mutated non-small-cell lung cancer.
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
PMID 41934258 · 2026Multi-omics analysis identified SPRR2D as a potential biomarker for tumor prognosis and immune microenvironment infiltration: a pan-cancer perspective.
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
PMID 41933926 · 2026Steroid receptor coactivator 3-deficient regulatory T cells eradicate multiple solid tumors in syngeneic mouse models.
Drs Han, Lonard, and Dacso are founding members of a new non-public company, called CoRegen, Inc. Laboratory research support exists for Drs Han, Lonard, and Dacso from CoRegen. Dr Gilad is a paid consultant by and disclose an equity position in CoRegen, Inc.
PMID 41772940 · 2026Clinical characteristics of ALK-positive NSCLC patients treated with sequential ALK-TKI therapies in a single-centre.
Yuki Yamamoto is the Chief Executive Officer of HiLung. The other authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
PMID 42505144 · 2026The NTP chronic inhalation study does not support an inherent lung cancer hazard of talc: Implications of lung particle overload and maximum tolerated dose.
Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:Kevin E. Driscoll reports financial support was provided by Eurotalc IMA-Europe aisbl 26, Rue des Deux Eglises B-1000 Brussels, Belgium and reports a prior consulting relationship with The International Carbon Black Association, Poydras St. New Orleans, LA.Jeffery I Everitt reports financial support was provided by Eurotalc, IMA-Europe aisbl 26, Rue des Deux Eglises B-1000 Brussels, Belgium.Paul J.A. Borm reports financial support was provided by Nanoconsult. Paul J.A. Borm also reports a relationship with Eurotalc that includes: consulting or advisory; a relationship with Imerys SA that includes: consulting or advisory; a relationship with IMA Europe that includes: consulting or advisory; a relationship with Cosentino Research and Development SL that includes: consulting or advisory; a relationship with Nano4Imaging GmbH that includes: consulting or advisory, equity or stocks, and travel reimbursement.
PMID 42373004 · 2026Assessing the Impact on Health and Productivity Outcomes of Anti-PD-(L)1 Agents to Treat Early-Stage Cancers in Italy.
Declarations. Conflict of Interest: Andrea Marcellusi has received honoraria as a speaker and adviser for MSD, Astra Zeneca, Eli Lilly and other pharma companies. He is an Editorial Board member of Clinical Drug Investigation, but was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Fabio Calabrò has received honoraria as speaker for MSD, Astra Zeneca, Pfizer, Novartis, Bayer, Ipsen, Johnson and Johnson, Recordati and Astellas. Anna Maria Di Giacomo has served as an advisor or board member for MSD, Bristol Myers Squibb, Incyte, Pierre Fabre, Sanofi, GSK, Novartis, SunPharma and Immunocore. She has also received honoraria for MSD, Roche, Bristol Myers Squibb, Sanofi, Pierre Fabre, GSP and Vyvamed. Fabio Puglisi has received honoraria for advisory boards, activities as a speaker, travel grants and research grants from Amgen, Astra Zeneca, Bayer, Daiichi Sankyo, Celgene, Eisai, Eli Lilly, Exact Sciences, Gilead, Ipsen, Italfarmaco, Menarini, MSD, Novartis, Pierre Fabre, Pfizer, Roche, Seagen, Takeda and Viatris. He has also received research funding from Astra Zeneca, Eisai and Roche. Alessio Cortellini received grants for consultancies/advisory boards: MSD, OncoC4, Roche, Regeneron, Bristol Myers Squibb, Amgen, Daiichi Sankyo, Astra Zeneca, Access Infinity, Ardelis Health, Alpha Sight, Capvision, Techspert, Alira Health, Atheneum, Lightening Health. He also received speaker fees from Astra Zeneca, Roche, Pierre-Fabre, MSD, Sanofi/Regeneron and Yuhan corporation, compensation for writing/editorial activity from Bristol Myers Squibb, MSD and travel support from Sanofi, MSD, Roche and funding (to institution) from the International Association for the Study of Lung Cancer. Isobel Thornton, Yan Zhi Tan, Alessandro Catanzaro and Catarina Neves are employees of Lumanity, which have been contracted by MSD for this study, and do not have any further financial or nonfinancial interests to disclose. Fabrizio Ascone, Matilde Franceschini and Mario Calandriello are employees of MSD, Italy. Raquel Aguiar-Ibáñez is an employee of Merck Canada Inc., Kirkland, QC, Canada. Yizhen Lai is an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. Availability of Data and Material: The data used in this study can be made available from the corresponding author on reasonable request. Code Availability: Not applicable; no coding was used for this study. Ethical Approval: All data used in this study were fully de-identified; ethics approval was not required and was not sought. Consent to Participate: Not applicable; this modelling study is exempt from informed consent. Consent to Publication: Not applicable. Author Contributions: Study conceptualisation and design: all authors; study conduct: I.T., Y.Z.T., A.C., C.N. and Y.L.; analysis and interpretation of results: I.T., Y.Z.T., C.N. and Y.L.; draft manuscript preparation: I.T., Y.Z.T., C.N., R.A., M.F. and Y.L. All authors read and approved the final version and agree to be accountable for the research.
PMID 42250196 · 2026Lung cancer screening among people with HIV, 2018-2023.
Declaration of conflicting interestsThe authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: JJE is as consultant to Merck, ViiV Healthcare and Gilead Sciences and receives support on clinical research contracts to UNC-CH.
PMID 42532810 · 202601
Current Standard-of-Care Sources
Alexandria uses this label only for PubMed-indexed guidelines or consensus documents. These are source publications, not individualized recommendations.
ESTRO clinical practice guideline on high-dose thoracic reirradiation for non-small cell lung cancer.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2026
PMID 42468604SEPAR-SECT recommendations for perioperative invasive mediastinal staging of non-small cell lung cancer.
Cirugia espanola · 2026
PMID 42373333SEPAR-SECT Recommendations for Perioperative Invasive Mediastinal Staging of Non-small Cell Lung Cancer.
Archivos de bronconeumologia · 2026
PMID 42276952Program Guidelines for the National Lung Cancer Screening Program: Targeted Lung Cancer Screening in High-Risk Individuals in Australia.
The Medical journal of Australia · 2026
PMID 42438375The Society of Thoracic Surgeons Expert Consensus Document (2026) on Addressing Definition and Practices of Sublobar Resection in Non-Small Cell Lung Cancer.
The Annals of thoracic surgery · 2026
PMID 42320552Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.1.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026
PMID 42190143Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.1.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026
PMID 42190141ESTRO-EORTC expert guideline on target delineation and radiotherapy details for stage I-III small cell lung cancer.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2026
PMID 41932500ERS/ESGE/ESTS clinical practice guidelines on endobronchial and oesophageal endosonography for the diagnosis and staging of lung cancer.
The European respiratory journal · 2026
PMID 42167778Radiologist's Guide to the Ninth Edition TNM Staging System for Quantitative and Qualitative Assessment of Pleural Mesothelioma.
Radiology · 2025
PMID 40956163The Society of Thoracic Surgeons 2026 Expert Consensus on the Multimodal Treatment of Pleural Mesothelioma.
The Annals of thoracic surgery · 2026
PMID 42019659Patient-Centered Physical Activity Intervention in Lung Cancer Patients: A Clinical Severity and Functional Capacity Systematic Review and Meta-analysis.
Cancer nursing · 2026
PMID 3988866702
Highest-Priority Research
ESTRO clinical practice guideline on high-dose thoracic reirradiation for non-small cell lung cancer.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2026
PURPOSE: High-dose thoracic reirradiation is increasingly used in clinical practice for patients with non-small cell lung cancer (NSCLC) in a variety of clinical scenarios ranging from locoregional recurrence to selected metastatic settings. The treatment goals of thoracic reirradiation include durable local control, symptom palliation, and potential cure. Despite growing clinical adoption, high-quality randomised evidence guiding patient selection, treatment delivery, and integration with systemic therapy remains limited. This ESTRO- clinical practice guideline aims to provide expert consensus recommendations for high-dose thoracic reirradiation in NSCLC based on the available literature an…
PMID 42468604SEPAR-SECT recommendations for perioperative invasive mediastinal staging of non-small cell lung cancer.
Cirugia espanola · 2026
Accurate mediastinal nodal staging is essential for the management of non-small cell lung cancer (NSCLC), as it refines prognosis, guides multimodal treatment, and improves survival. This joint consensus document from the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) and the Spanish Society of Thoracic Surgeons (SECT) updates and expands the 2011 SEPAR guidelines, incorporating the 9th edition of the TNM classification and extending recommendations to the entire perioperative setting, including both preoperative and intraoperative mediastinal staging. The recommendations were developed through a structured review of the literature and multidisciplinary expert consensus. This do…
PMID 42373333SEPAR-SECT Recommendations for Perioperative Invasive Mediastinal Staging of Non-small Cell Lung Cancer.
Archivos de bronconeumologia · 2026
Accurate mediastinal nodal staging is essential for the management of non-small cell lung cancer (NSCLC), as it refines prognosis, guides multimodal treatment, and improves survival. This joint consensus document from the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) and the Spanish Society of Thoracic Surgeons (SECT) updates and expands the 2011 SEPAR guidelines, incorporating the 9th edition of the TNM classification and extending recommendations to the entire perioperative setting, including both preoperative and intraoperative mediastinal staging. The recommendations were developed through a structured review of the literature and multidisciplinary expert consensus. This do…
PMID 42276952Program Guidelines for the National Lung Cancer Screening Program: Targeted Lung Cancer Screening in High-Risk Individuals in Australia.
The Medical journal of Australia · 2026
INTRODUCTION: Lung cancer is the leading cause of cancer mortality in Australia. In July 2025, the Australian Government launched the National Lung Cancer Screening Program (the Program). The Program has been designed in accordance with the Medical Services Advisory Committee's recommendations. This article summarises the program guidelines, outlining Program parameters and delivery requirements. The screening and assessment pathway defines the Program structure. The purpose of the guidelines is to ensure safe, effective and high-quality Program delivery, detailing key steps for clinical practice and information for participating healthcare providers. MAIN RECOMMENDATIONS: The guidelines pro…
PMID 42438375The Society of Thoracic Surgeons Expert Consensus Document (2026) on Addressing Definition and Practices of Sublobar Resection in Non-Small Cell Lung Cancer.
The Annals of thoracic surgery · 2026
BACKGROUND: Two recent randomized clinical trials have shown sublobar resection to be noninferior to lobectomy in node-negative non-small cell lung cancer ≤2 cm. As a result, the use of sublobar resection in early lung cancer patients has significantly increased. Consensus recommendations are needed to guide its appropriate use. METHODS: The Society of Thoracic Surgeons Workforce on Evidence-Based Surgery assembled a panel of thoracic surgeons with clinical and methodological expertise to review the existing literature on this topic. A modified Delphi method, with boundaries and thresholds determined a priori, was used until 75% agreement on the statements was reached. RESULTS: The panel ide…
PMID 42320552Risk of Liver Cancer From Major Causes Compared to Smoking and Lung Cancer: A Systematic Review and Meta-Analysis.
Journal of viral hepatitis · 2026
Liver cancer is the second leading cause of premature cancer mortality globally, whose main causes-HBV, HCV, MASH and alcohol use-are preventable. Viral hepatitis' carcinogenicity is not as well-known as the risk of lung cancer from smoking, leading to rising rates of liver cancer worldwide. The aim of this study was to compare the risk of liver cancer in HBV, HCV, HDV, MASH and alcohol consumption with the better-known risk of lung cancer associated with smoking. We extracted the relative risk of liver cancer from HBV, HCV, HDV, MASH, and alcohol use and the relative risk of lung cancer from smoking from previous studies. We included cohort, case-control and nested case-control studies publ…
PMID 42605247Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.1.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026
Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual. ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines. Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating clinician and do not account for individual variation among patients. See appendix for disclaimers and other im…
PMID 42190143Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.1.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026
Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual. ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines. Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating clinician and do not account for individual variation among patients. See appendix for disclaimers and other im…
PMID 42190141ESTRO-EORTC expert guideline on target delineation and radiotherapy details for stage I-III small cell lung cancer.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2026
INTRODUCTION: Stage I-III limited-stage small cell lung cancer (SCLC) is a highly aggressive yet potentially curable disease with concurrent chemoradiotherapy. Thoracic radiation therapy (RT) plays a central role in the management of stage I-III SCLC; however significant variation exists in staging, target volume delineation, dose prescription, and integration with systemic therapy. This document provides an updated European recommendations on the use of RT in stage I-III SCLC, reflecting recent evidence and advancements in clinical practice. MATERIAL AND METHODS: A panel of European experts was convened under the auspices of the ESTRO Guidelines Committee, in collaboration with EORTC Lung C…
PMID 41932500ERS/ESGE/ESTS clinical practice guidelines on endobronchial and oesophageal endosonography for the diagnosis and staging of lung cancer.
The European respiratory journal · 2026
BACKGROUND: In lung cancer, adequate treatment selection relies on accurate diagnosis and staging. Tissue sampling is generally indicated. This guideline explores the role of endosonography via the major airways (endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)) and oesophagus (endoscopic transoesophageal ultrasound-guided fine-needle aspiration (EUS-FNA)). EUS-FNA can also be performed using an EBUS scope (EUS-B-FNA). METHODS: Task force members were selected from the European Respiratory Society, European Society of Gastrointestinal Endoscopy and European Society of Thoracic Surgeons. Members formulated 12 guideline questions. Systematic literature searches were…
PMID 42167778Management of Patients With Early-Stage Non-Small Cell Lung Cancer: An American College of Chest Physicians Clinical Practice Guideline.
Chest · 2025
BACKGROUND: Lung cancer remains the number 1 cause of cancer death in men and women in the United States and much of the world. This CHEST organization guideline examines the literature on primary treatment of patients with stage I and II non-small cell lung cancer (NSCLC) to provide evidence-based recommendations. STUDY DESIGN AND METHODS: An expert panel conducted a systematic review addressing the treatment options for patients with stage I/II NSCLC and applied the Grading of Recommendations, Assessment, Development, and Evaluations approach for assessing the certainty of evidence and grading of recommendations. A modified Delphi approach was used to reach consensus on recommendations. RE…
PMID 40562304Radiologist's Guide to the Ninth Edition TNM Staging System for Quantitative and Qualitative Assessment of Pleural Mesothelioma.
Radiology · 2025
Pleural mesothelioma is a highly lethal, rare thoracic malignant neoplasm arising from mesothelial cells. Previous versions of the clinical TNM staging classification have relied on a qualitative radiologic assessment of tumor invasion. However, these qualitative assessments have not proved practical to implement, with poor interobserver agreement and lack of prognostic significance. The updated ninth edition of the International Association for the Study of Lung Cancer TNM staging system for pleural mesothelioma, jointly published by the American Joint Committee on Cancer and Union for International Cancer Control, proposes key evidence-based changes. The ninth edition incorporates quantita…
PMID 4095616303
Latest Research — Last 24 Months
2027
2027
2027
2026
The Society of Thoracic Surgeons Expert Consensus Document (2026) on Addressing Definition and Practices of Sublobar Resection in Non-Small Cell Lung Cancer.
The Annals of thoracic surgery · PMID 42320552
2026
Risk of Liver Cancer From Major Causes Compared to Smoking and Lung Cancer: A Systematic Review and Meta-Analysis.
Journal of viral hepatitis · PMID 42605247
2026
The clinical value of adding immune checkpoint inhibitors to radiotherapy for cancer: a systematic review and meta-analysis.
Annals of medicine · PMID 42613912
2026
The risk of primary lung cancer in ANCA-associated vasculitis: systematic review and meta-analysis.
Proceedings (Baylor University. Medical Center) · PMID 42376993
2026
Efficacy and safety of durvalumab with or without tremelimumab in the treatment of metastatic non-small cell lung cancer: a meta-analysis of randomized controlled trials.
Proceedings (Baylor University. Medical Center) · PMID 42658167
2026
2026
Pulmonary Toxicities of Antibody-Drug Conjugates in Small Cell and Non-Small Cell Lung Cancer: A Systematic Review and Meta-analysis.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · PMID 42674256
2026
2026
Health risk assessment of inorganic arsenic: an umbrella review.
Reviews on environmental health · PMID 42494104
2026
2026
Evidence-based indications for proton therapy in adults determined using the GRADE approach.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · PMID 41557143
2026
SELECTIVE BRONCHIAL ARTERY CHEMOINFUSION IN NSCLC: CURRENT STATE OF REGIONAL THERAPY AND ITS ROLE IN MULTIMODAL APPROACHES.
Georgian medical news · PMID 42603327
04
Treatment Options Studied in the PubMed Collection
These are interventions detected in PubMed metadata and abstracts. Inclusion does not establish approval, effectiveness, suitability, or standard-of-care status.
preliminary evidence
surgery
44 linked PMIDs42225 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes, quality of life, mortality, adverse events, recurrence, overall survival
- Populations represented
- general population; non-small cell lung cancer; small cell lung cancer; advanced; non-small cell lung cancer; small cell lung cancer; metastatic; early-stage lung cancer; early-stage; localized; locally advanced; advanced; metastatic; EGFR
- Mechanism
- PURPOSE: To evaluate the effects of a symptom network-based core symptom management program targeting fatigue, cough, and dyspnea on symptom burden, symptom management self-efficacy, and quality of life in patients undergoing lung cancer surgery These findings support the clinical value of targeting network-identified core symptoms in perioperative symptom management
preliminary evidence
Biomarkers, Tumor
38 linked PMIDs114941 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes, overall survival, disease-free survival, mortality, adverse events, progression-free survival, response rate
- Populations represented
- general population; non-small cell lung cancer; small cell lung cancer; non-small cell lung cancer; small cell lung cancer; advanced; PD-L1; non-small cell lung cancer; small cell lung cancer; metastatic lung cancer; locally advanced; advanced; non-small cell lung cancer; small cell lung cancer; advanced; PD-L1
- Mechanism
- TREM1 and ODF2L represent promising macrophage-associated candidate biomarkers and potential therapeutic targets Here, we describe an RNaseH1-dependent, amplification-free detection of microRNAs, which is based on Förster resonance energy transfer (FRET) between donor (single-stranded DNA probe (ssDNA)-spiked, green fluorescent nanocage) and acceptor (RNaseH1-linked, orange fluorescent protein) and enables reliable cancer diagnosis with high accuracy for human lung and gastric cancer patients and healthy donors by directly quantifying serum microRNA targets
preliminary evidence
Antineoplastic Agents
34 linked PMIDs1442 reported cumulative sample signal
- Research status
- mostly neutral
- Outcomes represented
- reported clinical outcomes, adverse events, progression-free survival, recurrence, pneumonitis, overall survival, disease-free survival, objective response rate
- Populations represented
- general population; non-small cell lung cancer; small cell lung cancer; advanced; non-small cell lung cancer; small cell lung cancer; advanced; metastatic; non-small cell lung cancer; small cell lung cancer; stage III; EGFR
- Mechanism
- Besides the C2 also inhibits Topoisomerase II activity in a dose-dependent manner as envisaged by the kDNA decatenation assay IrFP6 showed the multifaceted mechanism of action including the accumulation in mitochondria and the arrest of cell cycle at S phase, a reduction of mitochondrial membrane potential and an accumulation of intracellular reactive oxygen species, resulting in A549 cell apoptosis
preliminary evidence
Immune Checkpoint Inhibitors
24 linked PMIDs134474 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes, adverse events, progression-free survival, overall survival, pneumonitis, recurrence, objective response rate, response rate
- Populations represented
- general population; non-small cell lung cancer; small cell lung cancer; advanced; non-small cell lung cancer; small cell lung cancer; PD-L1; non-small cell lung cancer; small cell lung cancer; stage III; non-small cell lung cancer; small cell lung cancer; metastatic
- Mechanism
- JS-201 is a dual antibody targeting PD-1 and TGF-β signaling OBJECTIVE: This study aimed to systematically synthesize and separately quantify the pooled safety profiles of bispecific antibodies (BsAbs) targeting PD-1/CTLA-4 or PD-1/VEGF in patients with non-small cell lung cancer (NSCLC), and to descriptively summarize class-specific safety patterns
preliminary evidence
radiotherapy
21 linked PMIDs10973 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes, quality of life, overall survival, adverse events, pneumonitis, progression-free survival, recurrence, objective response rate
- Populations represented
- general population; non-small cell lung cancer; small cell lung cancer; non-small cell lung cancer; small cell lung cancer; metastatic lung cancer; locally advanced; advanced; PD-L1; non-small cell lung cancer; small cell lung cancer; metastatic; first-line; second-line; PD-L1
- Mechanism
- FactsPhotodynamic therapy (PDT) is a minimally invasive anticancer modality based on the light-mediated activation of photosensitizers to generate reactive oxygen species and induce tumor cell death.PDT has demonstrated clinical efficacy in treating various tumor types, including esophageal cancer, gastric cancer, lung cancer, skin cancer, bladder cancer, cervical cancer, ovarian cancer, and glioblastoma.The antitumor effects of PDT are mediated not only by direct tumor cell killing but also by vascular damage, immunogenic cell death, and activation of antitumor immune responses.Nanotechnology-based photosensitizer delivery systems and tumor microenvironment modulation strategies have improv JS-201 is a dual antibody targeting PD-1 and TGF-β signaling
preliminary evidence
MicroRNAs
10 linked PMIDs116 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes
- Populations represented
- general population; non-small cell lung cancer; small cell lung cancer; metastatic; advanced
- Mechanism
- Here, we describe an RNaseH1-dependent, amplification-free detection of microRNAs, which is based on Förster resonance energy transfer (FRET) between donor (single-stranded DNA probe (ssDNA)-spiked, green fluorescent nanocage) and acceptor (RNaseH1-linked, orange fluorescent protein) and enables reliable cancer diagnosis with high accuracy for human lung and gastric cancer patients and healthy donors by directly quantifying serum microRNA targets Functionally, miR-664b-5p promotes cell proliferation, migration, and invasion and inhibits apoptosis, thereby promoting malignant progression and metastasis in NSCLC
preliminary evidence
Antibodies, Monoclonal, Humanized
9 linked PMIDs607 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes, overall survival, response rate, adverse events, progression-free survival, objective response rate
- Populations represented
- non-small cell lung cancer; small cell lung cancer; advanced; PD-L1; metastatic; early-stage lung cancer; early-stage; advanced; PD-L1; non-small cell lung cancer; small cell lung cancer; metastatic; first-line; non-small cell lung cancer; small cell lung cancer; advanced; metastatic; PD-L1; advanced; metastatic; treatment-naive
- Mechanism
- Additionally, while prior studies documented that IgG Ab responses to TAA can identify targets of a coordinated T and B cell response and evidence of immune surveillance, this study found that high autoantibody responses, while not statistically significant, trended toward a worse outcome (p = 0.06) Checkpoint blockade of PD-1 with pembrolizumab provides long-term survival to a significant proportion of patients with metastatic melanoma
preliminary evidence
Protein Kinase Inhibitors
9 linked PMIDs500 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes
- Populations represented
- non-small cell lung cancer; small cell lung cancer; non-small cell lung cancer; small cell lung cancer; EGFR; EGFR; non-small cell lung cancer; small cell lung cancer; EGFR; MET; first-line; ALK; first-line; EGFR
- Mechanism
- Guided by molecular docking, we herein developed a series of novel AURKB-targeting PROTACs Using multiple in vitro-derived resistant models, we found that acquired resistance was accompanied by cross-resistance to mechanistically distinct PRMT5 inhibitors
preclinical evidence only
Cisplatin
9 linked PMIDs148 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes, progression-free survival, quality of life, objective response rate, response rate, adverse events
- Populations represented
- general population; non-small cell lung cancer; small cell lung cancer; advanced; small cell lung cancer; PD-L1; non-small cell lung cancer; small cell lung cancer; advanced; metastatic; first-line; advanced; metastatic; treatment-naive
- Mechanism
- IrFP6 showed the multifaceted mechanism of action including the accumulation in mitochondria and the arrest of cell cycle at S phase, a reduction of mitochondrial membrane potential and an accumulation of intracellular reactive oxygen species, resulting in A549 cell apoptosis PURPOSE: This study aims to identify glycolysis-targeting active ingredients from Traditional Chinese Medicine (TCM) and to investigate their enhanced effect in reducing lactylation to inhibit lung cancer
moderate-confidence evidence
ErbB Receptors
7 linked PMIDs216 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes, progression-free survival, recurrence, adverse events, pneumonitis
- Populations represented
- non-small cell lung cancer; small cell lung cancer; EGFR; EGFR; non-small cell lung cancer; small cell lung cancer; stage III; EGFR; non-small cell lung cancer; small cell lung cancer; locally advanced; advanced; metastatic; first-line; first-line; EGFR
- Mechanism
- The discovery and promise of small-molecule allosteric modulators, including both reversible allosteric, ATP dual targeting inhibitors and targeted protein degraders (PROTACs) that employ allosteric binding for mutant-selective EGFR degradation that target mutant EGFR in NSCLC treatment are thoroughly evaluated in this study By bridging both the ATP and allosteric sites, these molecules offer a novel dual-targeting approach to counteract the heterogeneity of resistance mechanisms
preliminary evidence
pembrolizumab
7 linked PMIDs142 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- adverse events, reported clinical outcomes, overall survival, response rate, progression-free survival, objective response rate
- Populations represented
- metastatic; non-small cell lung cancer; small cell lung cancer; advanced; PD-L1; non-small cell lung cancer; small cell lung cancer; metastatic; non-small cell lung cancer; small cell lung cancer; metastatic; first-line; advanced; metastatic; treatment-naive
- Mechanism
- Checkpoint blockade of PD-1 with pembrolizumab provides long-term survival to a significant proportion of patients with metastatic melanoma Additionally, while prior studies documented that IgG Ab responses to TAA can identify targets of a coordinated T and B cell response and evidence of immune surveillance, this study found that high autoantibody responses, while not statistically significant, trended toward a worse outcome (p = 0.06)
preliminary evidence
B7-H1 Antigen
5 linked PMIDs148 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes, overall survival, progression-free survival, objective response rate, response rate, adverse events
- Populations represented
- non-small cell lung cancer; small cell lung cancer; PD-L1; PD-L1; non-small cell lung cancer; small cell lung cancer; advanced; first-line; PD-L1; non-small cell lung cancer; small cell lung cancer; advanced; first-line; treatment-naive; PD-L1
- Mechanism
- Not explicitly reported in the retrieved PubMed metadata or abstracts.
moderate-confidence evidence
osimertinib
4 linked PMIDs736 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- progression-free survival, recurrence, adverse events, pneumonitis, reported clinical outcomes, overall survival, quality of life
- Populations represented
- non-small cell lung cancer; small cell lung cancer; stage III; EGFR; non-small cell lung cancer; small cell lung cancer; locally advanced; advanced; metastatic; first-line; non-small cell lung cancer; small cell lung cancer; EGFR; MET; EGFR; MET
- Mechanism
- Network toxicology suggested potential nephrotoxicity and revealed 173 shared targets and prioritizing six hub genes (HSP90AA1, AKT1, EGFR, CASP3, TNF, SRC) Molecular docking revealed high-affinity binding between tepotiniband all six hub targets (Vina scores: -8.0 to -10.6 kcal/mol), providing a structural basis for the postulated mechanistic link to AKI
preliminary evidence
Carboplatin
4 linked PMIDs574 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- overall survival, response rate, adverse events, progression-free survival, objective response rate
- Populations represented
- metastatic; non-small cell lung cancer; small cell lung cancer; advanced; metastatic; PD-L1; advanced; metastatic; treatment-naive; non-small cell lung cancer; small cell lung cancer; stage II
- Mechanism
- Checkpoint blockade of PD-1 with pembrolizumab provides long-term survival to a significant proportion of patients with metastatic melanoma
preliminary evidence
alectinib
4 linked PMIDs510 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- overall survival, progression-free survival, adverse events, reported clinical outcomes
- Populations represented
- first-line; ALK; advanced; first-line; ALK; non-small cell lung cancer; small cell lung cancer; advanced; first-line; ALK
- Mechanism
- Not explicitly reported in the retrieved PubMed metadata or abstracts.
moderate-confidence evidence
Indoles
4 linked PMIDs324 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- progression-free survival, recurrence, adverse events, pneumonitis, reported clinical outcomes, mortality
- Populations represented
- non-small cell lung cancer; small cell lung cancer; stage III; EGFR; early-stage lung cancer; early-stage; advanced; PD-L1; non-small cell lung cancer; small cell lung cancer; locally advanced; advanced; metastatic; first-line; first-line
- Mechanism
- Not explicitly reported in the retrieved PubMed metadata or abstracts.
moderate-confidence evidence
EGFR protein, human
4 linked PMIDs216 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes, progression-free survival, recurrence, adverse events, pneumonitis
- Populations represented
- non-small cell lung cancer; small cell lung cancer; EGFR; non-small cell lung cancer; small cell lung cancer; stage III; EGFR; EGFR
- Mechanism
- The discovery and promise of small-molecule allosteric modulators, including both reversible allosteric, ATP dual targeting inhibitors and targeted protein degraders (PROTACs) that employ allosteric binding for mutant-selective EGFR degradation that target mutant EGFR in NSCLC treatment are thoroughly evaluated in this study By bridging both the ATP and allosteric sites, these molecules offer a novel dual-targeting approach to counteract the heterogeneity of resistance mechanisms
preliminary evidence
Programmed Cell Death 1 Receptor
4 linked PMIDs31 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes, overall survival, objective response rate, response rate, adverse events, progression-free survival
- Populations represented
- non-small cell lung cancer; small cell lung cancer; PD-L1; non-small cell lung cancer; small cell lung cancer; metastatic; first-line; second-line; PD-L1; non-small cell lung cancer; small cell lung cancer; advanced; first-line; PD-L1
- Mechanism
- Collectively, our findings highlight the therapeutic potential of targeting diet-microbiome-immune system interactions to improve cancer immunotherapy outcomes
05
Conflicting Research
higher-confidence evidence
28 studiessurgery · multiple reported outcomes
Status: apparently conflicting; different clinical questions. Population: general population. Comparator: multiple or inconsistently reported comparators.
- The records use different or inconsistently reported comparators.
- The records report different endpoints or outcome definitions.
- The evidence combines different study designs.
- Some abstracts do not state whether the primary endpoint was met.
unknown: 20null: 7benefit: 1
higher-confidence evidence
21 studiesradiotherapy · multiple reported outcomes
Status: apparently conflicting; different clinical questions. Population: general population. Comparator: multiple or inconsistently reported comparators.
- The records use different or inconsistently reported comparators.
- The records report different endpoints or outcome definitions.
- The evidence combines different study designs.
- Some abstracts do not state whether the primary endpoint was met.
unknown: 17null: 1benefit: 3
higher-confidence evidence
14 studiessurgery · multiple reported outcomes
Status: apparently conflicting; different clinical questions. Population: non-small cell lung cancer; small cell lung cancer. Comparator: multiple or inconsistently reported comparators.
- The records use different or inconsistently reported comparators.
- The records report different endpoints or outcome definitions.
- The evidence combines different study designs.
- Some abstracts do not state whether the primary endpoint was met.
unknown: 11harm: 1null: 1benefit: 1
higher-confidence evidence
3 studiesDrugs, Chinese Herbal · multiple reported outcomes
Status: apparently conflicting; different clinical questions. Population: non-small cell lung cancer; small cell lung cancer. Comparator: multiple or inconsistently reported comparators.
- The records use different or inconsistently reported comparators.
- The records report different endpoints or outcome definitions.
- The evidence combines different study designs.
- Some abstracts do not state whether the primary endpoint was met.
null: 1unknown: 1benefit: 1
06
Failed or Negative Trials
Morning versus afternoon administration of immune checkpoint inhibitors in metastatic non-small-cell lung cancer.
randomized controlled trial · 2026 · PMID 42134900
Preliminary Effects of Hydrogen-Oxygen Inhalation on Nodule Size, IL-6, and Neutrophils in Patients with Small Pulmonary Nodules.
randomized controlled trial · 2026 · PMID 42453934
Artificial Intelligence-Assisted Lung Nodule Evaluation on Low-Dose Chest CT in Asymptomatic Individuals: A Prospective Randomized Controlled Trial.
randomized controlled trial · 2026 · PMID 41848489
First-line serplulimab plus chemotherapy with or without HLX04 versus chemotherapy in locally advanced or metastatic non-squamous non-small-cell lung cancer (ASTRUM-002): a randomised, double-blind, multicentre phase 3 trial.
randomized controlled trial · 2026 · PMID 41354044
Benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3 trial.
randomized controlled trial · 2026 · PMID 41825453
Efficacy of alectinib for ALK-positive NSCLC according to tumor burden and body mass index: A pooled analysis of the randomized phase III trials ALEX and J-ALEX.
randomized controlled trial · 2026 · PMID 42269244
Adjuvant Nivolumab vs Observation in Resected Non-Small Cell Lung Cancer: A Randomized Clinical Trial.
randomized controlled trial · 2026 · PMID 42224490
Final overall survival analysis of the APPLE study: atezolizumab and platinum-pemetrexed with or without bevacizumab for metastatic nonsquamous non-small cell lung cancer.
randomized controlled trial · 2026 · PMID 42127535
Evaluating the prognostic impact of multiple 18FDG-PET imaging parameters in small-cell lung cancer: Insights from the long-term analysis of the CONVERT trial.
randomized controlled trial · 2026 · PMID 41801367
Ten-year overall survival in resectable stage-III NSCLC - Results of the randomized ESPATUE trial - Long-term survival and competing risk analysis.
randomized controlled trial · 2026 · PMID 41702246
07
Emerging and Experimental Research
Increasing hydrophobicity in poly(amino acid) adjuvants elicits potent and durable anti-tumor immunity via coordinated cellular and humoral responses.
preclinical or laboratory · 2027 · PMID 42662463
Concurrent chemoradiotherapy with or without simultaneous integrated boost for unresectable stage III non-small-cell lung cancer: a randomized phase II trial with exploratory EGFR and PD-L1 analyses.
randomized controlled trial · 2026 · PMID 42456525
Long-Term Analysis of One Versus Three Fractions of Stereotactic Body Radiation Therapy for Peripheral Stage I to II Non-Small Cell Lung Cancer: A Randomized, Multi-Institution, Phase 2 Trial.
randomized controlled trial · 2026 · PMID 41833909
Comparison of Computed Tomography Ventilation Imaging and Hyperpolarized 3He Magnetic Resonance Imaging in Patients With Lung Cancer.
randomized controlled trial · 2026 · PMID 41802548
Final Analysis of Neoadjuvant Sintilimab Plus Chemotherapy in IB-IIIA Non-Small-Cell Lung Cancer: Phase 2 neoSCORE Trial.
randomized controlled trial · 2026 · PMID 42252705
Endobronchial Intratumoral Immuno- and Gene Therapies in Lung Cancer: Mechanisms of Local Delivery, Systemic Immune Effects, and Global Feasibility.
phase 1 clinical trial · 2026 · PMID 42589640
A phase II, multicenter, open-label, single-arm study of berzosertib plus topotecan in patients with relapsed platinum-resistant small-cell lung cancer (DDRiver SCLC 250).
phase 2 clinical trial · 2026 · PMID 41421295
Efficacy and biomarker exploration of anlotinib plus penpulimab in second-line ES-SCLC: Results from the phase 2 ALTER-L041 trial.
phase 2 clinical trial · 2026 · PMID 42486095
DNA hypomethylation identifying clinical benefit subgroup of small-cell lung cancer: multi-omics analysis of a phase II trial with durvalumab plus olaparib as maintenance therapy.
phase 2 clinical trial · 2026 · PMID 42601174
Safety and efficacy of first-line iparomlimab and tuvonralimab (QL1706) plus carboplatin and etoposide in patients with extensive-stage small cell lung cancer: an open-label, single-arm, phase 2 trial (DUBHE-L-209).
phase 3 clinical trial · 2026 · PMID 42643500
08
Evidence Gaps
Detailed risk-of-bias assessment remains limited
PubMed abstracts often do not include enough methodological detail for a complete study-level risk-of-bias assessment.
R
Complete Ranked PubMed Index
The retrieval-priority score orders records using publication type, recency, sample-size signals, and replication signals. It is not a recommendation or a formal risk-of-bias grade.
Current Standard Of Care88 records
Rank112.0
SEPAR-SECT recommendations for perioperative invasive mediastinal staging of non-small cell lung cancer.
Cirugia espanola · 2026 · PMID 42373333
Accurate mediastinal nodal staging is essential for the management of non-small cell lung cancer (NSCLC), as it refines prognosis, guides multimodal treatment, and improves survival. This joint consensus document from the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) and the Spanish Society of Thoracic Surgeons (SECT) updates and expands the 2011 SEPAR guidelines, incorporating the 9th edition of the TNM classification and extending recommendations to the entire perioperative setting, including both p…
Rank112.0
SEPAR-SECT Recommendations for Perioperative Invasive Mediastinal Staging of Non-small Cell Lung Cancer.
Archivos de bronconeumologia · 2026 · PMID 42276952
Accurate mediastinal nodal staging is essential for the management of non-small cell lung cancer (NSCLC), as it refines prognosis, guides multimodal treatment, and improves survival. This joint consensus document from the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) and the Spanish Society of Thoracic Surgeons (SECT) updates and expands the 2011 SEPAR guidelines, incorporating the 9th edition of the TNM classification and extending recommendations to the entire perioperative setting, including both p…
Rank112.0
ESTRO clinical practice guideline on high-dose thoracic reirradiation for non-small cell lung cancer.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2026 · PMID 42468604
PURPOSE: High-dose thoracic reirradiation is increasingly used in clinical practice for patients with non-small cell lung cancer (NSCLC) in a variety of clinical scenarios ranging from locoregional recurrence to selected metastatic settings. The treatment goals of thoracic reirradiation include durable local control, symptom palliation, and potential cure. Despite growing clinical adoption, high-quality randomised evidence guiding patient selection, treatment delivery, and integration with systemic therapy remains …
Rank110.0
Radiologist's Guide to the Ninth Edition TNM Staging System for Quantitative and Qualitative Assessment of Pleural Mesothelioma.
Radiology · 2025 · PMID 40956163
Pleural mesothelioma is a highly lethal, rare thoracic malignant neoplasm arising from mesothelial cells. Previous versions of the clinical TNM staging classification have relied on a qualitative radiologic assessment of tumor invasion. However, these qualitative assessments have not proved practical to implement, with poor interobserver agreement and lack of prognostic significance. The updated ninth edition of the International Association for the Study of Lung Cancer TNM staging system for pleural mesothelioma, …
Rank110.0
Management of Central Airway Obstruction: An American College of Chest Physicians Clinical Practice Guideline.
Chest · 2025 · PMID 39029785
BACKGROUND: Central airway obstruction (CAO), seen in a variety of malignant and nonmalignant airway disorders, is associated with a poor prognosis. The management of CAO is dependent on provider training and local resources, which may make the clinical approach and outcomes highly variable. We reviewed the current literature and provided evidence-based recommendations for the management of CAO. METHODS: A multidisciplinary expert panel developed key questions using the Patient, Intervention, Comparator, and Outcom…
Rank110.0
Acquisition and Handling of Endobronchial Ultrasound Transbronchial Needle Samples: An American College of Chest Physicians Clinical Practice Guideline.
Chest · 2025 · PMID 39343294
BACKGROUND: Endobronchial ultrasound-guided transbronchial aspiration (EBUS-TBNA) has become the standard for initial lung cancer diagnosis and staging. Previous guidelines have generally focused on the "when" and "how" of EBUS-TBNA; however, little guidance is available on handling and processing specimens during and after acquisition to help optimize both diagnostic yield and tissue integrity for ancillary studies. This document examines the available literature on EBUS-TBNA specimen processing and handling. STUD…
Rank110.0
NCCN Guidelines® Insights: Small Cell Lung Cancer, Version 2.2026.
Journal of the National Comprehensive Cancer Network : JNCCN · 2026 · PMID 41671459
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Small Cell Lung Cancer provide recommendations for diagnostic workup, staging, and treatment. These NCCN Guidelines Insights highlight recent updates, with a particular focus on changes to systemic therapies and radiation treatment in the NCCN Guidelines for Small Cell Lung Cancer.
Rank110.0
ERS/ESGE/ESTS clinical practice guidelines on endobronchial and oesophageal endosonography for the diagnosis and staging of lung cancer.
The European respiratory journal · 2026 · PMID 42167778
BACKGROUND: In lung cancer, adequate treatment selection relies on accurate diagnosis and staging. Tissue sampling is generally indicated. This guideline explores the role of endosonography via the major airways (endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)) and oesophagus (endoscopic transoesophageal ultrasound-guided fine-needle aspiration (EUS-FNA)). EUS-FNA can also be performed using an EBUS scope (EUS-B-FNA). METHODS: Task force members were selected from the European Respirato…
Rank110.0
Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology.
Journal of the National Comprehensive Cancer Network : JNCCN · 2024 · PMID 38754467
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC) provide recommendations for the treatment of patients with NSCLC, including diagnosis, primary disease management, surveillance for relapse, and subsequent treatment. The panel has updated the list of recommended targeted therapies based on recent FDA approvals and clinical data. This selection from the NCCN Guidelines for NSCLC focuses on treatment recommendations for advanced or metastatic NSCLC with actiona…
Rank110.0
The Society of Thoracic Surgeons Expert Consensus Document (2026) on Addressing Definition and Practices of Sublobar Resection in Non-Small Cell Lung Cancer.
The Annals of thoracic surgery · 2026 · PMID 42320552
BACKGROUND: Two recent randomized clinical trials have shown sublobar resection to be noninferior to lobectomy in node-negative non-small cell lung cancer ≤2 cm. As a result, the use of sublobar resection in early lung cancer patients has significantly increased. Consensus recommendations are needed to guide its appropriate use. METHODS: The Society of Thoracic Surgeons Workforce on Evidence-Based Surgery assembled a panel of thoracic surgeons with clinical and methodological expertise to review the existing litera…
Rank110.0
Program Guidelines for the National Lung Cancer Screening Program: Targeted Lung Cancer Screening in High-Risk Individuals in Australia.
The Medical journal of Australia · 2026 · PMID 42438375
INTRODUCTION: Lung cancer is the leading cause of cancer mortality in Australia. In July 2025, the Australian Government launched the National Lung Cancer Screening Program (the Program). The Program has been designed in accordance with the Medical Services Advisory Committee's recommendations. This article summarises the program guidelines, outlining Program parameters and delivery requirements. The screening and assessment pathway defines the Program structure. The purpose of the guidelines is to ensure safe, eff…
Rank110.0
Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.1.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026 · PMID 42190143
Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual. ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines. Living Guidelines and updates are not intended…
Rank110.0
Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.1.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026 · PMID 42190141
Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual. ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines. Living Guidelines and updates are not intended…
Rank110.0
Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.2.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026 · PMID 42372216
[Box: see text]Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual. ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines. Living Guidelines and updates a…
Rank110.0
ESTRO-EORTC expert guideline on target delineation and radiotherapy details for stage I-III small cell lung cancer.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2026 · PMID 41932500
INTRODUCTION: Stage I-III limited-stage small cell lung cancer (SCLC) is a highly aggressive yet potentially curable disease with concurrent chemoradiotherapy. Thoracic radiation therapy (RT) plays a central role in the management of stage I-III SCLC; however significant variation exists in staging, target volume delineation, dose prescription, and integration with systemic therapy. This document provides an updated European recommendations on the use of RT in stage I-III SCLC, reflecting recent evidence and advanc…
Rank109.6
Mortality burden of pre-treatment weight loss in patients with non-small-cell lung cancer: A systematic literature review and meta-analysis.
Journal of cachexia, sarcopenia and muscle · 2024 · PMID 38650388
Cachexia, with weight loss (WL) as a major component, is highly prevalent in patients with cancer and indicates a poor prognosis. The primary objective of this study was to conduct a meta-analysis to estimate the risk of mortality associated with cachexia (using established WL criteria prior to treatment initiation) in patients with non-small-cell lung cancer (NSCLC) in studies identified through a systematic literature review. The review was conducted according to PRISMA guidelines. Embase® and PubMed were searche…
Rank102.0
The Society of Thoracic Surgeons 2026 Expert Consensus on the Multimodal Treatment of Pleural Mesothelioma.
The Annals of thoracic surgery · 2026 · PMID 42019659
BACKGROUND: Pleural mesothelioma (PM) is a rare and complex thoracic malignancy for which treatment regimens continue to evolve. The role of surgery in the management of PM is controversial. We reviewed contemporary literature to provide consensus recommendations from an expert multidisciplinary panel on the multimodal treatment of PM with an emphasis on surgical intervention to update management pathways. METHODS: An international, multidisciplinary panel developed Population, Intervention, Comparator, Outcomes (P…
Rank100.0
Tobacco Use, Stigma, and Coping in Lung Cancer: A Systematic Review of Their Psychosocial Interactions and Clinical Implications.
Current oncology (Toronto, Ont.) · 2026 · PMID 42505210
BACKGROUND: Lung cancer carries a high psychosocial burden. Tobacco use, the stigma attached to the disease, and coping strategies are thought to interact and shape psychological outcomes, yet they have rarely been examined together. This review aimed to synthesise the evidence on the relationship between tobacco use, lung cancer stigma, and coping, and how these factors interact and influence patients' psychological outcomes. METHODS: Following the PRISMA 2020 guideline, PubMed/MEDLINE and Dialnet were searched (w…
Rank100.0
Exercise medicine for individuals diagnosed with Lung Cancer: A systematic review and meta-analysis of health outcomes.
Lung cancer (Amsterdam, Netherlands) · 2025 · PMID 39983446
Consensus exists regarding the need to provide exercise interventions to individuals diagnosed with lung cancer (LC). Exercise interventions for this populations usually include multidisciplinary approaches, making the attempt to understand the effects of exercise a real challenge. Therefore, we designed a systematic review to identify the effects of exercise interventions among individuals with a LC diagnosis. Following the PRISMA guidelines, studies across 5 different databases were systematically screened. Eligi…
Rank100.0
Patient-Centered Physical Activity Intervention in Lung Cancer Patients: A Clinical Severity and Functional Capacity Systematic Review and Meta-analysis.
Cancer nursing · 2026 · PMID 39888667
BACKGROUND: Increasing physical activity levels is a significant unmet need in cancer survivors, and it can likely be enhanced through a better understanding of the interventions developed. Some studies on patient-centered physical activity interventions have shown promising results in increasing daily activity levels among lung cancer survivors. However, the programs present a high heterogeneity, and there is no consensus on the parameters and their effectiveness. OBJECTIVE: To examine the effectiveness of patient…
Rank100.0
Use of antibacterial prophylaxis for patients with neutropenia. Australian Consensus Guidelines 2011 Steering Committee.
Internal medicine journal · 2011 · PMID 21272174
The use of oral prophylactic antibiotics in patients with neutropenia is controversial and not recommended by this group because of a lack of evidence showing a reduction in mortality and concerns that such practice promotes antimicrobial resistance. Recent evidence has demonstrated non-significant but consistent, improvement in all-cause mortality when fluoroquinolones (FQs) are used as primary prophylaxis. However, the consensus was that this evidence was not strong enough to recommend prophylaxis. The evidence b…
Rank97.0
Systematic comparison of ranking aggregation methods for gene lists in experimental results.
Bioinformatics (Oxford, England) · 2022 · PMID 36094347
MOTIVATION: A common experimental output in biomedical science is a list of genes implicated in a given biological process or disease. The gene lists resulting from a group of studies answering the same, or similar, questions can be combined by ranking aggregation methods to find a consensus or a more reliable answer. Evaluating a ranking aggregation method on a specific type of data before using it is required to support the reliability since the property of a dataset can influence the performance of an algorithm.…
Rank96.0
Evaluation of patient-reported outcome assessment tools for lung cancer: protocol for a systematic review of measurement properties.
JBI evidence synthesis · 2026 · PMID 41923706
OBJECTIVE: The objective of this review will be to appraise the measurement properties of patient-reported outcome assessment tools for lung cancer. INTRODUCTION: Patients with lung cancer manifest varying degrees of physical and psychosocial symptoms attributable to disease pathology and treatment-related complications, which significantly impair their quality of life. Although a few patient-reported outcome assessment tools are available for lung cancer, a comprehensive and standardized comparative analysis of th…
Rank96.0
Lung cancer multidisciplinary care status and evidence-practice gap: a scoping review protocol.
BMJ open · 2026 · PMID 42642084
INTRODUCTION: Lung cancer is the leading cause of cancer-related death worldwide, with substantial variations in incidence, stage at diagnosis and outcomes across regions. High-quality, standardised diagnosis and treatment are essential to improving survival and quality of life. Multidisciplinary care (MDC) is a cornerstone of cancer care; however, its implementation faces barriers such as limited resources, uneven policy support and inequitable access to specialised care, particularly in low- and middle-income cou…
Rank87.0
Definitive Radiotherapy to the Primary Tumor in Stage IV NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer Advanced Radiation Technology Subcommittee.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2026 · PMID 41934464
The role of radiotherapy (RT) in stage IV NSCLC has traditionally been palliative; however, with advancements in systemic therapies and insights into the evolutionary processes underpinning advanced disease, the rationale for aggressive primary-tumor control has received renewed interest. This International Association for the Study of Lung Cancer (IASLC) consensus statement evaluates the current evidence for the role, timing, dosing, target volumes, and safety of primary-tumor RT in both actionable genomic alterat…
Diagnosis And Screening363 records
Rank112.0
SEPAR-SECT Recommendations for Perioperative Invasive Mediastinal Staging of Non-small Cell Lung Cancer.
Archivos de bronconeumologia · 2026 · PMID 42276952
Accurate mediastinal nodal staging is essential for the management of non-small cell lung cancer (NSCLC), as it refines prognosis, guides multimodal treatment, and improves survival. This joint consensus document from the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) and the Spanish Society of Thoracic Surgeons (SECT) updates and expands the 2011 SEPAR guidelines, incorporating the 9th edition of the TNM classification and extending recommendations to the entire perioperative setting, including both p…
Rank110.0
Radiologist's Guide to the Ninth Edition TNM Staging System for Quantitative and Qualitative Assessment of Pleural Mesothelioma.
Radiology · 2025 · PMID 40956163
Pleural mesothelioma is a highly lethal, rare thoracic malignant neoplasm arising from mesothelial cells. Previous versions of the clinical TNM staging classification have relied on a qualitative radiologic assessment of tumor invasion. However, these qualitative assessments have not proved practical to implement, with poor interobserver agreement and lack of prognostic significance. The updated ninth edition of the International Association for the Study of Lung Cancer TNM staging system for pleural mesothelioma, …
Rank109.3
Renin-angiotensin system inhibitors and immunotherapy outcomes in lung cancer: a systematic review and meta-analysis with complementary transcriptomic analyses.
Frontiers in immunology · 2026 · PMID 42688457
BACKGROUND: The tumor microenvironment has emerged as an important determinant of response to immune checkpoint inhibitors (ICIs), with increasing attention directed toward stromal components such as cancer-associated fibroblasts (CAFs). Experimental evidence suggests that renin-angiotensin system (RAS) signaling may participate in stromal remodeling and immune regulation, raising interest in whether RAS inhibitors could influence immunotherapy outcomes. However, clinical findings remain inconsistent and the extent…
Rank108.6
Incidence and risk factors for malignancy in patients with incidental solitary pulmonary nodules: a systematic review and meta-analysis.
Annals of medicine · 2026 · PMID 41641734
BACKGROUND: The increasing use of chest imaging has led to a higher detection rate of incidental solitary pulmonary nodules (SPNs), often causing patient anxiety. Determining the malignancy rate and associated risk factors is crucial for developing appropriate follow-up strategies to prevent overdiagnosis, overtreatment, or missed diagnoses. This meta-analysis aims to investigate the malignancy rate and risk factors in patients with incidental SPNs. METHODS: A systematic search of PubMed, Embase, Web of Science, an…
Rank107.8
The risk of primary lung cancer in ANCA-associated vasculitis: systematic review and meta-analysis.
Proceedings (Baylor University. Medical Center) · 2026 · PMID 42376993
BACKGROUND: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a systemic inflammatory disorder that affects small blood vessels. However, the association between AAV and lung cancer risk remains uncertain. We performed a systematic review and meta-analysis to evaluate the relationship between AAV and the risk of lung cancer. METHODS: We systematically searched PubMed, Embase, Scopus, and Web of Science from inception through March 2025. Studies reporting relative risks (RRs), odds ratios (OR…
Rank107.8
First-line systemic treatment for people with extensive-stage small cell lung cancer: a network meta-analysis.
The Cochrane database of systematic reviews · 2026 · PMID 42578486
RATIONALE: Extensive-stage small cell lung cancer (SCLC) carries a poor prognosis and has limited therapeutic options. The addition of immune-checkpoint inhibitors (ICIs) to platinum-etoposide (PE) chemotherapy has become an important first-line treatment strategy. However, the comparative benefits and harms of different first-line chemotherapy-based regimens, including ICI-containing combinations, remain unclear. OBJECTIVES: To evaluate the comparative benefits and harms of immunotherapy (anti-PD-1, anti-PD-L1, or…
Rank106.9
Efficacy and safety of durvalumab with or without tremelimumab in the treatment of metastatic non-small cell lung cancer: a meta-analysis of randomized controlled trials.
Proceedings (Baylor University. Medical Center) · 2026 · PMID 42658167
BACKGROUND: The therapeutic role of combining PD-L1 and CTLA-4 blockade in metastatic non-small cell lung cancer (NSCLC) remains unclear, with individual trials yielding discrepant results. METHODS: We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) to assess the efficacy and safety of durvalumab with or without tremelimumab in advanced NSCLC. The primary outcome was overall survival. Secondary outcomes included immune-related adverse events. Hazard ratios (HRs) and odds ratio…
Rank106.5
Associations between tertiary lymphoid structure density and immune checkpoint inhibitor efficacy in solid tumors: systematic review and meta-analysis.
Frontiers in immunology · 2024 · PMID 39544934
BACKGROUND: Tertiary lymphoid structures (TLS) play a crucial role in tumor immunity, yet their relationship with the efficacy of immune checkpoint inhibitors (ICI) in cancer therapy is not fully understood. This study aims to systematically evaluate how TLS density influences treatment outcomes in cancer patients receiving ICI therapy. METHODS: The PubMed, Embase, Cochrane Library, and Web of Science databases were searched for eligible studies published before January 22, 2024. Our analysis encompassed odds ratio…
Rank105.2
Fibroblast-activation protein inhibitors based positron emission tomography (PET) for assessing lung disease: A systematic review with meta-analysis.
Pulmonology · 2026 · PMID 41810601
BACKGROUND: The incidence of lung diseases has been increasing in recent years, especially lung cancer and interstitial lung disease. However, the diagnosis of lung diseases such as lung cancer and ILD still has some limitations. Therefore, finding an appropriate imaging agent and technique is of great clinical value for the diagnostic evaluation of lung diseases. METHOD: A thorough search of all relevant literature up to 20 June 2024 was undertaken. Studies evaluating lung lesions with FAPI PET were screened and p…
Rank104.5
Lung cancer risk in systemic sclerosis: data from an inception cohort and meta-analysis of published studies.
Clinical and experimental rheumatology · 2026 · PMID 42544606
OBJECTIVES: Population-based cohort studies show an association between systemic sclerosis (SSc) and lung cancer; however, a Mendelian randomisation analysis refutes causality. Herein, lung cancer risk is analysed in an academic inception SSc cohort, complemented by a meta-analysis of published data. METHODS: Patients evaluated within 12 months of SSc onset, between January 1995 and December 2020, with regular follow-up until December 2024, were included. Clinical manifestations, laboratory parameters, treatments a…
Rank102.2
Endobronchial ultrasound-guided mediastinal biopsies for the diagnosis of mediastinal diseases: A network meta-analysis.
Pulmonology · 2026 · PMID 41560513
BACKGROUND: Clinical guidelines recommend endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) as the initial diagnostic tool for lung cancer staging. However, despite the availability of mediastinal forceps biopsy and cryobiopsy, the optimal diagnostic approaches for other mediastinal conditions remain unclear. METHODS: We searched multiple databases and sources up to February 21, 2025, and employed single-arm, pairwise, and network meta-analytical approaches to comprehensively evaluate EBU…
Rank100.0
Association between elevated multiple circulating biomarkers and short-term mortality in critically ill lung cancer patients: a meta-analysis.
Frontiers in oncology · 2026 · PMID 42688014
BACKGROUND AND AIMS: While traditional circulating biomarkers have demonstrated prognostic value in general lung cancer patients, their short-term predictive value in critical care settings remains unclear. This study aims to systematically evaluate the association between elevated multiple circulating biomarkers and short-term mortality in critically ill lung cancer patients. METHODS: This study searched databases including PubMed, Embase, Web of Science, Cochrane Library, and CNKI from inception to February 2026.…
Rank100.0
Economic burden of advanced non-small cell lung cancer (NSCLC): a systematic literature review.
Journal of medical economics · 2026 · PMID 41723781
AIMS: A systematic review of the economic burden of advanced non-small-cell lung cancer (NSCLC). METHODS: Articles from 2011 onwards reporting the economic burden of locally advanced (stage IIIB/C)/metastatic (stage IV) NSCLC were identified through systematic and supplementary searches. Outcomes included hospitalizations, emergency department (ED) and outpatient visits, and direct and indirect costs, amongst others. RESULTS: Across 50 publications (43 studies), patients with advanced NSCLC had high rates of health…
Rank100.0
The Cardiotoxicity Risk of Immune Checkpoint Inhibitors Compared with Chemotherapy: A Systematic Review and Meta-analysis of Observational Studies.
Cardiovascular toxicology · 2025 · PMID 40053271
Immune checkpoint inhibitors (ICIs) have demonstrated favorable outcomes in various cancers. However, it has been observed that ICIs may induce life-threatening cardiovascular toxicity. In this study, a meta-analysis was conducted to determine the risk of cardiovascular toxicities in patients exposed to ICIs or in combination with chemotherapy. PubMed, Cochrane Library, and Embase databases were searched from inception to September 24, 2023. This study was conducted in accordance with the PRISMA guidelines. A meta-…
Rank99.9
Tumor Purity as a Prognostic and Predictive Biomarker of Postoperative Radiation Therapy Outcomes in Stage IIIA-N2 Non-Small Cell Lung Cancer: A Transcriptomic Analysis From the Lung ART Trial.
International journal of radiation oncology, biology, physics · 2026 · PMID 41833910
PURPOSE: Tumor purity (TP), the proportion of malignant cells within a tumor sample, is an important feature of the tumor microenvironment. Using transcriptomic data from the Lung ART-IFCT 0503 trial, we investigated the relevance of TP and its potential to predict benefit from postoperative radiation therapy (PORT). METHODS AND MATERIALS: RNA sequencing was successfully performed on 285 samples. TP was inferred using the ESTIMATE algorithm. Associations with overall survival (OS) and disease-free survival (DFS) we…
Rank97.9
Artificial Intelligence-Assisted Lung Nodule Evaluation on Low-Dose Chest CT in Asymptomatic Individuals: A Prospective Randomized Controlled Trial.
AJR. American journal of roentgenology · 2026 · PMID 41848489
BACKGROUND. The impact of artificial intelligence (AI) tools for lung nodule evaluation on low-dose CT (LDCT) has been evaluated primarily using experimental retrospective reader designs, outside of clinical practice. OBJECTIVE. The purpose of this study was to compare interpretation times and lung nodule detection rates between real-world interpretations conducted with versus without an AI-based lung nodule evaluation tool for LDCT examinations in asymptomatic individuals. METHODS. This prospective single-center, …
Rank96.9
Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small-cell lung cancer: 7-year update from the phase III CROWN study.
Annals of oncology : official journal of the European Society for Medical Oncology · 2026 · PMID 42217582
BACKGROUND: Due to the unprecedented progression-free survival (PFS) benefit with lorlatinib after 5 years of follow-up in the phase III CROWN study, we aimed to quantify long-term outcomes at 7 years. PATIENTS AND METHODS: Treatment-naive patients (N = 296) with advanced anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) were randomly assigned 1:1 to receive lorlatinib 100 mg once a day (n = 149) or crizotinib 250 mg twice a day (n = 147). This post hoc analysis presents investigator-asse…
Rank96.5
Real-time AR navigation with dynamic tracking for millimeter-level pulmonary nodule localization: A randomized clinical trial.
Cell reports. Medicine · 2026 · PMID 42520806
Precise localization of small pulmonary nodules is crucial for surgery. Augmented reality (AR) navigation provides real-time guidance, potentially improving localization efficiency. This open-label randomized controlled trial compares AR-guided localization with conventional computed tomography (CT)-guided localization in 168 participants with peripheral pulmonary nodules ≤2 cm. The primary outcome is localization accuracy; secondary outcomes are success rate, procedural time, radiation dose, insertion attempts, an…
Rank96.0
Lung cancer multidisciplinary care status and evidence-practice gap: a scoping review protocol.
BMJ open · 2026 · PMID 42642084
INTRODUCTION: Lung cancer is the leading cause of cancer-related death worldwide, with substantial variations in incidence, stage at diagnosis and outcomes across regions. High-quality, standardised diagnosis and treatment are essential to improving survival and quality of life. Multidisciplinary care (MDC) is a cornerstone of cancer care; however, its implementation faces barriers such as limited resources, uneven policy support and inequitable access to specialised care, particularly in low- and middle-income cou…
Rank96.0
Best practices for respiratory function training in perioperative patients with lung cancer: A scoping review and evidence synthesis.
Asia-Pacific journal of oncology nursing · 2026 · PMID 42472225
OBJECTIVE: To identify, evaluate, and synthesize the best available evidence for respiratory function training (RFT) in perioperative patients with lung cancer, with the aim of providing guidance for clinical practice and facilitating evidence-based decision-making. METHODS: A dual design of scoping review and evidence synthesis was adopted. We comprehensively searched 9 Chinese and English academic databases, and 13 clinical guideline and professional society platforms, from the inception of each database to Febru…
Rank96.0
Systematic Review and Meta-Analysis of 2-[18F]Fluoro-2-Deoxy-d-Glucose PET-CT Imaging for Nodal Staging of Part-Solid Lung Adenocarcinomas.
Chest · 2026 · PMID 42556560
BACKGROUND: Lung adenocarcinoma is the most prevalent subtype of lung cancer. When presenting as ground-glass or part-solid nodules, lung adenocarcinomas typically show slow growth, rarely metastasize, and have low 2-[18F]fluoro-2-deoxy-d-glucose (FDG) avidity. Retrospective evidence demonstrated limited value of FDG PET-CT scan staging in T1 part-solid lung cancers. The National Institute for Health and Care Excellence recommends FDG PET-CT imaging to confirm localized disease in patients eligible for radical trea…
Rank96.0
Comment on "Artificial intelligence construction: a review of the bridge between CT imaging features of lung ground-glass nodules adenocarcinoma and carcinogenic driver genes".
Journal of cancer research and clinical oncology · 2026 · PMID 42661070
Xue and Chen et al.'s review connects AI-derived CT features of lung ground-glass nodule adenocarcinoma to driver gene status. Three aspects are missing. There is no stated search strategy no databases, date range, or inclusion criteria despite drawing on more than 150 references, so readers cannot tell whether weaker or null results were sought out or just left aside. Individual studies are cited by their best accuracy or AUC figures, from approximately 0.64 to above 0.95, with no attempt to weigh them by sample s…
Rank94.9
Comparison of Computed Tomography Ventilation Imaging and Hyperpolarized 3He Magnetic Resonance Imaging in Patients With Lung Cancer.
International journal of radiation oncology, biology, physics · 2026 · PMID 41802548
PURPOSE: Computed tomography ventilation imaging (CTVI) has great potential for clinical translation and has been validated in numerous studies. However, previous studies focused on image comparisons, and little is known about the dosimetric implications of "good" or "poor" image correlations or agreements in radiation therapy (RT). This study assessed the agreement of dose-function metrics between CTVI and hyperpolarized 3He magnetic resonance imaging (MRI) as a reference. METHODS AND MATERIALS: This study include…
Rank94.1
Validation of the lung immune prognostic index in extensive-stage small cell lung cancer: Post hoc analysis of the caspian and IMpower133 phase 3 trials.
European journal of cancer (Oxford, England : 1990) · 2026 · PMID 42520592
BACKGROUND: The Lung Immune Prognostic Index (LIPI) is an inflammation-based biomarker associated with outcomes to immunotherapy across several tumor types. Its prognostic value in extensive-stage small-cell lung cancer (ES-SCLC), however, remains insufficiently validated. We aimed to validate the prognostic impact of LIPI in ES-SCLC using data from two phase III trials. METHODS: Patients enrolled in the CASPIAN (NCT03043872) and IMpower133 (NCT02763579) trials were included. LIPI groups were defined as good (dNLR<…
Rank92.0
Randomised trial of delivering co-located, personalised stop-smoking support within lung cancer screening: the YESS study.
Thorax · 2026 · PMID 41825863
INTRODUCTION: Lung cancer screening (LCS) with low-dose CT offers a teachable moment for smoking cessation (SC), but the optimal way to implement SC within LCS is unclear. The Yorkshire Enhanced Stop Smoking (YESS) study assessed the efficacy of a personalised stop-smoking intervention delivered alongside LCS. METHODS: Opt-out, co-located SC support, comprising nicotine replacement therapy/e-cigarettes/pharmacotherapy and behavioural support, was offered to all individuals who currently smoked attending for LCS. Fo…
Evidence Syntheses113 records
Rank112.0
ESTRO clinical practice guideline on high-dose thoracic reirradiation for non-small cell lung cancer.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2026 · PMID 42468604
PURPOSE: High-dose thoracic reirradiation is increasingly used in clinical practice for patients with non-small cell lung cancer (NSCLC) in a variety of clinical scenarios ranging from locoregional recurrence to selected metastatic settings. The treatment goals of thoracic reirradiation include durable local control, symptom palliation, and potential cure. Despite growing clinical adoption, high-quality randomised evidence guiding patient selection, treatment delivery, and integration with systemic therapy remains …
Rank112.0
SEPAR-SECT recommendations for perioperative invasive mediastinal staging of non-small cell lung cancer.
Cirugia espanola · 2026 · PMID 42373333
Accurate mediastinal nodal staging is essential for the management of non-small cell lung cancer (NSCLC), as it refines prognosis, guides multimodal treatment, and improves survival. This joint consensus document from the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) and the Spanish Society of Thoracic Surgeons (SECT) updates and expands the 2011 SEPAR guidelines, incorporating the 9th edition of the TNM classification and extending recommendations to the entire perioperative setting, including both p…
Rank112.0
SEPAR-SECT Recommendations for Perioperative Invasive Mediastinal Staging of Non-small Cell Lung Cancer.
Archivos de bronconeumologia · 2026 · PMID 42276952
Accurate mediastinal nodal staging is essential for the management of non-small cell lung cancer (NSCLC), as it refines prognosis, guides multimodal treatment, and improves survival. This joint consensus document from the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) and the Spanish Society of Thoracic Surgeons (SECT) updates and expands the 2011 SEPAR guidelines, incorporating the 9th edition of the TNM classification and extending recommendations to the entire perioperative setting, including both p…
Rank110.0
ERS/ESGE/ESTS clinical practice guidelines on endobronchial and oesophageal endosonography for the diagnosis and staging of lung cancer.
The European respiratory journal · 2026 · PMID 42167778
BACKGROUND: In lung cancer, adequate treatment selection relies on accurate diagnosis and staging. Tissue sampling is generally indicated. This guideline explores the role of endosonography via the major airways (endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)) and oesophagus (endoscopic transoesophageal ultrasound-guided fine-needle aspiration (EUS-FNA)). EUS-FNA can also be performed using an EBUS scope (EUS-B-FNA). METHODS: Task force members were selected from the European Respirato…
Rank110.0
NCCN Guidelines® Insights: Small Cell Lung Cancer, Version 2.2026.
Journal of the National Comprehensive Cancer Network : JNCCN · 2026 · PMID 41671459
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Small Cell Lung Cancer provide recommendations for diagnostic workup, staging, and treatment. These NCCN Guidelines Insights highlight recent updates, with a particular focus on changes to systemic therapies and radiation treatment in the NCCN Guidelines for Small Cell Lung Cancer.
Rank110.0
Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology.
Journal of the National Comprehensive Cancer Network : JNCCN · 2024 · PMID 38754467
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC) provide recommendations for the treatment of patients with NSCLC, including diagnosis, primary disease management, surveillance for relapse, and subsequent treatment. The panel has updated the list of recommended targeted therapies based on recent FDA approvals and clinical data. This selection from the NCCN Guidelines for NSCLC focuses on treatment recommendations for advanced or metastatic NSCLC with actiona…
Rank110.0
Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.2.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026 · PMID 42372216
[Box: see text]Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual. ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines. Living Guidelines and updates a…
Rank110.0
Risk of Liver Cancer From Major Causes Compared to Smoking and Lung Cancer: A Systematic Review and Meta-Analysis.
Journal of viral hepatitis · 2026 · PMID 42605247
Liver cancer is the second leading cause of premature cancer mortality globally, whose main causes-HBV, HCV, MASH and alcohol use-are preventable. Viral hepatitis' carcinogenicity is not as well-known as the risk of lung cancer from smoking, leading to rising rates of liver cancer worldwide. The aim of this study was to compare the risk of liver cancer in HBV, HCV, HDV, MASH and alcohol consumption with the better-known risk of lung cancer associated with smoking. We extracted the relative risk of liver cancer from…
Rank110.0
The Society of Thoracic Surgeons Expert Consensus Document (2026) on Addressing Definition and Practices of Sublobar Resection in Non-Small Cell Lung Cancer.
The Annals of thoracic surgery · 2026 · PMID 42320552
BACKGROUND: Two recent randomized clinical trials have shown sublobar resection to be noninferior to lobectomy in node-negative non-small cell lung cancer ≤2 cm. As a result, the use of sublobar resection in early lung cancer patients has significantly increased. Consensus recommendations are needed to guide its appropriate use. METHODS: The Society of Thoracic Surgeons Workforce on Evidence-Based Surgery assembled a panel of thoracic surgeons with clinical and methodological expertise to review the existing litera…
Rank110.0
Radiologist's Guide to the Ninth Edition TNM Staging System for Quantitative and Qualitative Assessment of Pleural Mesothelioma.
Radiology · 2025 · PMID 40956163
Pleural mesothelioma is a highly lethal, rare thoracic malignant neoplasm arising from mesothelial cells. Previous versions of the clinical TNM staging classification have relied on a qualitative radiologic assessment of tumor invasion. However, these qualitative assessments have not proved practical to implement, with poor interobserver agreement and lack of prognostic significance. The updated ninth edition of the International Association for the Study of Lung Cancer TNM staging system for pleural mesothelioma, …
Rank109.8
Prognosis of Patients with Lung Cancer Admitted to the Intensive Care Unit: A Systematic Review and Meta-Analysis.
Journal of intensive care medicine · 2026 · PMID 40370214
IntroductionDespite recent advances in the care of critically ill patients with cancer, studies show that lung cancer is associated with higher Intensive Care Unit (ICU) mortality than other types of cancer. This systematic review and meta-analysis aim to investigate the ICU outcomes and predictors of mortality in critically ill patients with lung cancer.MethodsPubMed, OVID MEDLINE, Cochrane and Embase were searched to identify relevant studies. The primary outcome was ICU mortality. The secondary outcomes were hos…
Rank109.7
Robotic-assisted versus video-assisted thoracoscopic anatomical lung resection for early-stage non-small cell lung cancer: a systematic review and meta-analysis.
Journal of robotic surgery · 2026 · PMID 42684651
Non-small cell lung cancer (NSCLC) represents 80-85% of lung cancer cases. Anatomical resection remains the cornerstone treatment for early-stage disease. Video-assisted (VATS) and robotic-assisted (RATS) thoracic surgery are alternatives to thoracotomy, though RATS's advantages over VATS remain controversial. We conducted this systematic review and meta-analysis to compare their perioperative and oncologic outcomes for anatomical resection in early-stage NSCLC. We searched PubMed, Cochrane Library, CINAHL, Web of …
Rank109.6
Radiomics-Based AI for Predicting Neoadjuvant Immunochemotherapy Pathological Response in Non-Small Cell Lung Cancer: Systematic Review and Meta-Analysis.
Journal of medical Internet research · 2026 · PMID 42596052
BACKGROUND: Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality worldwide. Accurate early prediction of response to neoadjuvant therapy is critical. OBJECTIVE: We aimed to evaluate the diagnostic performance of radiomics-based AI in predicting pathological complete response (pCR) and major pathological response (MPR) following neoadjuvant immunochemotherapy in NSCLC and to compare it against traditional radiological criteria. METHODS: A systematic search of PubMed, Embase, Cochr…
Rank109.6
Mortality burden of pre-treatment weight loss in patients with non-small-cell lung cancer: A systematic literature review and meta-analysis.
Journal of cachexia, sarcopenia and muscle · 2024 · PMID 38650388
Cachexia, with weight loss (WL) as a major component, is highly prevalent in patients with cancer and indicates a poor prognosis. The primary objective of this study was to conduct a meta-analysis to estimate the risk of mortality associated with cachexia (using established WL criteria prior to treatment initiation) in patients with non-small-cell lung cancer (NSCLC) in studies identified through a systematic literature review. The review was conducted according to PRISMA guidelines. Embase® and PubMed were searche…
Rank109.3
Long-term hormone therapy for perimenopausal and postmenopausal women.
The Cochrane database of systematic reviews · 2026 · PMID 42695385
BACKGROUND: Hormone therapy is widely provided to control menopausal symptoms and has been used for the management and prevention of cardiovascular disease, osteoporosis and dementia in older women. This is an updated version of a Cochrane review first published in 2005. OBJECTIVES: To assess the long-term effects of prolonged use (at least one year) of hormone therapy on mortality, cardiovascular outcomes, cancer, gallbladder disease, fractures and cognition in perimenopausal and postmenopausal women. SEARCH METHO…
Rank109.3
Renin-angiotensin system inhibitors and immunotherapy outcomes in lung cancer: a systematic review and meta-analysis with complementary transcriptomic analyses.
Frontiers in immunology · 2026 · PMID 42688457
BACKGROUND: The tumor microenvironment has emerged as an important determinant of response to immune checkpoint inhibitors (ICIs), with increasing attention directed toward stromal components such as cancer-associated fibroblasts (CAFs). Experimental evidence suggests that renin-angiotensin system (RAS) signaling may participate in stromal remodeling and immune regulation, raising interest in whether RAS inhibitors could influence immunotherapy outcomes. However, clinical findings remain inconsistent and the extent…
Rank109.1
Efficacy and safety of bispecific antibodies versus other antitumor therapies in solid tumors: a systematic review and meta-analysis.
Frontiers in immunology · 2026 · PMID 42694493
BACKGROUND: Bispecific antibodies (BsAbs) have emerged as a promising strategy for solid tumor treatment, yet their comparative efficacy and safety versus other antitumor therapies remain unclear. MATERIALS AND METHODS: Literature was systematically searched in PubMed, Embase, Cochrane Library, and Scopus from inception up to August 2026. American Society of Clinical Oncology (ASCO), European Society for Medical Oncology (ESMO) and clinicaltrials.gov were also checked. Progression-free survival (PFS), overall survi…
Rank108.7
Dosimetric Parameters of the Heart and Its Substructures in Predicting Cardiac Events or Survival in Patients With Lung Cancer After Radiation Therapy: A Systematic Review and Meta-analysis.
International journal of radiation oncology, biology, physics · 2026 · PMID 42288290
The predictive value of radiation dose to the whole heart (WH) and cardiac substructures (CS) for cardiac events (CEs) and survival in patients with lung cancer remains uncertain. The goal of this study was to conduct a systematic review and meta-analysis to provide an evidence-based estimate of the relationship between these associations. A systematic meta-analysis was performed following PRISMA guidelines. Risk of bias was assessed using the JBI Critical Appraisal Checklist for Case Series. Outcomes were classifi…
Rank108.6
Incidence and risk factors for malignancy in patients with incidental solitary pulmonary nodules: a systematic review and meta-analysis.
Annals of medicine · 2026 · PMID 41641734
BACKGROUND: The increasing use of chest imaging has led to a higher detection rate of incidental solitary pulmonary nodules (SPNs), often causing patient anxiety. Determining the malignancy rate and associated risk factors is crucial for developing appropriate follow-up strategies to prevent overdiagnosis, overtreatment, or missed diagnoses. This meta-analysis aims to investigate the malignancy rate and risk factors in patients with incidental SPNs. METHODS: A systematic search of PubMed, Embase, Web of Science, an…
Rank108.6
Prognostic values and clinical significance of POU2F3 expression in neuroendocrine carcinomas: a meta-analysis with a focus on small cell lung cancer.
Annals of medicine · 2025 · PMID 40931642
BACKGROUND: Small cell lung cancer (SCLC) is a highly aggressive neuroendocrine carcinoma (NEC) with poor prognosis due to chemotherapy resistance. Molecular subtypes, including ASCL1, NEUROD1, YAP1 and POU2F3, have distinct clinical implications. POU2F3, linked to a tuft cell-like lineage, represents a non-neuroendocrine subtype found in SCLC and extrapulmonary NECs. However, its prognostic and clinical significance remain unclear. METHODS: A meta-analysis was performed to assess the relationship between POU2F3 ex…
Rank108.3
Outcomes of robotic vs video-assisted thoracoscopic segmentectomy in early-stage NSCLC: A meta-analysis of propensity-matched studies.
Lung cancer (Amsterdam, Netherlands) · 2026 · PMID 42456640
INTRODUCTION: Robotic-assisted thoracoscopic segmentectomy (RATS) has been increasingly adopted for early-stage non-small cell lung cancer (NSCLC), yet comparative effectiveness versus video-assisted thoracoscopic segmentectomy (VATS) remains uncertain. We performed a meta-analysis restricted to propensity-matched studies to compare perioperative and oncologic outcomes between approaches. METHODS: A comprehensive literature search was conducted to identify studies comparing RATS and VATS. Pooled odds ratios (ORs) a…
Rank108.3
Efficacy and safety of immunotherapy in driver mutation-negative advanced non-small cell lung cancer: A systematic review and meta-analysis.
The Indian journal of medical research · 2026 · PMID 42555694
Background and objectives Despite substantial research on immunotherapy, its efficacy and safety in treating advanced non-small cell lung cancer (NSCLC) without identifiable driver mutations remain unclear. The objective of this review was to examine the efficacy and safety of immunotherapy, used as monotherapy or alongside chemotherapy, vs. chemotherapy alone in patients with advanced driver mutation-negative NSCLC. Methods A comprehensive literature search of PubMed, Embase, Scopus, and CENTRAL databases was cond…
Rank107.8
First-line systemic treatment for people with extensive-stage small cell lung cancer: a network meta-analysis.
The Cochrane database of systematic reviews · 2026 · PMID 42578486
RATIONALE: Extensive-stage small cell lung cancer (SCLC) carries a poor prognosis and has limited therapeutic options. The addition of immune-checkpoint inhibitors (ICIs) to platinum-etoposide (PE) chemotherapy has become an important first-line treatment strategy. However, the comparative benefits and harms of different first-line chemotherapy-based regimens, including ICI-containing combinations, remain unclear. OBJECTIVES: To evaluate the comparative benefits and harms of immunotherapy (anti-PD-1, anti-PD-L1, or…
Rank107.8
The risk of primary lung cancer in ANCA-associated vasculitis: systematic review and meta-analysis.
Proceedings (Baylor University. Medical Center) · 2026 · PMID 42376993
BACKGROUND: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a systemic inflammatory disorder that affects small blood vessels. However, the association between AAV and lung cancer risk remains uncertain. We performed a systematic review and meta-analysis to evaluate the relationship between AAV and the risk of lung cancer. METHODS: We systematically searched PubMed, Embase, Scopus, and Web of Science from inception through March 2025. Studies reporting relative risks (RRs), odds ratios (OR…
Rank107.8
The clinical value of adding immune checkpoint inhibitors to radiotherapy for cancer: a systematic review and meta-analysis.
Annals of medicine · 2026 · PMID 42613912
BACKGROUND: While several randomized clinical trials (RCTs) have explored the addition of immune checkpoint inhibitor (ICI) treatment for patients undergoing radiotherapy, studies systematically assessing the clinical value of such interventions are lacking. METHODS: PubMed, Embase, and Cochrane Library databases were searched for relevant RCTs of cancers that received ICIs plus radiotherapy or radiotherapy. Eligible studies were those published in English as of 14 April 2024. Two independent reviewers screened the…
Landmark Evidence79 records
Rank110.0
Radiologist's Guide to the Ninth Edition TNM Staging System for Quantitative and Qualitative Assessment of Pleural Mesothelioma.
Radiology · 2025 · PMID 40956163
Pleural mesothelioma is a highly lethal, rare thoracic malignant neoplasm arising from mesothelial cells. Previous versions of the clinical TNM staging classification have relied on a qualitative radiologic assessment of tumor invasion. However, these qualitative assessments have not proved practical to implement, with poor interobserver agreement and lack of prognostic significance. The updated ninth edition of the International Association for the Study of Lung Cancer TNM staging system for pleural mesothelioma, …
Rank110.0
The Society of Thoracic Surgeons Expert Consensus Document (2026) on Addressing Definition and Practices of Sublobar Resection in Non-Small Cell Lung Cancer.
The Annals of thoracic surgery · 2026 · PMID 42320552
BACKGROUND: Two recent randomized clinical trials have shown sublobar resection to be noninferior to lobectomy in node-negative non-small cell lung cancer ≤2 cm. As a result, the use of sublobar resection in early lung cancer patients has significantly increased. Consensus recommendations are needed to guide its appropriate use. METHODS: The Society of Thoracic Surgeons Workforce on Evidence-Based Surgery assembled a panel of thoracic surgeons with clinical and methodological expertise to review the existing litera…
Rank110.0
Management of Patients With Early-Stage Non-Small Cell Lung Cancer: An American College of Chest Physicians Clinical Practice Guideline.
Chest · 2025 · PMID 40562304
BACKGROUND: Lung cancer remains the number 1 cause of cancer death in men and women in the United States and much of the world. This CHEST organization guideline examines the literature on primary treatment of patients with stage I and II non-small cell lung cancer (NSCLC) to provide evidence-based recommendations. STUDY DESIGN AND METHODS: An expert panel conducted a systematic review addressing the treatment options for patients with stage I/II NSCLC and applied the Grading of Recommendations, Assessment, Develop…
Rank110.0
Risk of Liver Cancer From Major Causes Compared to Smoking and Lung Cancer: A Systematic Review and Meta-Analysis.
Journal of viral hepatitis · 2026 · PMID 42605247
Liver cancer is the second leading cause of premature cancer mortality globally, whose main causes-HBV, HCV, MASH and alcohol use-are preventable. Viral hepatitis' carcinogenicity is not as well-known as the risk of lung cancer from smoking, leading to rising rates of liver cancer worldwide. The aim of this study was to compare the risk of liver cancer in HBV, HCV, HDV, MASH and alcohol consumption with the better-known risk of lung cancer associated with smoking. We extracted the relative risk of liver cancer from…
Rank109.6
Recurrence-Free Survival in Patients With Surgically Resected Non-Small Cell Lung Cancer: A Systematic Literature Review and Meta-Analysis.
Chest · 2024 · PMID 38065405
BACKGROUND: Standard treatment for early-stage or locoregionally advanced non-small cell lung cancer (NSCLC) includes surgical resection. Recurrence after surgery is commonly reported, but a summary estimate for postsurgical recurrence-free survival (RFS) in patients with NSCLC is lacking. RESEARCH QUESTION: What is the RFS after surgery in patients with stage I-III NSCLC at different time points, and what factors are associated with RFS? STUDY DESIGN AND METHODS: A systematic search was performed in MEDLINE, EMBAS…
Rank107.8
The risk of primary lung cancer in ANCA-associated vasculitis: systematic review and meta-analysis.
Proceedings (Baylor University. Medical Center) · 2026 · PMID 42376993
BACKGROUND: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a systemic inflammatory disorder that affects small blood vessels. However, the association between AAV and lung cancer risk remains uncertain. We performed a systematic review and meta-analysis to evaluate the relationship between AAV and the risk of lung cancer. METHODS: We systematically searched PubMed, Embase, Scopus, and Web of Science from inception through March 2025. Studies reporting relative risks (RRs), odds ratios (OR…
Rank107.2
Estrogen receptor subtypes and survival outcomes in non-small cell lung cancer.
Pathology, research and practice · 2025 · PMID 40009905
AIM: Estrogen receptors (ERs), ERα and ERβ, are frequently detected in lung cancers, yet their prognostic impact on non-small cell lung cancer (NSCLC) outcomes remains uncertain. This study aims to assess the pooled prevalence and prognostic significance of ERα and ERβ in NSCLC, with a focus on gender differences. METHODS: We performed a systematic review and meta-analysis, identifying studies from major databases, including PubMed, Cochrane Library, and Embase, that reported ERα and ERβ expression and survival out…
Rank107.1
Surgical and safety outcomes in patients with non-small cell lung cancer receiving neoadjuvant chemoimmunotherapy versus chemotherapy alone: A systematic review and meta-analysis.
Cancer treatment reviews · 2024 · PMID 39369455
Neoadjuvant immune checkpoint blockade (ICB) combined with chemotherapy has improved survival outcomes in locally-advanced non-small cell lung cancer (NSCLC). However, its impact on surgery has not been fully elucidated. We performed a systematic review and meta-analysis to compare surgical outcomes between neoadjuvant chemoimmunotherapy and chemotherapy alone in resectable NSCLC. PubMed and Embase were searched to select randomized controlled trials (RCTs) evaluating neoadjuvant ICB therapy for resectable NSCLC. T…
Rank106.9
Efficacy and safety of durvalumab with or without tremelimumab in the treatment of metastatic non-small cell lung cancer: a meta-analysis of randomized controlled trials.
Proceedings (Baylor University. Medical Center) · 2026 · PMID 42658167
BACKGROUND: The therapeutic role of combining PD-L1 and CTLA-4 blockade in metastatic non-small cell lung cancer (NSCLC) remains unclear, with individual trials yielding discrepant results. METHODS: We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) to assess the efficacy and safety of durvalumab with or without tremelimumab in advanced NSCLC. The primary outcome was overall survival. Secondary outcomes included immune-related adverse events. Hazard ratios (HRs) and odds ratio…
Rank106.6
Prognostic value of albumin-bilirubin grade in lung cancer: a meta-analysis.
Journal of cardiothoracic surgery · 2024 · PMID 39734193
PURPOSE: To clarify the prognostic role of pretreatment albumin-bilirubin (ALBI) grade in lung cancer patients. METHODS: The PubMed, EMBASE, Web of Science and CNKI databases were searched up to April 20, 2024. Primary outcomes included the overall survival (OS), progression-free survival (PFS) and cancer-specific survival (CSS). Hazard ratios (HRs) with 95% confidence intervals (CIs) were combined and subgroup analysis based on the type of lung cancer [non-small cell lung cancer (NSCLC) vs. small cell lung cancer …
Rank106.5
Associations between tertiary lymphoid structure density and immune checkpoint inhibitor efficacy in solid tumors: systematic review and meta-analysis.
Frontiers in immunology · 2024 · PMID 39544934
BACKGROUND: Tertiary lymphoid structures (TLS) play a crucial role in tumor immunity, yet their relationship with the efficacy of immune checkpoint inhibitors (ICI) in cancer therapy is not fully understood. This study aims to systematically evaluate how TLS density influences treatment outcomes in cancer patients receiving ICI therapy. METHODS: The PubMed, Embase, Cochrane Library, and Web of Science databases were searched for eligible studies published before January 22, 2024. Our analysis encompassed odds ratio…
Rank105.0
Sex difference in response to non-small cell lung cancer immunotherapy: an updated meta-analysis.
Annals of medicine · 2022 · PMID 36128737
BACKGROUND: Studying sex differences in the efficacy of immunotherapy may contribute to the practice of the precision medicine, especially in non-small cell lung cancer (NSCLC), a kind of cancer with sexual bimorphism. METHODS: Published randomized controlled trials (RCTs), published by PubMed, Medline, Embase, and Scopus, before 15 June 2022, testing immunotherapy (CTLA-4 or PD-1/L1 inhibitor alone, combination or with chemotherapy) versus non-immunotherapy (receiving chemotherapy or placebo only) were included to…
Rank105.0
Prognostic value of consolidation-to-tumor ratio on computed tomography in NSCLC: a meta-analysis.
World journal of surgical oncology · 2023 · PMID 37349739
BACKGROUND: Although several studies have confirmed the prognostic value of the consolidation to tumor ratio (CTR) in non-small cell lung cancer (NSCLC), there still remains controversial about it. METHODS: We systematically searched the PubMed, Embase, and Web of Science databases from inception to April, 2022 for eligible studies that reported the correlation between CTR and prognosis in NSCLC. Hazard ratios (HRs) with 95% confidence intervals (95% CIs) were extracted and pooled to assess the overall effects. Het…
Rank104.8
Perioperative antifibrotic therapy for patients with idiopathic pulmonary fibrosis undergoing lung cancer surgery: A systematic review and meta-analysis.
Heart & lung : the journal of critical care · 2025 · PMID 40789229
BACKGROUND: Patients with idiopathic pulmonary fibrosis (IPF) undergoing lung cancer surgery face a 4.4-20 % risk of acute exacerbation (AE-IPF) with mortality exceeding 50 %. The potential role of perioperative antifibrotic therapy in reducing surgical complications in this high-risk population remains unclear. OBJECTIVES: To evaluate whether perioperative antifibrotic therapy (pirfenidone/nintedanib) reduces complications, particularly acute exacerbations and mortality, in IPF patients undergoing lung cancer surg…
Rank104.8
Necrotizing and Nonnecrotizing Granulomatous Reactions in Patients With Cancer Treated With Immune Checkpoint Inhibitors: A Systematic Literature Review.
The Journal of rheumatology · 2025 · PMID 40664481
OBJECTIVE: Immune checkpoint inhibitors (ICI) have improved cancer outcomes but often cause immune-related adverse events, including granulomatous reactions (GRs). We analyzed GRs in patients receiving anticytotoxic T-lymphocyte-associated protein 4 (anti-CTLA4), antiprogrammed cell death protein 1 (anti-PD1)/antiprogrammed death ligand 1 (anti-PDL1), and anti-CTLA4/anti-PD1 therapies. METHODS: We performed a literature review of GRs in patients receiving ICI. Data were extracted from 166 articles, including demogr…
Rank104.3
Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies.
European journal of cancer (Oxford, England : 1990) · 2023 · PMID 37948842
BACKGROUND: In non-small cell lung cancer (NSCLC), the immune checkpoint inhibitors (ICI) revolution is rapidly moving from metastatic to early-stage, however, the impact of clinicopathological variables and optimal treatment sequencing remain unclear. METHODS: Randomized controlled trials (RCTs) in patients with early-stage NSCLC treated with ICI as single agent or in combination with platinum-based chemotherapy (PCT) were included. Primary outcomes were pathological complete response (pCR), event free survival (E…
Rank104.1
Comprehensive Analysis of Lung Cancer Metastasis: Sites, Rates, Survival, and Risk Factors-A Systematic Review and Meta-Analysis.
The clinical respiratory journal · 2025 · PMID 40650339
OBJECTIVES: Lung cancer metastasis constitutes a critical aspect of disease progression and patient outcomes. It is imperative to illuminate the complex landscape of lung cancer metastasis, offering a thorough evaluation of sites, rates, risk factors, and survival implications. METHODS: Studies on the prevalence of lung cancer metastasis, the risk factors, the overall survival (OS) after metastasis, or the risk factors for OS were included. Two independent reviewers used a standardized data extraction and quality a…
Rank104.0
Asbestos exposure and small cell lung cancer: Systematic review and meta-analysis.
Journal of occupational and environmental hygiene · 2023 · PMID 37405865
Asbestos is a mineral that is carcinogenic to humans. Its use has been banned in many occidental countries yet it is still produced in the United States, and materials that contain asbestos remain in many occupational settings and indoor environments. Even though asbestos carcinogenicity is well known, there is scant literature on its specific effects regarding small cell lung cancer (SCLC). We therefore conducted a systematic review and meta-analysis to determine SCLC risk among workers exposed to asbestos. A syst…
Rank103.9
Chemotherapy or chemo-immunotherapy as first-line treatment for extensive-stage small-cell lung cancer: a meta-analysis.
Immunotherapy · 2021 · PMID 34261336
This meta-analysis investigated the clinical benefits of chemo-immunotherapy in extensive-stage small-cell lung cancer (ES-SCLC). Seven randomized controlled trials with a total of 2862 patients were analyzed. Compared with chemotherapy alone, chemo-immunotherapy provided a better progression-free survival (PFS) with a hazard ratio (HR) of 0.81, p < 0.00001, and overall survival (OS) with a HR of 0.82, p < 0.0001; however, the incidence of treatment-related adverse effects (TRAEs) was significantly increased. Subgr…
Rank103.5
Osimertinib in the Treatment of EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer: A Meta-Analysis.
Pharmacology · 2023 · PMID 36470213
BACKGROUND: Non-small cell lung cancer (NSCLC) accounts for about 85% of generally reported lung cancer patients. OBJECTIVES: This is a systematic review of the clinical efficacy and safety of osimertinib in treating epidermal growth factor receptor (EGFR) mutation-positive advanced NSCLC. METHODS: A network search was completed for clinical research literature (from inception of each database to May 30, 2020) on osimertinib for EGFR mutation-positive advanced NSCLC. Strict inclusion and exclusion criteria were for…
Rank103.4
Stevens-Johnson syndrome and toxic epidermal necrolysis associated with immune checkpoint inhibitors: a systematic review.
Frontiers in immunology · 2024 · PMID 39072330
INTRODUCTION: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare yet life-threatening adverse events associated with immune checkpoint inhibitors (ICIs). This systematic review synthesizes the current literature to elucidate the clinical characteristics and outcomes of patients with ICI-related SJS/TEN. METHODS: We conducted a thorough search across databases including Embase, Web of Science, Cochrane, MEDLINE, Scopus, and PubMed. Selection criteria focused on reports of SJS/TEN among canc…
Rank103.0
ACR Appropriateness Criteria® Noninvasive Clinical Staging of Primary Lung Cancer.
Journal of the American College of Radiology : JACR · 2019 · PMID 31054745
Lung cancer is the leading cause of cancer-related deaths in both men and women. The major risk factor for lung cancer is personal tobacco smoking, particularly for small-cell lung cancer (SCLC) and squamous cell lung cancers, but other significant risk factors include exposure to secondhand smoke, environmental radon, occupational exposures, and air pollution. Education and socioeconomic status affect both incidence and outcomes. Non-small-cell lung cancer (NSCLC), including adenocarcinoma, squamous cell carcinoma…
Rank102.8
Neoadjuvant Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer.
Journal of the College of Physicians and Surgeons--Pakistan : JCPSP · 2022 · PMID 35686412
Lung cancer is the leading cause of cancer-related death worldwide. A meta-analysis was conducted to assess the benefits and risks of neoadjuvant immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC). Online databases, including PubMed, Embase, Web of Science, Cochrane Library, and clinicaltrials.gov, were retrospectively and systematically searched for eligible trials from database inception to May 2021. A total of 792 patients from 21 clinical trials were included. For surgical data, the poole…
Rank102.0
The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis.
Oncotarget · 2016 · PMID 27738317
OBJECTIVES: Estimate the epidermal growth factor receptor (EGFR) mutation prevalence in all non-small cell lung cancer (NSCLC) patients and patient subgroups. RESULTS: A total of 456 studies were included, reporting 30,466 patients with EGFR mutation among 115,815 NSCLC patients. The overall pooled prevalence for EGFR mutations was 32.3% (95% CI 30.9% to 33.7%), ranging from 38.4% (95% CI: 36.5% to 40.3%) in China to 14.1% (95% CI: 12.7% to 15.5%) in Europe. The pooled prevalence of EGFR mutation was higher in fema…
Rank101.5
Clinical Outcomes of Immune Checkpoint Inhibitor Therapy in Patients With Advanced Non-small Cell Lung Cancer and Preexisting Interstitial Lung Diseases: A Systematic Review and Meta-analysis.
Chest · 2022 · PMID 35026298
BACKGROUND: Patients with non-small cell lung cancer (NSCLC) and preexisting interstitial lung disease (ILD) are often excluded from clinical trials of immune checkpoint inhibitors (ICIs), leaving a gap in knowledge. RESEARCH QUESTION: What are the clinical outcomes of ICIs in patients with NSCLC and preexisting ILD? STUDY DESIGN AND METHODS: Systematic searches were conducted of PubMed, EMBASE, and Cochrane Library through April 2021 with no language or study design restrictions. Studies reporting the safety and e…
Most Effective Evidence Supported Treatments160 records
Rank112.0
ESTRO clinical practice guideline on high-dose thoracic reirradiation for non-small cell lung cancer.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2026 · PMID 42468604
PURPOSE: High-dose thoracic reirradiation is increasingly used in clinical practice for patients with non-small cell lung cancer (NSCLC) in a variety of clinical scenarios ranging from locoregional recurrence to selected metastatic settings. The treatment goals of thoracic reirradiation include durable local control, symptom palliation, and potential cure. Despite growing clinical adoption, high-quality randomised evidence guiding patient selection, treatment delivery, and integration with systemic therapy remains …
Rank112.0
SEPAR-SECT Recommendations for Perioperative Invasive Mediastinal Staging of Non-small Cell Lung Cancer.
Archivos de bronconeumologia · 2026 · PMID 42276952
Accurate mediastinal nodal staging is essential for the management of non-small cell lung cancer (NSCLC), as it refines prognosis, guides multimodal treatment, and improves survival. This joint consensus document from the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) and the Spanish Society of Thoracic Surgeons (SECT) updates and expands the 2011 SEPAR guidelines, incorporating the 9th edition of the TNM classification and extending recommendations to the entire perioperative setting, including both p…
Rank110.0
Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.2.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026 · PMID 42372216
[Box: see text]Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual. ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines. Living Guidelines and updates a…
Rank110.0
Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology.
Journal of the National Comprehensive Cancer Network : JNCCN · 2024 · PMID 38754467
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC) provide recommendations for the treatment of patients with NSCLC, including diagnosis, primary disease management, surveillance for relapse, and subsequent treatment. The panel has updated the list of recommended targeted therapies based on recent FDA approvals and clinical data. This selection from the NCCN Guidelines for NSCLC focuses on treatment recommendations for advanced or metastatic NSCLC with actiona…
Rank110.0
NCCN Guidelines® Insights: Small Cell Lung Cancer, Version 2.2026.
Journal of the National Comprehensive Cancer Network : JNCCN · 2026 · PMID 41671459
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Small Cell Lung Cancer provide recommendations for diagnostic workup, staging, and treatment. These NCCN Guidelines Insights highlight recent updates, with a particular focus on changes to systemic therapies and radiation treatment in the NCCN Guidelines for Small Cell Lung Cancer.
Rank110.0
ERS/ESGE/ESTS clinical practice guidelines on endobronchial and oesophageal endosonography for the diagnosis and staging of lung cancer.
The European respiratory journal · 2026 · PMID 42167778
BACKGROUND: In lung cancer, adequate treatment selection relies on accurate diagnosis and staging. Tissue sampling is generally indicated. This guideline explores the role of endosonography via the major airways (endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)) and oesophagus (endoscopic transoesophageal ultrasound-guided fine-needle aspiration (EUS-FNA)). EUS-FNA can also be performed using an EBUS scope (EUS-B-FNA). METHODS: Task force members were selected from the European Respirato…
Rank110.0
The Society of Thoracic Surgeons Expert Consensus Document (2026) on Addressing Definition and Practices of Sublobar Resection in Non-Small Cell Lung Cancer.
The Annals of thoracic surgery · 2026 · PMID 42320552
BACKGROUND: Two recent randomized clinical trials have shown sublobar resection to be noninferior to lobectomy in node-negative non-small cell lung cancer ≤2 cm. As a result, the use of sublobar resection in early lung cancer patients has significantly increased. Consensus recommendations are needed to guide its appropriate use. METHODS: The Society of Thoracic Surgeons Workforce on Evidence-Based Surgery assembled a panel of thoracic surgeons with clinical and methodological expertise to review the existing litera…
Rank109.8
Prognosis of Patients with Lung Cancer Admitted to the Intensive Care Unit: A Systematic Review and Meta-Analysis.
Journal of intensive care medicine · 2026 · PMID 40370214
IntroductionDespite recent advances in the care of critically ill patients with cancer, studies show that lung cancer is associated with higher Intensive Care Unit (ICU) mortality than other types of cancer. This systematic review and meta-analysis aim to investigate the ICU outcomes and predictors of mortality in critically ill patients with lung cancer.MethodsPubMed, OVID MEDLINE, Cochrane and Embase were searched to identify relevant studies. The primary outcome was ICU mortality. The secondary outcomes were hos…
Rank109.7
Robotic-assisted versus video-assisted thoracoscopic anatomical lung resection for early-stage non-small cell lung cancer: a systematic review and meta-analysis.
Journal of robotic surgery · 2026 · PMID 42684651
Non-small cell lung cancer (NSCLC) represents 80-85% of lung cancer cases. Anatomical resection remains the cornerstone treatment for early-stage disease. Video-assisted (VATS) and robotic-assisted (RATS) thoracic surgery are alternatives to thoracotomy, though RATS's advantages over VATS remain controversial. We conducted this systematic review and meta-analysis to compare their perioperative and oncologic outcomes for anatomical resection in early-stage NSCLC. We searched PubMed, Cochrane Library, CINAHL, Web of …
Rank109.6
Mortality burden of pre-treatment weight loss in patients with non-small-cell lung cancer: A systematic literature review and meta-analysis.
Journal of cachexia, sarcopenia and muscle · 2024 · PMID 38650388
Cachexia, with weight loss (WL) as a major component, is highly prevalent in patients with cancer and indicates a poor prognosis. The primary objective of this study was to conduct a meta-analysis to estimate the risk of mortality associated with cachexia (using established WL criteria prior to treatment initiation) in patients with non-small-cell lung cancer (NSCLC) in studies identified through a systematic literature review. The review was conducted according to PRISMA guidelines. Embase® and PubMed were searche…
Rank109.6
Radiomics-Based AI for Predicting Neoadjuvant Immunochemotherapy Pathological Response in Non-Small Cell Lung Cancer: Systematic Review and Meta-Analysis.
Journal of medical Internet research · 2026 · PMID 42596052
BACKGROUND: Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality worldwide. Accurate early prediction of response to neoadjuvant therapy is critical. OBJECTIVE: We aimed to evaluate the diagnostic performance of radiomics-based AI in predicting pathological complete response (pCR) and major pathological response (MPR) following neoadjuvant immunochemotherapy in NSCLC and to compare it against traditional radiological criteria. METHODS: A systematic search of PubMed, Embase, Cochr…
Rank109.3
Renin-angiotensin system inhibitors and immunotherapy outcomes in lung cancer: a systematic review and meta-analysis with complementary transcriptomic analyses.
Frontiers in immunology · 2026 · PMID 42688457
BACKGROUND: The tumor microenvironment has emerged as an important determinant of response to immune checkpoint inhibitors (ICIs), with increasing attention directed toward stromal components such as cancer-associated fibroblasts (CAFs). Experimental evidence suggests that renin-angiotensin system (RAS) signaling may participate in stromal remodeling and immune regulation, raising interest in whether RAS inhibitors could influence immunotherapy outcomes. However, clinical findings remain inconsistent and the extent…
Rank109.3
Long-term hormone therapy for perimenopausal and postmenopausal women.
The Cochrane database of systematic reviews · 2026 · PMID 42695385
BACKGROUND: Hormone therapy is widely provided to control menopausal symptoms and has been used for the management and prevention of cardiovascular disease, osteoporosis and dementia in older women. This is an updated version of a Cochrane review first published in 2005. OBJECTIVES: To assess the long-term effects of prolonged use (at least one year) of hormone therapy on mortality, cardiovascular outcomes, cancer, gallbladder disease, fractures and cognition in perimenopausal and postmenopausal women. SEARCH METHO…
Rank109.1
Efficacy and safety of bispecific antibodies versus other antitumor therapies in solid tumors: a systematic review and meta-analysis.
Frontiers in immunology · 2026 · PMID 42694493
BACKGROUND: Bispecific antibodies (BsAbs) have emerged as a promising strategy for solid tumor treatment, yet their comparative efficacy and safety versus other antitumor therapies remain unclear. MATERIALS AND METHODS: Literature was systematically searched in PubMed, Embase, Cochrane Library, and Scopus from inception up to August 2026. American Society of Clinical Oncology (ASCO), European Society for Medical Oncology (ESMO) and clinicaltrials.gov were also checked. Progression-free survival (PFS), overall survi…
Rank108.7
Dosimetric Parameters of the Heart and Its Substructures in Predicting Cardiac Events or Survival in Patients With Lung Cancer After Radiation Therapy: A Systematic Review and Meta-analysis.
International journal of radiation oncology, biology, physics · 2026 · PMID 42288290
The predictive value of radiation dose to the whole heart (WH) and cardiac substructures (CS) for cardiac events (CEs) and survival in patients with lung cancer remains uncertain. The goal of this study was to conduct a systematic review and meta-analysis to provide an evidence-based estimate of the relationship between these associations. A systematic meta-analysis was performed following PRISMA guidelines. Risk of bias was assessed using the JBI Critical Appraisal Checklist for Case Series. Outcomes were classifi…
Rank108.3
Outcomes of robotic vs video-assisted thoracoscopic segmentectomy in early-stage NSCLC: A meta-analysis of propensity-matched studies.
Lung cancer (Amsterdam, Netherlands) · 2026 · PMID 42456640
INTRODUCTION: Robotic-assisted thoracoscopic segmentectomy (RATS) has been increasingly adopted for early-stage non-small cell lung cancer (NSCLC), yet comparative effectiveness versus video-assisted thoracoscopic segmentectomy (VATS) remains uncertain. We performed a meta-analysis restricted to propensity-matched studies to compare perioperative and oncologic outcomes between approaches. METHODS: A comprehensive literature search was conducted to identify studies comparing RATS and VATS. Pooled odds ratios (ORs) a…
Rank108.3
Efficacy and safety of immunotherapy in driver mutation-negative advanced non-small cell lung cancer: A systematic review and meta-analysis.
The Indian journal of medical research · 2026 · PMID 42555694
Background and objectives Despite substantial research on immunotherapy, its efficacy and safety in treating advanced non-small cell lung cancer (NSCLC) without identifiable driver mutations remain unclear. The objective of this review was to examine the efficacy and safety of immunotherapy, used as monotherapy or alongside chemotherapy, vs. chemotherapy alone in patients with advanced driver mutation-negative NSCLC. Methods A comprehensive literature search of PubMed, Embase, Scopus, and CENTRAL databases was cond…
Rank107.8
The clinical value of adding immune checkpoint inhibitors to radiotherapy for cancer: a systematic review and meta-analysis.
Annals of medicine · 2026 · PMID 42613912
BACKGROUND: While several randomized clinical trials (RCTs) have explored the addition of immune checkpoint inhibitor (ICI) treatment for patients undergoing radiotherapy, studies systematically assessing the clinical value of such interventions are lacking. METHODS: PubMed, Embase, and Cochrane Library databases were searched for relevant RCTs of cancers that received ICIs plus radiotherapy or radiotherapy. Eligible studies were those published in English as of 14 April 2024. Two independent reviewers screened the…
Rank107.8
First-line systemic treatment for people with extensive-stage small cell lung cancer: a network meta-analysis.
The Cochrane database of systematic reviews · 2026 · PMID 42578486
RATIONALE: Extensive-stage small cell lung cancer (SCLC) carries a poor prognosis and has limited therapeutic options. The addition of immune-checkpoint inhibitors (ICIs) to platinum-etoposide (PE) chemotherapy has become an important first-line treatment strategy. However, the comparative benefits and harms of different first-line chemotherapy-based regimens, including ICI-containing combinations, remain unclear. OBJECTIVES: To evaluate the comparative benefits and harms of immunotherapy (anti-PD-1, anti-PD-L1, or…
Rank107.6
Comparative efficacy and safety of traditional Chinese medicine injections combined with chemotherapy for advanced non-small cell lung cancer: a Bayesian network meta-analysis.
Frontiers in immunology · 2026 · PMID 42688223
BACKGROUND: Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide. Although chemotherapy is an important treatment strategy for advanced NSCLC, its efficacy is limited by treatment resistance and adverse events. Traditional Chinese medicine injections (TCMIs) are widely used as adjunctive therapies; however, the comparative efficacy and safety of different TCMI-based regimens remain unclear. This study aimed to compare the efficacy and safety of various TCMIs combined with…
Rank107.6
Time-of-Day Immunotherapy Administration and Outcomes in Advanced Cancers: A Systematic Review and Meta-Analysis.
JAMA network open · 2026 · PMID 42084869
IMPORTANCE: Circadian rhythms affect immunity, which could affect the effectiveness of immune checkpoint inhibitor (ICI). Whether the time of ICI administration is associated with clinical outcomes in advanced cancers remains unclear. OBJECTIVE: To evaluate the association between time of day of ICI administration and oncologic outcomes in patients with advanced solid tumors. DATA SOURCES: MEDLINE (via PubMed), Embase, and Web of Science Core Collection were searched in February 2026 to identify eligible studies. S…
Rank107.5
A systematic review and network meta-analysis of first-line EGFR-TKI-based combination strategies for EGFR-mutant non-small cell lung cancer with brain metastases.
Scientific reports · 2026 · PMID 42686799
Brain metastases are common in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) and remain clinically challenging despite the improved central nervous system activity of third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs). Because direct comparisons between active first-line combination strategies are limited, this systematic review and network meta-analysis (NMA) evaluated the relative efficacy and safety of EGFR-TKI-based combinations in this population. PubMed, Embase, …
Rank107.4
Cough, dyspnea, or chest pain? an examination of the composite endpoint in metastatic non-small cell lung cancer clinical trials.
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026 · PMID 42319550
PURPOSE: Many clinical trials of metastatic non-small cell lung cancer (mNSCLC) include a composite endpoint of cough, chest pain and dyspnea to assess patient-reported symptomatic deterioration using time-to-confirmed deterioration (TTCD) analyses. We sought to determine the robustness of this composite, and whether composites involving other patient-relevant symptoms of mNSCLC are more sensitive to progression. METHODS: Data from nine mNSCLC trials with the EORTC QLQ-C30 and QLQ-LC13 were pooled. Spearman's corre…
Rank107.2
Efficacy and safety of first-line immune checkpoint inhibitors combinations for extensive-stage small-cell lung cancer: A systematic review and network meta-analysis.
Medicine · 2026 · PMID 42566592
BACKGROUND: Combining immune checkpoint inhibitors (ICIs) with chemotherapy has become a major clinical research focus. Patients with extensive-stage small-cell lung cancer (ES-SCLC) have been treated with different first-line ICI combinations in randomized controlled trials (RCTs), but the optimal combination strategy has not yet been determined. Our aim was to evaluate this strategy through a systematic review and meta-analysis. METHODS: Articles published from inception to October 20, 2024 were systematically se…
Rank106.9
Efficacy and safety of durvalumab with or without tremelimumab in the treatment of metastatic non-small cell lung cancer: a meta-analysis of randomized controlled trials.
Proceedings (Baylor University. Medical Center) · 2026 · PMID 42658167
BACKGROUND: The therapeutic role of combining PD-L1 and CTLA-4 blockade in metastatic non-small cell lung cancer (NSCLC) remains unclear, with individual trials yielding discrepant results. METHODS: We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) to assess the efficacy and safety of durvalumab with or without tremelimumab in advanced NSCLC. The primary outcome was overall survival. Secondary outcomes included immune-related adverse events. Hazard ratios (HRs) and odds ratio…
New Research Last 24 Months437 records
Rank112.0
SEPAR-SECT Recommendations for Perioperative Invasive Mediastinal Staging of Non-small Cell Lung Cancer.
Archivos de bronconeumologia · 2026 · PMID 42276952
Accurate mediastinal nodal staging is essential for the management of non-small cell lung cancer (NSCLC), as it refines prognosis, guides multimodal treatment, and improves survival. This joint consensus document from the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) and the Spanish Society of Thoracic Surgeons (SECT) updates and expands the 2011 SEPAR guidelines, incorporating the 9th edition of the TNM classification and extending recommendations to the entire perioperative setting, including both p…
Rank110.0
Risk of Liver Cancer From Major Causes Compared to Smoking and Lung Cancer: A Systematic Review and Meta-Analysis.
Journal of viral hepatitis · 2026 · PMID 42605247
Liver cancer is the second leading cause of premature cancer mortality globally, whose main causes-HBV, HCV, MASH and alcohol use-are preventable. Viral hepatitis' carcinogenicity is not as well-known as the risk of lung cancer from smoking, leading to rising rates of liver cancer worldwide. The aim of this study was to compare the risk of liver cancer in HBV, HCV, HDV, MASH and alcohol consumption with the better-known risk of lung cancer associated with smoking. We extracted the relative risk of liver cancer from…
Rank110.0
The Society of Thoracic Surgeons Expert Consensus Document (2026) on Addressing Definition and Practices of Sublobar Resection in Non-Small Cell Lung Cancer.
The Annals of thoracic surgery · 2026 · PMID 42320552
BACKGROUND: Two recent randomized clinical trials have shown sublobar resection to be noninferior to lobectomy in node-negative non-small cell lung cancer ≤2 cm. As a result, the use of sublobar resection in early lung cancer patients has significantly increased. Consensus recommendations are needed to guide its appropriate use. METHODS: The Society of Thoracic Surgeons Workforce on Evidence-Based Surgery assembled a panel of thoracic surgeons with clinical and methodological expertise to review the existing litera…
Rank109.7
Robotic-assisted versus video-assisted thoracoscopic anatomical lung resection for early-stage non-small cell lung cancer: a systematic review and meta-analysis.
Journal of robotic surgery · 2026 · PMID 42684651
Non-small cell lung cancer (NSCLC) represents 80-85% of lung cancer cases. Anatomical resection remains the cornerstone treatment for early-stage disease. Video-assisted (VATS) and robotic-assisted (RATS) thoracic surgery are alternatives to thoracotomy, though RATS's advantages over VATS remain controversial. We conducted this systematic review and meta-analysis to compare their perioperative and oncologic outcomes for anatomical resection in early-stage NSCLC. We searched PubMed, Cochrane Library, CINAHL, Web of …
Rank107.8
The risk of primary lung cancer in ANCA-associated vasculitis: systematic review and meta-analysis.
Proceedings (Baylor University. Medical Center) · 2026 · PMID 42376993
BACKGROUND: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a systemic inflammatory disorder that affects small blood vessels. However, the association between AAV and lung cancer risk remains uncertain. We performed a systematic review and meta-analysis to evaluate the relationship between AAV and the risk of lung cancer. METHODS: We systematically searched PubMed, Embase, Scopus, and Web of Science from inception through March 2025. Studies reporting relative risks (RRs), odds ratios (OR…
Rank107.8
The clinical value of adding immune checkpoint inhibitors to radiotherapy for cancer: a systematic review and meta-analysis.
Annals of medicine · 2026 · PMID 42613912
BACKGROUND: While several randomized clinical trials (RCTs) have explored the addition of immune checkpoint inhibitor (ICI) treatment for patients undergoing radiotherapy, studies systematically assessing the clinical value of such interventions are lacking. METHODS: PubMed, Embase, and Cochrane Library databases were searched for relevant RCTs of cancers that received ICIs plus radiotherapy or radiotherapy. Eligible studies were those published in English as of 14 April 2024. Two independent reviewers screened the…
Rank106.9
Efficacy and safety of durvalumab with or without tremelimumab in the treatment of metastatic non-small cell lung cancer: a meta-analysis of randomized controlled trials.
Proceedings (Baylor University. Medical Center) · 2026 · PMID 42658167
BACKGROUND: The therapeutic role of combining PD-L1 and CTLA-4 blockade in metastatic non-small cell lung cancer (NSCLC) remains unclear, with individual trials yielding discrepant results. METHODS: We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) to assess the efficacy and safety of durvalumab with or without tremelimumab in advanced NSCLC. The primary outcome was overall survival. Secondary outcomes included immune-related adverse events. Hazard ratios (HRs) and odds ratio…
Rank106.0
Association between smoking and prognosis in idiopathic pulmonary fibrosis: A systematic review and meta-analysis.
Pulmonology · 2026 · PMID 42339520
BACKGROUND: Although smoking is a well-established risk factor for idiopathic pulmonary fibrosis (IPF) development, its impact on clinical outcomes remains unclear. RESEARCH QUESTION: Is smoking associated with clinical outcomes of IPF? METHODS: A systematic search of PubMed, Embase, and the Cochrane Library was conducted to identify studies reporting associations between smoking status and IPF outcomes, including mortality, acute exacerbation (AE), lung cancer development, and baseline lung function. Summary estim…
Rank103.2
Pulmonary Toxicities of Antibody-Drug Conjugates in Small Cell and Non-Small Cell Lung Cancer: A Systematic Review and Meta-analysis.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2026 · PMID 42674256
BACKGROUND: Antibody-drug conjugates (ADCs) are increasingly used in the treatment of small cell (SCLC) and non-small cell lung cancer (NSCLC). Despite their targeted design, clinically significant pulmonary adverse events (AEs) have been reported, but the incidence and toxicity profile in lung cancer remain incompletely defined. We aimed to quantify the incidence and severity of pulmonary AEs associated with ADCs and to evaluate differences by tumor type and drug design features. METHODS: We performed a PRISMA-gui…
Rank103.0
Long-term oncologic outcomes after non-intubated versus intubated video-assisted thoracoscopic surgery for non-small cell lung cancer: a systematic review and meta-analysis.
Frontiers in oncology · 2026 · PMID 42666271
BACKGROUND: Non-intubated video-assisted thoracoscopic surgery (NIVATS) is increasingly used for selected non-small cell lung cancer (NSCLC) patients, but its long-term oncologic outcomes versus conventional VATS remain unclear. We therefore conducted this systematic review and meta-analysis to compare long-term oncologic outcomes between NIVATS and conventional intubated video-assisted thoracoscopic surgery (VATS). METHODS: We searched major databases and trial registries through June 30, 2026 for comparative stud…
Rank100.0
Therapeutic Impact of Third-generation Tyrosine Kinase Inhibitors on Lung Squamous Cell Carcinoma with Epidermal Growth Factor Receptor Mutations: A Case Description and Systematic Literature Review.
Internal medicine (Tokyo, Japan) · 2026 · PMID 41621872
Epidermal growth factor receptor (EGFR) mutations are uncommon in lung squamous cell carcinoma (SQC). However, the role of third-generation EGFR-tyrosine kinase inhibitors (TKIs) remains unclear. The present study provides a case description and a systematic literature review of 34 eligible cases. Third-generation EGFR-TKIs demonstrate superior initial responsiveness compared to earlier-generation TKIs. The efficacy of TKIs was consistent across SQC forms (including de novo or adenocarcinoma-transformed cases) and …
Rank100.0
SELECTIVE BRONCHIAL ARTERY CHEMOINFUSION IN NSCLC: CURRENT STATE OF REGIONAL THERAPY AND ITS ROLE IN MULTIMODAL APPROACHES.
Georgian medical news · 2026 · PMID 42603327
UNLABELLED: Regional intra-arterial delivery of cytotoxic drugs into bronchial arteries (bronchial artery infusion - BAI; bronchial arterial chemoembolization - BACE; drug-eluting bead BACE - DEB-BACE) aims to maximize local tumor exposure while minimizing systemic toxicity. Recent single-center series suggest potential for symptom control, local tumor downstaging and conversion to resectability in locally advanced NSCLC, but evidence remains heterogeneous. OBJECTIVE: To systematically review and critically apprais…
Rank100.0
Health risk assessment of inorganic arsenic: an umbrella review.
Reviews on environmental health · 2026 · PMID 42494104
Inorganic arsenic (iAs) is a toxic environmental pollutant linked to serious health risks, prompting global regulatory efforts. This study identifies major health conditions associated with iAs exposure using text network analysis, and assesses health risk assessments through an umbrella review and dose-response analysis. It synthesizes previous systematic reviews to offer a broader perspective on iAs-related health effects. An optimized text network analysis-based search strategy was applied across multiple databa…
Rank100.0
Patient-Centered Physical Activity Intervention in Lung Cancer Patients: A Clinical Severity and Functional Capacity Systematic Review and Meta-analysis.
Cancer nursing · 2026 · PMID 39888667
BACKGROUND: Increasing physical activity levels is a significant unmet need in cancer survivors, and it can likely be enhanced through a better understanding of the interventions developed. Some studies on patient-centered physical activity interventions have shown promising results in increasing daily activity levels among lung cancer survivors. However, the programs present a high heterogeneity, and there is no consensus on the parameters and their effectiveness. OBJECTIVE: To examine the effectiveness of patient…
Rank100.0
Treatment Strategies and Outcomes for Single-Site Recurrent Pancreatic Ductal Adenocarcinoma After Curative-Intent Surgery: Local Therapies are Associated with Longer Survival in Selected Cases: A Systematic Review and Meta-analysis.
Annals of surgical oncology · 2026 · PMID 42303818
BACKGROUND: After curative-intent pancreatectomy for pancreatic ductal adenocarcinoma (PDAC), disease recurrence occurs almost invariably. Evidence guiding treatment of recurrence remains limited and may differ across single-site recurrence patterns. METHODS: Scopus, MEDLINE, and the Cochrane Library were systematically searched for observational studies of adults with recurrent PDAC reporting liver-only, lung-only, or locoregional recurrence and post-recurrence treatments. Hazard ratio (HR) meta-analyses were perf…
Rank100.0
Evidence-based indications for proton therapy in adults determined using the GRADE approach.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026 · PMID 41557143
PURPOSE: Proton therapy (PT) offers dosimetric advantages over conventional X-ray-based radiotherapy (XRT), aiming to reduce toxicity and better spare healthy tissues. The Agency for Health Quality and Assessment of Catalonia (AQuAS), commissioned by the Spanish Ministry of Health, conducted a Health Technology Assessment to evaluate the safety and clinical effectiveness of PT for cancer indications not yet approved for PT in Spain. This article summarizes the main findings regarding PT's safety and clinical perfor…
Rank99.9
Tumor Purity as a Prognostic and Predictive Biomarker of Postoperative Radiation Therapy Outcomes in Stage IIIA-N2 Non-Small Cell Lung Cancer: A Transcriptomic Analysis From the Lung ART Trial.
International journal of radiation oncology, biology, physics · 2026 · PMID 41833910
PURPOSE: Tumor purity (TP), the proportion of malignant cells within a tumor sample, is an important feature of the tumor microenvironment. Using transcriptomic data from the Lung ART-IFCT 0503 trial, we investigated the relevance of TP and its potential to predict benefit from postoperative radiation therapy (PORT). METHODS AND MATERIALS: RNA sequencing was successfully performed on 285 samples. TP was inferred using the ESTIMATE algorithm. Associations with overall survival (OS) and disease-free survival (DFS) we…
Rank97.2
Safety Evaluation of Tarlatamab in SCLC: A Systematic Review and Meta-Analysis.
JTO clinical and research reports · 2026 · PMID 42668666
INTRODUCTION: Tarlatamab, a bispecific T-cell engager targeting delta-like ligand 3 and CD3, demonstrated clinical activity both in previously treated SCLC and as intensification of maintenance immunotherapy. Owing to its action mechanism, tarlatamab exerts a new toxicity profile, needing careful management. Based on these premises, we performed a systematic review and meta-analysis to evaluate treatment-related adverse events (TRAEs) among available clinical trials enrolling patients with SCLC receiving tarlatamab…
Rank96.9
Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small-cell lung cancer: 7-year update from the phase III CROWN study.
Annals of oncology : official journal of the European Society for Medical Oncology · 2026 · PMID 42217582
BACKGROUND: Due to the unprecedented progression-free survival (PFS) benefit with lorlatinib after 5 years of follow-up in the phase III CROWN study, we aimed to quantify long-term outcomes at 7 years. PATIENTS AND METHODS: Treatment-naive patients (N = 296) with advanced anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) were randomly assigned 1:1 to receive lorlatinib 100 mg once a day (n = 149) or crizotinib 250 mg twice a day (n = 147). This post hoc analysis presents investigator-asse…
Rank96.8
SKYSCRAPER-01: Tiragolumab in Combination With Atezolizumab in Previously Untreated PD-L1-High, Locally Advanced, Unresectable or Metastatic Non-Small Cell Lung Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026 · PMID 42507968
PURPOSE: Tiragolumab plus atezolizumab has shown encouraging survival outcomes in metastatic non-small cell lung cancer (NSCLC), primarily in patients with PD-L1-high tumors. We further evaluated the combination of tiragolumab plus atezolizumab in the phase III SKYSCRAPER-01 study. METHODS: Patients with untreated, locally advanced unresectable/metastatic PD-L1-high (by central laboratory testing) NSCLC were randomly assigned 1:1 to receive either tiragolumab (600 mg) plus atezolizumab (1,200 mg) or placebo plus at…
Rank96.5
Real-time AR navigation with dynamic tracking for millimeter-level pulmonary nodule localization: A randomized clinical trial.
Cell reports. Medicine · 2026 · PMID 42520806
Precise localization of small pulmonary nodules is crucial for surgery. Augmented reality (AR) navigation provides real-time guidance, potentially improving localization efficiency. This open-label randomized controlled trial compares AR-guided localization with conventional computed tomography (CT)-guided localization in 168 participants with peripheral pulmonary nodules ≤2 cm. The primary outcome is localization accuracy; secondary outcomes are success rate, procedural time, radiation dose, insertion attempts, an…
Rank96.1
Behavioral speech therapy intervention can improve the postoperative pain and performance status of lung cancer patients undergoing thoracoscopic surgery.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026 · PMID 42611082
BACKGROUND: Pain is common after lung surgery, yet non-pharmacological strategies remain underutilized. Behavioral Speech Therapy (BST) may improve recovery for thoracoscopic surgery patients. PURPOSE: To evaluate whether BST reduces pain and improves physical function after thoracoscopic lung cancer surgery. METHODS: This secondary analysis of a registered trial (ChiCTR2400084313, originally evaluating BST for postoperative cough) used data from 112 patients who were assigned to routine care alone (control) or rou…
Rank96.0
Long-Term Analysis of One Versus Three Fractions of Stereotactic Body Radiation Therapy for Peripheral Stage I to II Non-Small Cell Lung Cancer: A Randomized, Multi-Institution, Phase 2 Trial.
International journal of radiation oncology, biology, physics · 2026 · PMID 41833909
PURPOSE: Stereotactic body radiation therapy is standard of care for inoperable early-stage non-small cell lung cancer. Here, we report the long-term outcomes of 30 Gy in 1 fraction (arm 1) versus 60 Gy in 3 fractions (arm 2). METHODS AND MATERIALS: This was a multi-institutional randomized, phase 2, 2-arm clinical trial. Medically inoperable patients with peripheral clinical T1-T2/N0M0 disease were enrolled. All patients had biopsy-confirmed disease. Patients were stratified by performance status and randomized to…
Rank96.0
Comment on "Artificial intelligence construction: a review of the bridge between CT imaging features of lung ground-glass nodules adenocarcinoma and carcinogenic driver genes".
Journal of cancer research and clinical oncology · 2026 · PMID 42661070
Xue and Chen et al.'s review connects AI-derived CT features of lung ground-glass nodule adenocarcinoma to driver gene status. Three aspects are missing. There is no stated search strategy no databases, date range, or inclusion criteria despite drawing on more than 150 references, so readers cannot tell whether weaker or null results were sought out or just left aside. Individual studies are cited by their best accuracy or AUC figures, from approximately 0.64 to above 0.95, with no attempt to weigh them by sample s…
Rank96.0
Lung cancer multidisciplinary care status and evidence-practice gap: a scoping review protocol.
BMJ open · 2026 · PMID 42642084
INTRODUCTION: Lung cancer is the leading cause of cancer-related death worldwide, with substantial variations in incidence, stage at diagnosis and outcomes across regions. High-quality, standardised diagnosis and treatment are essential to improving survival and quality of life. Multidisciplinary care (MDC) is a cornerstone of cancer care; however, its implementation faces barriers such as limited resources, uneven policy support and inequitable access to specialised care, particularly in low- and middle-income cou…
Preclinical Research112 records
Rank47.7
Immunotherapy plus chemotherapy improves survival in SMARCA4-deficient NSCLC: a real-world cohort study.
Frontiers in immunology · 2026 · PMID 42676634
INTRODUCTION: SMARCA4‑deficient non‑small‑cell lung cancer (SMARCA4‑dNSCLC) is a rare, aggressive NSCLC subtype driven by SWI/SNF complex dysfunction with no standardized therapeutic strategies. Although chemoimmunotherapy represents standard first‑line therapy for driver‑negative advanced NSCLC, its real‑world efficacy in SMARCA4‑dNSCLC remains controversial. SMARCA4 loss frequently generates an immune‑desert tumor microenvironment with low PD‑L1 and sparse CD8⁺ T‑cell infiltration, potentially conferring intrinsi…
Rank45.0
Histomorphologic and immunohistochemical characteristics of intraocular metastatic carcinomas of presumed pulmonary origin in cats: A retrospective case series from 2019 to 2025.
Veterinary pathology · 2026 · PMID 42117343
Carcinomas have been reported to metastasize to the globe, specifically the uvea; however, the distinguishing histologic features of intraocular metastatic carcinomas in cats are not well-documented. Eleven cases of feline ocular biopsies with intraocular metastatic carcinomas and history of a pulmonary mass submitted to the Comparative Ocular Pathology Laboratory of Wisconsin from 2019 to 2025 were collected and reviewed. Alcian blue stains and immunohistochemical markers for thyroid transcription factor-1 and vim…
Rank45.0
Pemetrexed potentiates γδ T cell-based immunotherapy in NSCLC through ATM-STING-NF-κB-mediated induction of NKG2D ligands.
International immunopharmacology · 2026 · PMID 42447803
Adoptive T-cell therapy is a promising strategy for cancer immunotherapy; however, its efficacy is often limited by the immunosuppressive tumor microenvironment. γδ T cells, particularly the Vγ9Vδ2 subset, exhibit innate-like cytotoxicity and are emerging candidates for adoptive immunotherapy. Pemetrexed, an antifolate chemotherapeutic agent, has documented immunomodulatory effects in αβ T-cell settings; however, its impact on γδ T-cell antitumor responses remains insufficiently defined. Here, Vγ9Vδ2 T cells were i…
Rank45.0
The NTP chronic inhalation study does not support an inherent lung cancer hazard of talc: Implications of lung particle overload and maximum tolerated dose.
Regulatory toxicology and pharmacology : RTP · 2026 · PMID 42373004
Interpretation of inhalation carcinogenicity studies for poorly soluble particles requires explicit consideration of lung particle overload in relation to maximum tolerated dose (MTD). In the NTP talc inhalation study, lung tumors occurred in female rats following chronic exposure to 18 mg/m3. Detailed analysis of lung burden data shows that both 6 and 18 mg/m3 exposures resulted in lung overload, with lung volume burdens at 18 mg/m3 exceeding 10 μL/g lung, a level associated with clearance cessation. Together with…
Rank45.0
Extracellular vesicles derived from cancer-associated fibroblasts facilitate NSCLC progression and metastasis via miR-664b-5p-mediated activation of the CXCL12/CXCR4 chemokine pathway.
Biochimica et biophysica acta. Molecular basis of disease · 2026 · PMID 42425467
Exosomal miRNAs mediate intracellular communication between the tumor microenvironment and cancer cells in non-small cell lung cancer (NSCLC). However, effects of exosomal miRNAs on NSCLC and its mechanisms have not been completely clarified. Here, exosome miRNA profiling and patient serum analysis revealed that the expression level of exosomal miR-664b-5p is significantly elevated in NSCLC, with particularly high levels in cancer-associated fibroblasts (CAFs) and their secreted exosomes. Functionally, miR-664b-5p …
Rank45.0
Single-cell RNA sequencing analysis of bone cancer pain model induced by Lewis lung cancer cells in male mice.
Annals of medicine · 2026 · PMID 41758238
BACKGROUND: Bone cancer pain (BCP) is one of the most severe complications faced by cancer patients, with complex physiological and pathological mechanisms and unclear molecular characteristics. METHODS: The BCP model was established by inoculating Lewis lung cancer cells into the femur to induce hyperalgesia and spontaneous pain. Single-cell RNA sequencing technology was used to characterize the cell composition and molecular features of the L2-L4 spinal cord after BCP modelling. RESULTS: Our research results iden…
Rank36.9
Deciphering lung adenocarcinoma heterogeneity: a multi-omics approach reveals nuclear division fibroblasts as prognosticators and therapeutic targets.
Journal of translational medicine · 2026 · PMID 41862916
BACKGROUND: Lung adenocarcinoma (LUAD) is a predominant contributor to cancer‑related mortality globally. Lung‑associated fibroblasts (LAFs) are intricately linked to tumorigenesis and the tumor microenvironment (TME), but their heterogeneity and prognostic relevance in LUAD remain incompletely understood. This study aimed to systematically characterize LAF subsets across the spectrum of pulmonary disease, identify LAF subpopulations associated with LUAD prognosis, and construct a robust LAF‑based prognostic signat…
Rank35.0
Personalized treatment of HER2-positive lung adenocarcinoma using Human Organoid Drug Sensitivity Test.
Human vaccines & immunotherapeutics · 2026 · PMID 41700896
Human Epidermal Growth Factor Receptor 2 (HER2) mutations account for approximately 3% of non-small cell lung cancer (NSCLC) patients. Currently, targeted therapies for HER2-mutant NSCLC include HER2 tyrosine kinase inhibitors (TKIs) and HER2 Antibody-drug conjugates (ADC). However, resistance often develops, and effective treatments for HER2 mutations remain lacking. We report a case of HER2-mutant lung adenocarcinoma where the patient developed resistance and severe interstitial lung disease following antibody-dr…
Rank33.9
Mechanism study of serum extracellular nano-vesicles miR-412-3p targeting regulation of TEAD1 in promoting malignant biological behavior of sub-centimeter lung nodules.
Cancer biomarkers : section A of Disease markers · 2024 · PMID 39269825
OBJECTIVE: To investigate the impact and potential mechanisms of serum extracellular nano-vesicles (sEVs) miR-412-3p released from sub-centimeter lung nodules with a diameter of ⩽ 10 mm on the malignant biological function of micro-nodular lung cancer (mnLC). METHODS: A total of 87 participants were included and divided into a mnLC group (n= 30), a benign lung nodule (BLN) group (n= 27), and a healthy people control group (n= 30). Transmission electron microscopy (TEM), nanoparticle tracking analysis (NTA) and West…
Rank33.7
Profiling the tumor-resident microbiota in small cell lung cancer and its influence on clinical outcomes.
Journal of translational medicine · 2026 · PMID 41981675
BACKGROUND: Increasing evidence has confirmed the existence of resident microbial communities within solid tumors and indicates that the tumor microbiota may represent a novel component of the tumor microenvironment, actively regulating cancer initiation, progression, metastasis, and therapeutic responsiveness. However, the role of tumor microbiota in small cell lung cancer (SCLC) has not been well explored. METHODS: Tumor samples were collected from 71 patients with SCLC at Shanghai Pulmonary Hospital between 2019…
Rank31.6
Protective Effects of Luteolin Against Cisplatin-Induced Hepatic and Renal Toxicity: Biochemical and Cellular Evidence.
Journal of biochemical and molecular toxicology · 2026 · PMID 42671218
Cisplatin is a widely used chemotherapeutic agent; however, its clinical utility is frequently limited by dose-dependent adverse effects, particularly hepatotoxicity and nephrotoxicity. Luteolin, a naturally occurring flavonoid abundant in various medicinal plants, exhibits well-documented antioxidant and anticancer activities. This study investigated whether Luteolin isolated from Pistacia terebinthus fruits could attenuate Cisplatin-induced organ toxicity while enhancing its antiproliferative effects. For the in …
Rank31.0
Low, plasma level‑informed native curcumin concentrations fail to induce cell death in human lung and colorectal cancer cells.
Pharmaceutical biology · 2026 · PMID 41858052
BACKGROUND/OBJECTIVES: Curcumin, a dietary polyphenol derived from turmeric, has been widely studied for its anti-cancer properties, yet its effects at clinically relevant concentrations remain unclear. This study investigates the anti-cancer effects of curcumin at low in vitro concentrations selected based on reported plasma ranges using in vitro lung and CRC models, with a focus on underlying cellular mechanisms. METHODS: Curcumin was tested at 4, 10, 20, and 50 µg/mL in two CRC cell lines (Caco-2 and HT29) and t…
Rank30.0
Cancer associated fibroblast-T cell crosstalk promotes purinergic synthesis in non-small cell lung cancer (NSCLC).
Oncoimmunology · 2026 · PMID 42530085
The most abundant stromal cells of the tumor microenvironment (TME), cancer-associated fibroblasts (CAFs), inhibit the cytotoxic T cell response in solid tumors. CD39 and CD73 together deplete extracellular ATP in the TME to produce adenosine, which can promote tumor immune evasion. We aimed to investigate the role of CAF-T-cell crosstalk in the adenosine pathway in NSCLC. CD4+ and CD8+ T cells were flow sorted from in vitro culture with or without CAFs, and RNA-Seq was performed using the nCounter platform (NanoSt…
Rank30.0
Delivering the blueprint: Advances and challenges in mRNA therapeutics for the respiratory system.
International journal of pharmaceutics: X · 2026 · PMID 42662466
The success of mRNA vaccines has established lipid nanoparticles (LNPs) as a clinically validated delivery platform, yet their application to pulmonary therapeutics presents formidable challenges. This review systematically summarizes the mechanisms, delivery methods, key challenges, safety considerations, and translational gaps associated with mRNA-LNP therapeutics for pulmonary disorders. It surveys LNP-mediated delivery to pulmonary cell populations, distinguishing readily accessible targets (such as alveolar ty…
Rank30.0
JMB2403, a potential best-in-class PD-1-dependent IL2Rβγ-activating tri-specific antibody for safe and potent immunotherapy.
mAbs · 2026 · PMID 42543223
PD-1-based immunocytokines, such as interleukin (IL)-2 fused with anti-PD-1, have been designed to increase efficacy, but their use is hampered by dose-limiting toxicity. To overcome this, substantial efforts have focused on engineering attenuated IL-2 variants, albeit with limited success to date. Taking an alternative approach, we screened a naïve alpaca library for weak agonistic nanobodies of IL-2/15Rβ and the common γ chain and attached a potent anti-PD-1 IgG to generate a tri-specific antibody JMB2403. JMB240…
Rank30.0
Small molecule allosteric modulators of mutant EGFR for non-small cell lung cancer therapy: An insight into design strategies and structure activity relationships.
European journal of medicinal chemistry · 2026 · PMID 42501451
Non-small cell lung cancer (NSCLC) is one of the deadliest malignancies, which is mostly caused by activating mutations in the epidermal growth factor receptor (EGFR). While EGFR tyrosine kinase inhibitors (TKIs) of the first, second, and third generations have improved patient outcomes, long-term efficacy is often compromised by acquired resistance caused by mutations like T790 M and C797S. The discovery and promise of small-molecule allosteric modulators, including both reversible allosteric, ATP dual targeting i…
Rank30.0
Targeting the adaptor protein Gab1 overcomes MET/Src-driven alectinib resistance in ALK-rearranged NSCLC.
Cellular signalling · 2026 · PMID 42492818
BACKGROUND: In non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) rearrangement, bypass signaling activation commonly leads to resistance against alectinib. Identifying key molecular targets that integrate signals from resistance-driving kinases is crucial for overcoming this resistance. However, these targets have not yet been identified. METHODS: We generated alectinib-resistant (AR) subclones from H3122 and H2228 cells. Subsequently, we analyzed bypass signaling pathways using western blott…
Rank30.0
CST1 suppresses ferroptosis and restricts CD8+ T-cell infiltration and effector function in lung adenocarcinoma via activation of the WNT/β-catenin signaling pathway.
Cellular signalling · 2026 · PMID 42471072
BACKGROUND: Ferroptosis dysregulation and immune evasion are central features of lung adenocarcinoma (LUAD) progression, yet the molecular mechanisms that coordinately govern both processes remain poorly understood. This study aimed to identify ferroptosis-associated genes in LUAD and characterize their functional and mechanistic roles in tumor progression and anti-tumor immunity. METHODS: Differentially expressed genes (DEGs) were identified from two GEO microarray datasets (GSE32863 and GSE118370) and intersected…
Rank30.0
BRD8 promotes non-small cell lung cancer progression by stabilizing MBD2 and activating the MAPK pathway.
Cellular signalling · 2026 · PMID 42401357
Lung cancer is the leading cause of cancer-related mortality worldwide, and non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cases with limited therapeutic options and poor clinical outcomes. Bromodomain-containing protein 8 (BRD8), an epigenetic regulator, has been reported to exert oncogenic roles in multiple solid tumors. Nevertheless, its biological functions and molecular mechanisms in NSCLC remain largely uncharacterized, which motivates us to explore its role in NSCLC progression…
Rank30.0
Tumor cell membrane-camouflaged biomimetic liposomes for targeted delivery of phytosphingosine with enhanced anti-lung cancer activity.
Colloids and surfaces. B, Biointerfaces · 2026 · PMID 42296942
Lung cancer remains the leading cause of cancer-related mortality worldwide, with non-small cell lung cancer (NSCLC) accounting for over 80% of cases. Conventional chemotherapy is severely limited by insufficient tumor targeting, severe off-target systemic toxicity, and poor bioavailability of hydrophobic antitumor agents, which greatly compromise therapeutic efficacy and patient quality of life. Phytosphingosine (PHS), a natural sphingolipid with potent antitumor activity via cell cycle regulation and apoptosis in…
Rank30.0
Flavokawain A inhibits high glucose-induced malignant progression of lung cancer cells by suppressing PRMT5-mediated PTEN neddylation and nuclear translocation.
Oncology letters · 2026 · PMID 42639435
A high-glucose microenvironment is a key feature of tumor metabolic reprogramming that promotes lung cancer cell progression. Previous studies have revealed that protein arginine methyltransferase 5 (PRMT5) is overactivated in various cancers and regulates neddylation of the tumor suppressor phosphatase and tensin homolog (PTEN). This study established a high-glucose (25 mM) in vitro model using human non-small cell lung cancer A549 cells. Cell proliferation, invasion and cell cycle progression were assessed using …
Rank30.0
Combination of lonidamine with devimistat induces synergistic antitumor effects in lung cancer via multifaceted disruption of cellular energy metabolism.
Oncology reports · 2026 · PMID 42627059
Disrupting energy metabolic pathways has emerged as a promising strategy for cancer therapy including non‑small cell lung cancer (NSCLC). However, the ultimate anticancer effects have not been satisfactory. This is likely because cellular energy metabolism encompasses multiple processes and pathways, and tumor cells can flexibly regulate these processes and pathways to adapt to external disturbances and changes in the microenvironment in order to maintain their growth and proliferation. As a result, current strateg…
Rank30.0
In silico and in vitro evaluation of synergistic anticancer effects of erucin and kaempferol from Eruca sativa against human A549 non-small cell lung cancer cells (NSCLC).
Cytotechnology · 2026 · PMID 42621169
UNLABELLED: Dietary phytochemicals exhibit anticancer activity, and increasing evidence suggests that the combinations of co-occurring compounds may provide greater therapeutic efficacy than individual compounds. Eruca sativa Mill. (rocket salad) contains both erucin and kaempferol; however, their synergistic anticancer activity against non-small cell lung cancer (NSCLC) has not been systematically investigated. Network pharmacology, molecular docking, and molecular dynamics (MD) simulations were performed to ident…
Rank30.0
LAPTM4B promotes gefitinib resistance and tumor stemness in non-small cell lung cancer by stabilizing RPS3 through inhibiting its ubiquitination.
Biochimica et biophysica acta. Molecular cell research · 2026 · PMID 42612828
Gefitinib resistance remains a major obstacle to the effective treatment of non-small cell lung cancer (NSCLC), and the underlying molecular mechanisms have not yet been fully elucidated. Lysosomal-associated transmembrane protein 4B (LAPTM4B) has been shown to be involved in cancer progression, but its specific role in gefitinib resistance and the prognosis of NSCLC patients remains unclear. In this study, we conducted functional experiments including CCK-8, Transwell, and tumor sphere formation assays in LAPTM4B-…
Rank30.0
Chelerythrine and chelidonine synergistically target the adenosine pathway to improve anti-PD-L1 immunotherapy efficacy in lung cancer.
Phytomedicine : international journal of phytotherapy and phytopharmacology · 2026 · PMID 42607553
BACKGROUND: Despite the success of immune checkpoint blockade in advanced cancer, non-redundant immunosuppressive mechanisms within the tumor microenvironment (TME) limit its effectiveness in many patients. Extracellular adenosine (eADO) signaling is a major contributor to immunosuppression, and inhibitors of eADO production or signaling have entered clinical trials as monotherapies or in combination with anti-PD-L1 therapy. PURPOSE: We aimed to identify potent compounds from Chelidonium majus L. (C. majus) that ta…
Promising Experimental Therapies84 records
Rank97.9
Artificial Intelligence-Assisted Lung Nodule Evaluation on Low-Dose Chest CT in Asymptomatic Individuals: A Prospective Randomized Controlled Trial.
AJR. American journal of roentgenology · 2026 · PMID 41848489
BACKGROUND. The impact of artificial intelligence (AI) tools for lung nodule evaluation on low-dose CT (LDCT) has been evaluated primarily using experimental retrospective reader designs, outside of clinical practice. OBJECTIVE. The purpose of this study was to compare interpretation times and lung nodule detection rates between real-world interpretations conducted with versus without an AI-based lung nodule evaluation tool for LDCT examinations in asymptomatic individuals. METHODS. This prospective single-center, …
Rank96.5
Concurrent chemoradiotherapy with or without simultaneous integrated boost for unresectable stage III non-small-cell lung cancer: a randomized phase II trial with exploratory EGFR and PD-L1 analyses.
Cancer genetics · 2026 · PMID 42456525
BACKGROUND AND PURPOSE: Based on the assumption that radiation dose escalation to the primary tumor improves local control and therefore produces survival benefits under the condition of limiting the dose to the organ at risk (OAR), we launched a study to evaluate the effect of simultaneous integrated boost (SIB) radiotherapy implemented in stage III locally advanced non-small cell lung cancer (LA-NSCLC) patients. MATERIALS AND METHODS: A prospective, single-center, open-label, randomized phase II trial was perform…
Rank96.0
Long-Term Analysis of One Versus Three Fractions of Stereotactic Body Radiation Therapy for Peripheral Stage I to II Non-Small Cell Lung Cancer: A Randomized, Multi-Institution, Phase 2 Trial.
International journal of radiation oncology, biology, physics · 2026 · PMID 41833909
PURPOSE: Stereotactic body radiation therapy is standard of care for inoperable early-stage non-small cell lung cancer. Here, we report the long-term outcomes of 30 Gy in 1 fraction (arm 1) versus 60 Gy in 3 fractions (arm 2). METHODS AND MATERIALS: This was a multi-institutional randomized, phase 2, 2-arm clinical trial. Medically inoperable patients with peripheral clinical T1-T2/N0M0 disease were enrolled. All patients had biopsy-confirmed disease. Patients were stratified by performance status and randomized to…
Rank94.9
Comparison of Computed Tomography Ventilation Imaging and Hyperpolarized 3He Magnetic Resonance Imaging in Patients With Lung Cancer.
International journal of radiation oncology, biology, physics · 2026 · PMID 41802548
PURPOSE: Computed tomography ventilation imaging (CTVI) has great potential for clinical translation and has been validated in numerous studies. However, previous studies focused on image comparisons, and little is known about the dosimetric implications of "good" or "poor" image correlations or agreements in radiation therapy (RT). This study assessed the agreement of dose-function metrics between CTVI and hyperpolarized 3He magnetic resonance imaging (MRI) as a reference. METHODS AND MATERIALS: This study include…
Rank92.0
Final Analysis of Neoadjuvant Sintilimab Plus Chemotherapy in IB-IIIA Non-Small-Cell Lung Cancer: Phase 2 neoSCORE Trial.
Cancer science · 2026 · PMID 42252705
The optimal number of neoadjuvant chemoimmunotherapy cycles for resectable non-small cell lung cancer (NSCLC) remains uncertain. The randomized phase 2 neoSCORE trial (NCT04459611) conducted a comprehensive final analysis, comparing the outcomes of two versus three cycles of neoadjuvant sintilimab combined with platinum-doublet chemotherapy in 60 stage IB-IIIA NSCLC patients, among whom 55 underwent surgery. After a median follow-up period of 56.9 months, no statistically significant differences in disease-free sur…
Rank92.0
Clinical value of modified Shenling Baizhu powder in treating targeted therapy-induced diarrhea in non-small cell lung cancer.
Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2024 · PMID 39380231
OBJECTIVE: To assess clinical value of modified Shenling Baizhu powder (, SBP) in intervening targeted therapy-induced diarrhea. METHODS: This study was a prospective randomized controlled study. Eighty-five non-small cell lung cancer (NSCLC) patients with diarrhea who took targeted drugs were randomly divided into two groups. The experimental group received modified SBP, while the control group received imodium. During 2 courses of treatment (1 week/course) and 2 weeks of follow-up, we observed remission and recur…
Rank83.6
DNA hypomethylation identifying clinical benefit subgroup of small-cell lung cancer: multi-omics analysis of a phase II trial with durvalumab plus olaparib as maintenance therapy.
Journal for immunotherapy of cancer · 2026 · PMID 42601174
BACKGROUND: Long-term survival of extensive-stage small-cell lung cancer (ES-SCLC) remains rare, with most patients experiencing disease progression during maintenance therapy. Poly (ADP-ribose) polymerase (PARP) inhibitors have the potential to confer antitumor activity, modify tumor immunogenicity, and sensitize tumors to anti-programmed cell death protein 1/programmed death-ligand 1 therapy. We conducted this phase 2 trial to investigate the efficacy and safety of durvalumab plus olaparib as maintenance therapy …
Rank83.6
Efficacy and biomarker exploration of anlotinib plus penpulimab in second-line ES-SCLC: Results from the phase 2 ALTER-L041 trial.
Cell reports. Medicine · 2026 · PMID 42486095
Treatment options are limited for patients with extensive-stage small cell lung cancer (ES-SCLC) after platinum-based therapy. This open-label, single-arm, multicenter phase 2 trial evaluates penpulimab plus anlotinib in 65 patients with first-line platinum-resistant ES-SCLC. The confirmed objective response rate by blinded independent central review is 41.5% (95% confidence interval [CI]: 29.2%-53.8%), and the disease control rate is 75.4% (95% CI: 64.6%-86.1%). Median progression-free survival and overall surviva…
Rank83.2
Safety and efficacy of first-line iparomlimab and tuvonralimab (QL1706) plus carboplatin and etoposide in patients with extensive-stage small cell lung cancer: an open-label, single-arm, phase 2 trial (DUBHE-L-209).
Frontiers in immunology · 2026 · PMID 42643500
BACKGROUND: Iparomlimab and tuvonralimab (QL1706) is a MabPair product consisting of PD-1 and CTLA-4 monoclonal antibodies. This single-arm, multicenter, phase 2 study assessed the safety and efficacy of first-line QL1706 plus etoposide and carboplatin (EC) for extensive-stage small cell lung cancer (ES-SCLC). METHODS: Patients with ES-SCLC received QL1706 plus EC every 3 weeks for 4-6 cycles, followed by QL1706 maintenance therapy until disease progression. Primary endpoint was safety. RESULTS: Among 40 patients e…
Rank83.0
Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy in One Fraction (SMART ONE): A Multicenter, Single-Arm, Phase 2 Trial.
International journal of radiation oncology, biology, physics · 2025 · PMID 40158734
PURPOSE: Stereotactic body radiation therapy (SBRT) is an advanced technique that enables precise delivery of radiation directly to a tumor, typically in ≤5 fractions. Single-fraction SBRT for visceral tumors is uncommon, likely related to concerns about risks of geographic tumor miss because of suboptimal cone beam computed tomography scan quality on conventional linear accelerators (linacs). Magnetic resonance (MR) guided linacs are a novel technology offering superior imaging that might facilitate the safe deliv…
Rank82.2
Genomic Profiling of Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer after Progression on First-line Osimertinib: Phase II ORCHARD Study.
Clinical cancer research : an official journal of the American Association for Cancer Research · 2026 · PMID 41790029
PURPOSE: Osimertinib is the standard of care for first-line treatment for epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). Understanding the tumor molecular profile of patients following progression on osimertinib could help inform optimal second-line treatment. PATIENTS AND METHODS: ORCHARD (NCT03944772), a phase II biomarker-directed study, enrolled patients with EGFRm NSCLC who progressed on first-line osimertinib to receive treatment based on their tumor molecular profile aft…
Rank80.9
Efficacy and Safety of Olomorasib in Combination With Pembrolizumab in Treatment of Patients With KRAS G12C-Mutant Advanced NSCLC.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2026 · PMID 41319864
INTRODUCTION: Immunotherapy-based regimens are the standard first-line treatment for KRAS G12C-mutant NSCLC, but outcomes remain suboptimal. Prior attempts to combine KRAS G12C inhibitors with immunotherapy have been challenged by toxicity. We report results from LOXO-RAS-20001, a phase 1/2 trial evaluating the combination of olomorasib with pembrolizumab in KRAS G12C-mutant NSCLC, including in first-line setting. METHODS: Patients with advanced KRAS G12C-mutant NSCLC in any treatment line, including prior KRAS G12…
Rank80.4
Mature Outcomes and Patterns of Failure in the Phase II FLARE-RT Trial of Biological Image-Guided and Risk-Adaptive Chemoradiation for Unresectable NSCLC.
Clinical cancer research : an official journal of the American Association for Cancer Research · 2026 · PMID 42207168
PURPOSE: The nonrandomized phase II trial Functional Lung Avoidance and Response-adaptive Escalation Radiation Therapy (FLARE-RT) tested personalized risk-adaptive radiotherapy for unresectable non-small cell lung cancer (NSCLC) using 2[18F]fluoro-2-deoxy-D-glucose (FDG)-PET/CT and single-photon emission computed tomography/CT. We report radiation dosimetry, mature outcomes, adverse events, failure patterns, and risk stratification models. PATIENTS AND METHODS: Forty-nine patients with American Joint Committee on C…
Rank80.0
Ifebemtinib plus garsorasib as first-line treatment for KRASG12C-mutated non-small-cell lung cancer in China: a multicentre, single-arm expansion cohort from a phase 1b/2 trial.
The Lancet. Respiratory medicine · 2026 · PMID 42413526
BACKGROUND: Ifebemtinib, a potent selective oral inhibitor of FAK, has shown preclinical synergistic activity with KRASG12C inhibitors. Garsorasib is a novel KRASG12C inhibitor approved in China for patients with KRASG12C-mutated non-small-cell lung cancer (NSCLC). This study aimed to evaluate the safety and efficacy of ifebemtinib plus garsorasib in KRASG12C-mutated solid tumours. METHODS: This multicentre study had a phase 1b component to establish the recommended phase 2 dose and a phase 2 multitumour expansion.…
Rank80.0
Prophylactic Recombinant Human Thrombopoietin Prevents Cancer Therapy-Induced Thrombocytopenia During Concurrent Chemoradiation Therapy in Limited-Stage Small Cell Lung Cancer: A Prospective, Multicenter, Phase II Clinical Trial.
International journal of radiation oncology, biology, physics · 2026 · PMID 41831791
PURPOSE: Concurrent chemoradiation therapy is the standard therapy for limited-stage small cell lung cancer (LS-SCLC) but induces cancer therapy-induced thrombocytopenia (CTIT), which leads to treatment delays. This study aims to assess the efficacy and safety of prophylactic recombinant human thrombopoietin (rhTPO) in preventing CTIT in this patient population. METHODS AND MATERIALS: This prospective, multicenter, phase II trial was conducted across 14 Chinese centers. LS-SCLC patients receiving etoposide plus cis…
Rank79.9
Phase 2 Trial of Consolidative Stereotactic Body Radiation Therapy in Patients With Metastatic Oncogene-driven Non-small Cell Lung Carcinoma Treated With Tyrosine Kinase Inhibitors.
International journal of radiation oncology, biology, physics · 2025 · PMID 39577475
PURPOSE: The role of stereotactic body radiation therapy (SBRT) in the management of advanced EGFR/ALK/ROS1-driven non-small cell lung carcinoma (NSCLC) remains undefined. In EGFR-mutant NSCLC, 50-60% of recurrences on first-line tyrosine kinase inhibitors (TKIs) occur in originally involved sites and may lead to subsequent distant failures (DFs). We sought to determine whether consolidative SBRT to residual sites reduces DF. METHODS AND MATERIALS: This is a single-arm, phase 2 trial of SBRT to residual sites of di…
Rank79.9
Long-term follow-up of a phase 1/2 trial of anti-GDF-15 antibody visugromab plus anti-PD-1 antibody nivolumab in anti-PD-1/-L1 relapsed/refractory solid tumors.
Journal of hematology & oncology · 2026 · PMID 42426863
BACKGROUND: Resistance to anti-PD-1/PD-L1 therapy is a major unmet need. Growth Differentiation Factor 15 (GDF-15) has been identified as a key resistance factor for anti-PD-1/PD-L1 immunotherapy. Visugromab, a neutralizing anti-GDF-15 antibody, plus the anti-PD-1 antibody nivolumab (V+N) was evaluated in the first-in-human phase 1/2a GDFATHER-01 trial in heavily pretreated participants with locally advanced/metastatic non-squamous non-small-cell lung cancer (nsq NSCLC), urothelial carcinoma (UC), or hepatocellular…
Rank79.6
Neoadjuvant Atezolizumab and Chemotherapy for Non-Squamous Non-Small Cell Lung Cancer: Efficacy and Safety Results of an Open-Label, Single-Arm, Phase II Trial.
International journal of cancer · 2026 · PMID 42003237
Immune checkpoint inhibitors have shown promising results in the neoadjuvant treatment of resectable non-small cell lung cancer. This open-label, single-arm, prospective, monocentric trial evaluated the efficacy and safety of neoadjuvant atezolizumab plus carboplatin/nab-paclitaxel in patients with resectable non-squamous non-small cell lung cancer. Patients with previously untreated, pathologically confirmed, non-squamous non-small cell lung cancer in stage II, IIIA, and select IIIB (T3N2 only) were treated with a…
Rank79.2
A phase II multi-institutional single arm trial evaluating TG4010 vaccine plus nivolumab in non-small cell lung cancer.
Oncoimmunology · 2026 · PMID 42684015
Immune checkpoint inhibitors (ICIs) have transformed non-small cell lung cancer (NSCLC) therapy, but only 25% of patients have durable responses. TG4010, a mucin 1 (MUC1) vaccine, has demonstrated activity in NSCLC. We conducted a multi-institutional study to determine the safety and activity of nivolumab plus TG4010 in ICI naïve NSCLC patients (NCT02823990). The target accrual was 29 evaluable patients. The primary endpoint was the response rate requiring at least 10/29 responders. The study was terminated early d…
Rank78.0
Low-Dose Intestinal Irradiation Enhances the Efficacy and Prognosis of PD-1 Blockade in Metastatic Non-Small Cell Lung Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research · 2026 · PMID 41849236
PURPOSE: Intestinal low-dose irradiation (ILDR) may enhance immunotherapy efficacy by modulating the gut microbiota and metabolism; however, its role in metastatic non-small cell lung cancer (mNSCLC), particularly in the first-line setting, remains unclear. EXPERIMENTAL DESIGN: This multicenter retrospective and prospective study included patients with mNSCLC receiving first- and second-line programmed cell death protein 1 (PD-1) inhibitors along with abdominopelvic radiotherapy between 2018 and 2025. Patients were…
Rank77.0
A mixed inflammatory peripheral signature defines clinical outcomes in a phase II trial combining pembrolizumab with paclitaxel and carboplatin in melanoma.
Oncoimmunology · 2026 · PMID 41732954
Checkpoint blockade of PD-1 with pembrolizumab provides long-term survival to a significant proportion of patients with metastatic melanoma. Pembrolizumab has been successfully used in combination with chemotherapy in non-small-cell lung cancer to increase the response rate. This phase II trial combined pembrolizumab with carboplatin/paclitaxel (CP) to assess its safety and efficacy, and to identify correlates of responses. Thirty patients without prior immunotherapy for unresectable/metastatic melanoma were treate…
Rank77.0
A phase II study to evaluate the efficacy of commercially available molecularly matched targeted therapies in the second-line setting.
The oncologist · 2026 · PMID 42485262
BACKGROUND: Initial studies have shown improved outcomes in patients receiving cancer therapies matched to their molecular alterations. To improve the chances of finding a therapeutic match for patients, this study evaluated the preliminary antitumor activity of 3 commercially available multitargeted agents in the United States, regorafenib, afatinib, and cabozantinib. METHODS: In this phase II trial, patients who did not benefit from first-line treatment for non-small cell lung cancer (NSCLC), upper aerodigestive …
Rank77.0
Novel multiplex immunofluorescence-based tumor inflammation score provides apparent predictive biomarker in a phase I/II study of pembrolizumab with gemcitabine in patients with previously-treated advanced non-small cell lung cancer (NSCLC).
Oncoimmunology · 2026 · PMID 42126144
Retrospective characterization of cell‒cell relationships in the tumor microenvironment provides significantly better predictive power than PD-L1 expression, tumor mutational burden (TMB), or gene expression profiles. In this small study assessing the safety and possible efficacy of gemcitabine and pembrolizumab in immunotherapy-naïve patients with NSCLC who have received prior treatment, we investigated both standard and novel immune parameters in 16 enrolled patients (NCT03083808). The combination of gemcitabine …
Rank72.3
Daraxonrasib for Previously Treated RAS-Mutant Non-Small-Cell Lung Cancer.
The New England journal of medicine · 2026 · PMID 42685317
BACKGROUND: RAS mutations, as a group, are the most common oncogenic drivers of non-small-cell lung cancer (NSCLC), and they occur in approximately 30% of patients. Whether daraxonrasib (RMC-6236) - an oral RAS(ON) multiselective, tri-complex inhibitor of guanosine triphosphate-bound mutant and wild-type RAS protein isoforms - is safe and effective in patients with RAS-mutant NSCLC is unknown. METHODS: In this phase 1-2, multicenter, dose-escalation and dose-expansion study of daraxonrasib, we enrolled patients wit…
Rank70.2
SHR-A2102, a nectin-4 directed antibody-drug conjugate, in patients with pretreated advanced solid tumours: a multicentre, single-arm, phase 1 trial.
The Lancet. Oncology · 2026 · PMID 42636836
BACKGROUND: SHR-A2102 is a new antibody-drug conjugate consisting of a fully human nectin-4-directed monoclonal antibody bound to a topoisomerase I inhibitor payload via a cleavable linker. We did a phase 1 trial to evaluate the safety, preliminary activity, and pharmacokinetics of SHR-A2102 in advanced solid tumours. METHODS: This multicentre, single-arm, phase 1 trial was done at 39 hospitals in China and included dose-escalation (Bayesian Optimal Interval design), pharmacokinetic-expansion, and efficacy-expansio…
Prospective Cohort Studies108 records
Rank107.6
Time-of-Day Immunotherapy Administration and Outcomes in Advanced Cancers: A Systematic Review and Meta-Analysis.
JAMA network open · 2026 · PMID 42084869
IMPORTANCE: Circadian rhythms affect immunity, which could affect the effectiveness of immune checkpoint inhibitor (ICI). Whether the time of ICI administration is associated with clinical outcomes in advanced cancers remains unclear. OBJECTIVE: To evaluate the association between time of day of ICI administration and oncologic outcomes in patients with advanced solid tumors. DATA SOURCES: MEDLINE (via PubMed), Embase, and Web of Science Core Collection were searched in February 2026 to identify eligible studies. S…
Rank102.2
Endobronchial ultrasound-guided mediastinal biopsies for the diagnosis of mediastinal diseases: A network meta-analysis.
Pulmonology · 2026 · PMID 41560513
BACKGROUND: Clinical guidelines recommend endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) as the initial diagnostic tool for lung cancer staging. However, despite the availability of mediastinal forceps biopsy and cryobiopsy, the optimal diagnostic approaches for other mediastinal conditions remain unclear. METHODS: We searched multiple databases and sources up to February 21, 2025, and employed single-arm, pairwise, and network meta-analytical approaches to comprehensively evaluate EBU…
Rank100.0
Association Between Psychological Distress and Site-Specific Cancer Incidence: A Systematic Review and Meta-Analysis.
Psycho-oncology · 2026 · PMID 42592791
OBJECTIVE: Depression and anxiety are hypothesized to increase the risk for the development of chronic disease(s), including cancer. Several published observational studies and meta-analyses have investigated the link between depression and anxiety in cancer but have reported conflicting results. To clarify this relationship, a meta-analysis of observational studies reporting an association between depression, anxiety, and cancer incidence was performed. METHODS: Prospective and retrospective cohort studies investi…
Rank99.5
Impact of Different Mediastinal Staging Modalities on Target Volume Delineation in Locally Advanced Non-Small Cell Lung Cancer: A Secondary Analysis of the Multicenter Randomized PET-Plan Trial.
International journal of radiation oncology, biology, physics · 2025 · PMID 40054586
PURPOSE: To evaluate the role of different invasive and noninvasive mediastinal staging methods in patients with locally advanced non-small cell lung cancer treated with definitive chemoradiation therapy in the prospective PET-Plan trial (ARO-2009-09; NCT00697333) and to evaluate the impact of endobronchial ultrasound-guided transbronchial needle aspiration and mediastinoscopy on target volume definition. METHODS AND MATERIALS: Patients treated per protocol (n = 172), all receiving isotoxically dose-escalated chemo…
Rank99.3
Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial.
JAMA · 2026 · PMID 42574006
IMPORTANCE: Combination therapy has emerged as a promising therapeutic approach for patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). However, its clinical benefit-risk profile remains a focus of ongoing debate. Identifying patients most likely to derive benefit from such regimens remains an unmet clinical need. OBJECTIVE: To prospectively compare the efficacy and safety of first-line osimertinib plus chemotherapy with osimertinib monotherapy for patients with EGFR-mu…
Rank99.0
Smartphone App-Guided Pulmonary Rehabilitation in Chronic Respiratory Diseases: Randomized Controlled Trial.
JMIR mHealth and uHealth · 2025 · PMID 40854157
BACKGROUND: Pulmonary rehabilitation improves exercise capacity, dyspnea, quality of life, and survival in patients with chronic respiratory disease. However, center-based pulmonary rehabilitation programs remain unavailable in many health care facilities due to several barriers. To address this, we developed a smartphone app that enabled individuals to perform pulmonary rehabilitation at home. OBJECTIVE: We aimed to evaluate the efficacy of smartphone app-guided pulmonary rehabilitation in improving exercise capac…
Rank97.9
Artificial Intelligence-Assisted Lung Nodule Evaluation on Low-Dose Chest CT in Asymptomatic Individuals: A Prospective Randomized Controlled Trial.
AJR. American journal of roentgenology · 2026 · PMID 41848489
BACKGROUND. The impact of artificial intelligence (AI) tools for lung nodule evaluation on low-dose CT (LDCT) has been evaluated primarily using experimental retrospective reader designs, outside of clinical practice. OBJECTIVE. The purpose of this study was to compare interpretation times and lung nodule detection rates between real-world interpretations conducted with versus without an AI-based lung nodule evaluation tool for LDCT examinations in asymptomatic individuals. METHODS. This prospective single-center, …
Rank96.5
Concurrent chemoradiotherapy with or without simultaneous integrated boost for unresectable stage III non-small-cell lung cancer: a randomized phase II trial with exploratory EGFR and PD-L1 analyses.
Cancer genetics · 2026 · PMID 42456525
BACKGROUND AND PURPOSE: Based on the assumption that radiation dose escalation to the primary tumor improves local control and therefore produces survival benefits under the condition of limiting the dose to the organ at risk (OAR), we launched a study to evaluate the effect of simultaneous integrated boost (SIB) radiotherapy implemented in stage III locally advanced non-small cell lung cancer (LA-NSCLC) patients. MATERIALS AND METHODS: A prospective, single-center, open-label, randomized phase II trial was perform…
Rank92.0
A pilot study of precision treatment for patients with lung cancer pain by Longteng Tongluo recipe using serum genomics.
Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2024 · PMID 39380232
OBJECTIVE: To investigate the efficacy of Longteng Tongluo recipe (, LTTL) combined with three-step analgesia for the treatment of lung cancer pain, and the changes in serum miRNA expressions before- and after treatment with LTTL and its correlation with lung cancer pain. The possible mechanism underlying LTTL effects on the treatment of lung cancer pain was conducted. METHODS: The pilot study was conducted at the oncology ward of the Yueyang Hospital and the Longhua Hospital between March 2018 and October 2019. A …
Rank92.0
Comprehensive molecular profiling of advanced NSCLC in Greek patients:A prospective HeCOG study.
Cancer treatment and research communications · 2026 · PMID 42497607
BACKGROUND: We report for the first time the molecular landscape and outcome associations from the prospective CLIMEDIN trial in Greece. METHODS: Two hundred patients with newly diagnosed advanced NSCLC (March 2022-October 2023) were enrolled and randomized to standard-of-care education versus additional automated, adverse-event-targeted digital interventions. Within this study baseline testing (EGFR, ALK, PD-L1) was performed in all; 165 tumors underwent comprehensive NGS (Oncomine Comprehensive Assay v3). Primary…
Rank92.0
Clinical value of modified Shenling Baizhu powder in treating targeted therapy-induced diarrhea in non-small cell lung cancer.
Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2024 · PMID 39380231
OBJECTIVE: To assess clinical value of modified Shenling Baizhu powder (, SBP) in intervening targeted therapy-induced diarrhea. METHODS: This study was a prospective randomized controlled study. Eighty-five non-small cell lung cancer (NSCLC) patients with diarrhea who took targeted drugs were randomly divided into two groups. The experimental group received modified SBP, while the control group received imodium. During 2 courses of treatment (1 week/course) and 2 weeks of follow-up, we observed remission and recur…
Rank92.0
Spatially Fractionated Induction Radiotherapy to Widen the Therapeutic Window in Locally Advanced Non-Small-Cell Lung Cancer (SPARROW): Study Protocol of a Multicenter, Randomized, Open-Label Seamless Phase I/II Trial.
Clinical lung cancer · 2026 · PMID 42623891
BACKGROUND: Inoperable, locally advanced non-small-cell lung cancer (LA-NSCLC) remains associated with high rates of locoregional failure despite concurrent chemoradiotherapy and consolidation immunotherapy. Uniform dose escalation has failed to improve outcomes. We propose to address intra- and interindividual tumor heterogeneity by spatially fractionated radiotherapy (SFRT) and stereotactic body radiotherapy (SBRT). PATIENTS & METHODS: SPARROW is a prospective, multicenter, open-label seamless phase I/II randomiz…
Rank88.7
Effectiveness of preoperative pulmonary rehabilitation in patients with lung cancer combined with moderate to severe COPD: study protocol for a randomized controlled trial.
Respiratory medicine · 2026 · PMID 42309231
OBJECTIVE: The aim of this study is to evaluate the effectiveness of preoperative pulmonary rehabilitation in lung cancer patients with moderate to severe COPD by a randomized controlled trial protocol, and to explore the effect of preoperative pulmonary rehabilitation on surgical outcomes in high-risk patients. METHODS: A randomized, prospective, single-blind (evaluator) clinical trial. Participants(n = 70) will be randomly divided into two groups. The intervention group will receive 2 weeks preoperative pulmonary…
Rank82.0
Early ctDNA Stratifies Survival in Locally Advanced and Oligometastatic Lung Cancer Treated with Radiotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research · 2026 · PMID 42059900
PURPOSE: Circulating tumor fraction estimate (ctFE) is a machine learning-derived composite metric of circulating tumor DNA (ctDNA) burden. We hypothesized that pre-treatment and early on-treatment ctFE could robustly risk-stratify patients with locally advanced (LA) and oligometastatic non-small cell lung cancer (NSCLC) treated with radiotherapy (RT). EXPERIMENTAL DESIGN: In a prospective phase II clinical trial (NCT03916419), 26 patients with unresectable stage IIB to IIIC NSCLC received magnetic resonance (MR)-g…
Rank81.3
Prediction of Symptomatic Radiation Pneumonitis in Lung Cancer Patients: A Radiomics and Dosiomics Machine Learning Approach Using the Prospective Multicenter RTOG 0617 and REQUITE Trials.
International journal of radiation oncology, biology, physics · 2026 · PMID 41720170
PURPOSE: Radiation-induced pneumonitis (RP) is a side effect after thoracic radiation therapy (RT). The ability to predict RP would facilitate treatment modifications. This study investigates the predictive capacity for symptomatic RP (Common Terminology Criteria for Adverse Events ≥ 2) employing Radiomics and Dosiomics models. METHODS AND MATERIALS: Computed tomography scans, along with physical and 2-Gy equivalent dose volumes (EQD2), dose-volume histograms, and clinical parameters, were evaluated for 708 multice…
Rank80.6
High-Dose REirradiation for In-Field Recurrent Lung Cancer in the THOrax (RETHO): Outcomes of a Phase 2 Prospective Clinical Trial.
International journal of radiation oncology, biology, physics · 2026 · PMID 41429403
PURPOSE: Locoregional failures after (chemo)radiation therapy for primary lung cancer account for 30% of relapses. Reirradiation in this setting is challenging. To evaluate the outcome after thoracic reirradiation with radical doses, a prospective phase 2 trial was conducted for marginal or in-field recurrences of lung cancer. METHODS AND MATERIALS: The goal of this study was to treat recurrent lung cancer with high-dose (chemo)radiation therapy to reach a median overall survival (OS) of 12 months. Patients with re…
Rank80.3
Phase 2 Trial Assessing Toxicity of Personalized Response-Based Radiation Treatment in Patients With Locally Advanced Non-Small Cell Lung Cancer.
International journal of radiation oncology, biology, physics · 2024 · PMID 38971385
PURPOSE: Local failure rates after treatment for locally advanced non-small cell lung cancer (NSCLC) remain high. Efforts to improve local control with a uniform dose escalation or dose escalation to midtreatment positron emission tomography (PET)-avid residual disease have been limited by heightened toxicity. This trial aimed to refine response-based adaptive radiation therapy (RT) and minimize toxicity by incorporating fluorodeoxyglucose-PET (FDG-PET) and ventilation-perfusion single-photon emission computed tomo…
Rank80.0
Prophylactic Recombinant Human Thrombopoietin Prevents Cancer Therapy-Induced Thrombocytopenia During Concurrent Chemoradiation Therapy in Limited-Stage Small Cell Lung Cancer: A Prospective, Multicenter, Phase II Clinical Trial.
International journal of radiation oncology, biology, physics · 2026 · PMID 41831791
PURPOSE: Concurrent chemoradiation therapy is the standard therapy for limited-stage small cell lung cancer (LS-SCLC) but induces cancer therapy-induced thrombocytopenia (CTIT), which leads to treatment delays. This study aims to assess the efficacy and safety of prophylactic recombinant human thrombopoietin (rhTPO) in preventing CTIT in this patient population. METHODS AND MATERIALS: This prospective, multicenter, phase II trial was conducted across 14 Chinese centers. LS-SCLC patients receiving etoposide plus cis…
Rank79.6
Neoadjuvant Atezolizumab and Chemotherapy for Non-Squamous Non-Small Cell Lung Cancer: Efficacy and Safety Results of an Open-Label, Single-Arm, Phase II Trial.
International journal of cancer · 2026 · PMID 42003237
Immune checkpoint inhibitors have shown promising results in the neoadjuvant treatment of resectable non-small cell lung cancer. This open-label, single-arm, prospective, monocentric trial evaluated the efficacy and safety of neoadjuvant atezolizumab plus carboplatin/nab-paclitaxel in patients with resectable non-squamous non-small cell lung cancer. Patients with previously untreated, pathologically confirmed, non-squamous non-small cell lung cancer in stage II, IIIA, and select IIIB (T3N2 only) were treated with a…
Rank79.3
Dosimetry and Toxicity Comparison of Three-Dimensional Conformal Radiation Therapy and Intensity Modulated Radiation Therapy in Locally Advanced Lung Cancer Across a Large Statewide Quality Collaborative.
International journal of radiation oncology, biology, physics · 2025 · PMID 40074046
PURPOSE: Use of intensity modulated radiation therapy (IMRT) versus three-dimensional conformal external beam radiation therapy (3D-CRT) for definitive chemoradiation therapy (CRT) in locally advanced non-small cell lung cancer (LA-NSCLC) has been associated with decreased late pneumonitis, decreased high dose to the heart (itself associated with improved overall survival), and improved patient quality of life. In a statewide radiation oncology quality consortium, we sought to evaluate the impact of IMRT versus 3D-…
Rank78.1
Malnutrition Severity, Morphofunctional Assessment, and Survival in Patients with Lung Cancer: A Multicentre Prospective Cohort Study.
Lung · 2026 · PMID 42595921
PURPOSE: Malnutrition is common in lung cancer and may contribute to impaired functional status and poor survival. This study evaluated the association between GLIM-defined malnutrition, morphofunctional nutritional parameters, and one-year mortality in patients with lung cancer. METHODS: We conducted a multicentre prospective cohort study including 374 patients with primary lung cancer referred for nutritional and morphofunctional assessment before oncological treatment. Nutritional status was classified according…
Rank78.0
Low-Dose Intestinal Irradiation Enhances the Efficacy and Prognosis of PD-1 Blockade in Metastatic Non-Small Cell Lung Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research · 2026 · PMID 41849236
PURPOSE: Intestinal low-dose irradiation (ILDR) may enhance immunotherapy efficacy by modulating the gut microbiota and metabolism; however, its role in metastatic non-small cell lung cancer (mNSCLC), particularly in the first-line setting, remains unclear. EXPERIMENTAL DESIGN: This multicenter retrospective and prospective study included patients with mNSCLC receiving first- and second-line programmed cell death protein 1 (PD-1) inhibitors along with abdominopelvic radiotherapy between 2018 and 2025. Patients were…
Rank77.7
Early Prediction of Radiation Pneumonitis in Patients With Lung Cancer Treated With Immunotherapy Through Monitoring of Plasma Chemokines.
International journal of radiation oncology, biology, physics · 2025 · PMID 39993540
PURPOSE: This study is aimed to identify biomarkers for symptomatic radiation pneumonitis (RP) in patients with lung cancer treated with immune checkpoint inhibitors (ICIs). METHODS AND MATERIALS: This multicenter, prospective study enrolled patients with lung cancer receiving thoracic radiation therapy (RT) between 2021 and 2023. Plasma cytokines were measured using Luminex assays. Cox proportional hazards model was used to identify risk factors and biomarkers for RP. Sensitivity analysis was conducted using Fine-…
Rank77.4
Understanding pain in malignant mesothelioma: a prospective, longitudinal cohort study.
BMC palliative care · 2026 · PMID 42288902
BACKGROUND: Pain associated with malignant mesothelioma can be complex. The natural course of pain over the disease trajectory is not well studied. The aim of this study was to explore the prevalence, severity, impact and clinical course of pain for people with mesothelioma over a 12-month period. METHODS: A prospective observational study was conducted as a component of a larger national, multi-centre cohort study on mesothelioma - ASSESS-meso (A prospective obServational cohort Study collecting data on dEmographi…
Rank76.9
Real-World Evidence for Oncology Patients With Rare NTRK Gene Fusions: Final Results From the German Multicenter Patient Cohort Study REALTRK.
JCO precision oncology · 2026 · PMID 42550993
PURPOSE: TRK inhibitors (TRKis) have transformed the therapeutic landscape for patients with neurotrophic tyrosine receptor kinase (NTRK) gene fusion-positive tumors. However, approval of TRKis is based on evidence derived mainly from small, pooled, single-arm clinical trial cohorts. The REALTRK registry aims to describe real-world molecular diagnostic practices, treatment patterns, and clinical outcomes for adult patients with NTRK fusion-positive cancers. PATIENTS AND METHODS: The REALTRK registry was a multicent…
Quality Of Life70 records
Rank107.8
First-line systemic treatment for people with extensive-stage small cell lung cancer: a network meta-analysis.
The Cochrane database of systematic reviews · 2026 · PMID 42578486
RATIONALE: Extensive-stage small cell lung cancer (SCLC) carries a poor prognosis and has limited therapeutic options. The addition of immune-checkpoint inhibitors (ICIs) to platinum-etoposide (PE) chemotherapy has become an important first-line treatment strategy. However, the comparative benefits and harms of different first-line chemotherapy-based regimens, including ICI-containing combinations, remain unclear. OBJECTIVES: To evaluate the comparative benefits and harms of immunotherapy (anti-PD-1, anti-PD-L1, or…
Rank105.4
Update on the management of leptomeningeal disease in solid organ malignancy: Systemic, intrathecal and novel therapies.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia · 2026 · PMID 42140114
BACKGROUND: Leptomeningeal disease (LMD) is an increasingly recognised late-stage complication of solid tumours (primarily melanoma, lung and breast cancers). It involves dissemination to the leptomeninges surrounding the brain and spinal cord and carries a poor prognosis ranging from 2-6 months. Recent advances in emerging therapies such as CNS-active targeted therapy, intrathecal agents, and early-phase immunotherapy necessitate an updated appraisal of prospective data. METHODS: A systematic search of MEDLINE, Em…
Rank104.9
Postoperative survival in patients undergoing surgery for long bone metastases: a systematic review and Meta-analysis of outcomes across primary tumor types.
Journal of bone oncology · 2026 · PMID 42388270
BACKGROUND: Surgery for long bone metastases is performed to alleviate pain, restore function, and improve quality of life. Accurate postoperative survival estimates are essential for surgical planning and shared decision-making, yet no comprehensive synthesis exists across primary tumor types. This systematic review aimed to characterize postoperative survival and its temporal trend in patients undergoing surgery for long bone metastases. METHODS: A systematic literature search was performed in PubMed, EMBASE, and…
Rank103.8
Quality of life changes following treatment in patients with NSCLC: a systematic review and meta-analysis.
Cancer treatment and research communications · 2026 · PMID 42641462
BACKGROUND: Health-related quality of life (HRQoL) is central to treatment decisions. We conducted a meta-analysis to assess treatment effects on patient-reported HRQoL in non-small cell lung cancer (NSCLC). METHODS: We searched MEDLINE, Embase, PsycInfo and Scopus (January-May 2025) for studies reporting HRQoL in treated NSCLC patients. Article quality was assessed using CONSORT-PRO extension criteria, RoB 2 or ROBINS-I. We evaluated HRQoL changes from baseline to 4, 12, 24, 36 and 52 weeks post-treatment using st…
Rank102.0
What is the incidence and clinical significance of dry eye disease in patients treated with immune checkpoint inhibitors? A systematic review and meta-analysis of ocular immune-related adverse events.
Acta ophthalmologica · 2026 · PMID 41800487
PURPOSE: Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but may cause immune-related adverse events (irAEs), including dry eye disease (DED). This study aimed to quantify the incidence of ICI-associated DED and to evaluate factors contributing to variability across studies. METHODS: A systematic review and meta-analysis was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and was registered in the International Prospective Register o…
Rank100.0
Patient-Centered Physical Activity Intervention in Lung Cancer Patients: A Clinical Severity and Functional Capacity Systematic Review and Meta-analysis.
Cancer nursing · 2026 · PMID 39888667
BACKGROUND: Increasing physical activity levels is a significant unmet need in cancer survivors, and it can likely be enhanced through a better understanding of the interventions developed. Some studies on patient-centered physical activity interventions have shown promising results in increasing daily activity levels among lung cancer survivors. However, the programs present a high heterogeneity, and there is no consensus on the parameters and their effectiveness. OBJECTIVE: To examine the effectiveness of patient…
Rank99.5
First-Line Serplulimab in Extensive-Stage Small Cell Lung Cancer: Secondary Analysis of the ASTRUM-005 Phase 3 Randomized Clinical Trial.
JAMA oncology · 2026 · PMID 42240984
IMPORTANCE: The ASTRUM-005 phase 3 randomized clinical trial showed substantial survival benefit from adding serplulimab to chemotherapy for previously untreated extensive-stage small cell lung cancer (ES-SCLC). However, the long-term outcomes are unclear. OBJECTIVE: To investigate the efficacy, safety, patient-reported outcomes (PROs), and exploratory biomarker findings from ASTRUM-005 at an extended follow-up. DESIGN, SETTING, AND PARTICIPANTS: This international, double-blind, phase 3 randomized clinical trial e…
Rank98.8
Adjuvant alectinib versus chemotherapy in resected ALK-positive non-small-cell lung cancer (ALINA): health-related quality-of-life and safety outcomes from a randomised, open-label, phase 3 trial.
The Lancet. Oncology · 2026 · PMID 42636834
BACKGROUND: For patients with resected, ALK-positive non-small-cell lung cancer (NSCLC), adjuvant alectinib significantly improved disease-free survival versus platinum-based chemotherapy in the global, phase 3, open-label, randomised ALINA trial. We report safety and health-related quality-of-life (HRQoL) outcomes from the ALINA trial. METHODS: Eligible patients aged 18 years or older with resected, ALK-positive, stage IB (≥4 cm)-IIIA NSCLC (per the American Joint Committee on Cancer and the Union for Internationa…
Rank96.0
Efficacy of Chest Radiograph in Comparison to no Intervention in Screening for Lung Cancer in People who Smoke: A Systematic Review.
Annals of African medicine · 2026 · PMID 42573570
Smoking is the primary risk factor for lung cancer, which remains one of the leading causes of cancer-related mortality worldwide. Although chest radiography (CXR) is widely available and inexpensive, its role in lung cancer screening remains uncertain. This systematic review aimed to evaluate the efficacy of chest radiography compared with no screening for the detection of lung cancer, reduction in mortality and morbidity, screening-related harms, and quality of life among individuals who smoke. A systematic searc…
Rank96.0
Lung cancer multidisciplinary care status and evidence-practice gap: a scoping review protocol.
BMJ open · 2026 · PMID 42642084
INTRODUCTION: Lung cancer is the leading cause of cancer-related death worldwide, with substantial variations in incidence, stage at diagnosis and outcomes across regions. High-quality, standardised diagnosis and treatment are essential to improving survival and quality of life. Multidisciplinary care (MDC) is a cornerstone of cancer care; however, its implementation faces barriers such as limited resources, uneven policy support and inequitable access to specialised care, particularly in low- and middle-income cou…
Rank95.3
Digital Therapeutics-Based Cardio-Oncology Rehabilitation for Lung Cancer Survivors: Randomized Controlled Trial.
JMIR mHealth and uHealth · 2025 · PMID 39999435
BACKGROUND: Lung cancer ranks as the leading cause of cancer-related deaths. For lung cancer survivors, cardiopulmonary fitness is a strong independent predictor of survival, while surgical interventions impact both cardiovascular and pulmonary function. Home-based cardiac telerehabilitation through wearable devices and mobile apps is a substitution for traditional, center-based rehabilitation with equal efficacy and a higher completion rate. However, it has not been widely used in clinical practice. OBJECTIVE: The…
Rank93.4
Patient-reported outcomes with tarlatamab in extensive-stage small cell lung cancer after platinum-based chemotherapy: results from the phase 3 DeLLphi-304 trial.
Lung cancer (Amsterdam, Netherlands) · 2026 · PMID 42679738
BACKGROUND: Extensive-stage small cell lung cancer (ES-SCLC) is associated with a high symptom burden and impaired health-related quality of life (HRQoL). This prespecified analysis from the phase 3 DeLLphi-304 trial evaluated patient-reported outcomes (PROs) for tarlatamab versus standard-of-care (SoC) chemotherapy following first-line platinum-based therapy. METHODS: DeLLphi-304 is a multicenter, open-label, randomized phase 3 study in adults with ES-SCLC. PROs were assessed using validated instruments, including…
Rank92.3
Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial.
JAMA · 2026 · PMID 42574006
IMPORTANCE: Combination therapy has emerged as a promising therapeutic approach for patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). However, its clinical benefit-risk profile remains a focus of ongoing debate. Identifying patients most likely to derive benefit from such regimens remains an unmet clinical need. OBJECTIVE: To prospectively compare the efficacy and safety of first-line osimertinib plus chemotherapy with osimertinib monotherapy for patients with EGFR-mu…
Rank92.0
Assessing time to symptomatic progression, a patient-relevant efficacy endpoint, in the MARIPOSA study in non-small cell lung cancer.
European journal of cancer (Oxford, England : 1990) · 2026 · PMID 42492306
INTRODUCTION: In the phase 3 randomized MARIPOSA study, amivantamab and lazertinib combination therapy demonstrated improved progression-free survival (PFS) and overall survival (OS) versus osimertinib in participants with previously untreated, epidermal growth factor receptor-mutated advanced non-small cell lung cancer. Time to symptomatic progression (TTSP) was introduced to assess clinical worsening and complement endpoints that investigate radiographic disease progression and patient-reported outcomes. TTSP pro…
Rank91.9
Ivonescimab in combination with chemotherapy in advanced or metastatic gastric cancer (GC) or esophagogastric junction cancer (EGJC): The UCGI 52 - GRACIE trial.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2026 · PMID 42669571
BACKGROUND: While the addition of Ivonescimab to chemotherapy has demonstrated promising results in non-small cell lung cancer compared with chemotherapy alone, its efficacy as a first- or second-line treatment in advanced/metastatic gastric cancer remains to be established. AIMS: GRACIE aims to evaluate the efficacy and safety of Ivonescimab combined with FOLFOX chemotherapy as first-line treatment (Arm-1) or as second-line when combined with paclitaxel or irinotecan or FOLFIRI following progression (Arm-2), in pa…
Rank90.8
Five-Year Outcomes of Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer From the Randomized KEYNOTE-671 Study.
Annals of oncology : official journal of the European Society for Medical Oncology · 2026 · PMID 42628840
BACKGROUND: Adding perioperative pembrolizumab to neoadjuvant chemotherapy significantly improved survival outcomes compared with neoadjuvant chemotherapy and surgery alone in participants with early-stage non-small-cell lung cancer (NSCLC) in the phase 3, randomized KEYNOTE-671 study. We report results from KEYNOTE-671 after 5 years of follow-up. PATIENTS AND METHODS: Eligible participants with previously untreated, resectable stage II, IIIA, or IIIB (N2) NSCLC were randomized 1:1 to 4 cycles of pembrolizumab 200 …
Rank89.8
Patient-reported outcomes with a personalized follow-up program after lung cancer resection: A single-center randomized controlled trial.
Asia-Pacific journal of oncology nursing · 2026 · PMID 41625083
OBJECTIVE: This study aims to determine the impact of PROM with a personalized follow-up program on the evaluation of quality of life and self-management for patients after lung cancer resection. METHODS: Given a formal power calculation a total of 240 patients with lung cancer. Participants were randomly assigned to either the experimental or the control groups. Patients in the experimental group received a personalized follow-up program of patient-reported outcomes. The control group received only the telephone f…
Rank89.2
Daily low-dose carboplatin or weekly carboplatin plus nab-paclitaxel for concurrent chemoradiotherapy in older patients with locally advanced non-small cell lung cancer (JCOG1914): A randomized phase 3 trial.
Lung cancer (Amsterdam, Netherlands) · 2026 · PMID 42636548
BACKGROUND: Daily low-dose carboplatin with concurrent thoracic radiotherapy is the standard treatment for older patients with unresectable locally advanced non-small cell lung cancer (LA-NSCLC) in Japan. METHODS: This open-label phase 3 trial was conducted at 38 institutions in Japan. Patients aged ≥ 75 years with LA-NSCLC were randomly assigned (1:1) to receive daily carboplatin (30 mg/m2) or weekly carboplatin (area under the curve, 2 mg·min/mL) plus nab-paclitaxel (30 mg/m2) with thoracic radiotherapy. Durvalum…
Rank89.1
Effectiveness of a symptom network-based core symptom management program on symptom burden in lung cancer patients: A randomized controlled trial.
European journal of oncology nursing : the official journal of European Oncology Nursing Society · 2026 · PMID 42600403
PURPOSE: To evaluate the effects of a symptom network-based core symptom management program targeting fatigue, cough, and dyspnea on symptom burden, symptom management self-efficacy, and quality of life in patients undergoing lung cancer surgery. METHOD: This parallel-group randomized controlled trial was conducted at a tertiary hospital in Jiangsu Province, China, between March and December 2024. A total of 114 patients were randomly assigned to receive standard perioperative care or a symptom network-based core s…
Rank88.9
Protocol of a randomized trial of "pathways," a hope intervention for people undergoing treatment for advanced lung cancer.
Contemporary clinical trials · 2026 · PMID 42648399
OBJECTIVE: Advanced cancer and its treatment can disrupt personal goal pursuits and attainment, which can imperil patient quality of life and increase risk for depression. Hope interventions foster the goal-pursuit skills exemplified by high-hope individuals and, based on a pilot trial, are a promising approach to support these patients. The current Phase II trial (NCT06047301) aims to determine the efficacy of a brief, hope intervention, "Pathways," in improving depression symptoms for people undergoing treatment …
Rank88.7
Effectiveness of preoperative pulmonary rehabilitation in patients with lung cancer combined with moderate to severe COPD: study protocol for a randomized controlled trial.
Respiratory medicine · 2026 · PMID 42309231
OBJECTIVE: The aim of this study is to evaluate the effectiveness of preoperative pulmonary rehabilitation in lung cancer patients with moderate to severe COPD by a randomized controlled trial protocol, and to explore the effect of preoperative pulmonary rehabilitation on surgical outcomes in high-risk patients. METHODS: A randomized, prospective, single-blind (evaluator) clinical trial. Participants(n = 70) will be randomly divided into two groups. The intervention group will receive 2 weeks preoperative pulmonary…
Rank88.4
Prehabilitation in lung cancer patients undergoing lung resection surgery (Fit4LungNeo): study protocol.
Contemporary clinical trials communications · 2026 · PMID 42389378
BACKGROUND: Lung resection is the gold standard and the most effective curative treatment for lung cancer, especially in early-stage non-small cell lung cancer, improving long-term survival and quality of life. The growing body of evidence from randomized controlled trials supports the efficacy of prehabilitation in reducing both the incidence and severity of postoperative pulmonary complications and shortening the length of hospital stay. OBJECTIVE: The general objective is to compare the effects of a single educa…
Rank88.2
The Effect of a Nurse Navigation Program Based on Supportive Care Needs on Anxiety, Depression, Adaptation to Disease, and Quality of Life in Patients Diagnosed With Lung Cancer: A Randomized Controlled Trial.
Seminars in oncology nursing · 2026 · PMID 42686455
OBJECTIVES: A nurse navigation program can support individual patients' unsupported care needs and improve patient outcomes. This study, a nurse navigation program (LungCaNN) was developed to address the supportive care needs of patients newly diagnosed with non-small cell lung cancer (NSCLC). The primary aim of the study is to evaluate the effects of the LungCaNN program on patients' anxiety and depression levels, disease adaptation, and quality of life. Additionally, secondary outcome, the study investigates the …
Rank85.0
Strengthening awareness and community resources for early detection of lung cancer through navigation guided screening in American Indian/Alaska Native clinics (SACRED LUNGS): Study protocol.
Contemporary clinical trials · 2026 · PMID 42476254
BACKGROUND: Lung cancer remains the leading cause of cancer death in the United States. Annual lung cancer screening (LCS) with low-dose chest CT (LDCT) can prevent lung cancer deaths in individuals at high risk, and American Indian/Alaska Native (AI/AN) adults are among the highest risk populations; however, evidence suggests lower uptake of screening in this population compared to other groups. OBJECTIVE: To evaluate the impact of a culturally adapted patient navigation intervention delivered in Tribal healthcare…
Rank76.7
Quality of life and care experiences in a US multi-institutional neuroendocrine tumor cohort.
Journal of the National Cancer Institute · 2026 · PMID 41808486
BACKGROUND: Neuroendocrine tumors (NETs) are rare, heterogeneous neoplasms associated with prolonged survival and substantial symptom burden. However, patient-reported outcomes across NET subtypes remain poorly characterized, particularly in real-world settings. This study describes baseline health-related quality of life (HRQoL) and care experiences among patients with gastroenteropancreatic and lung NETs, examining differences by tumor site and time since diagnosis. METHODS: The Neuroendocrine Tumors-Patient Repo…
Randomized Controlled Trials120 records
Rank112.0
ESTRO clinical practice guideline on high-dose thoracic reirradiation for non-small cell lung cancer.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2026 · PMID 42468604
PURPOSE: High-dose thoracic reirradiation is increasingly used in clinical practice for patients with non-small cell lung cancer (NSCLC) in a variety of clinical scenarios ranging from locoregional recurrence to selected metastatic settings. The treatment goals of thoracic reirradiation include durable local control, symptom palliation, and potential cure. Despite growing clinical adoption, high-quality randomised evidence guiding patient selection, treatment delivery, and integration with systemic therapy remains …
Rank110.0
The Society of Thoracic Surgeons Expert Consensus Document (2026) on Addressing Definition and Practices of Sublobar Resection in Non-Small Cell Lung Cancer.
The Annals of thoracic surgery · 2026 · PMID 42320552
BACKGROUND: Two recent randomized clinical trials have shown sublobar resection to be noninferior to lobectomy in node-negative non-small cell lung cancer ≤2 cm. As a result, the use of sublobar resection in early lung cancer patients has significantly increased. Consensus recommendations are needed to guide its appropriate use. METHODS: The Society of Thoracic Surgeons Workforce on Evidence-Based Surgery assembled a panel of thoracic surgeons with clinical and methodological expertise to review the existing litera…
Rank109.7
Robotic-assisted versus video-assisted thoracoscopic anatomical lung resection for early-stage non-small cell lung cancer: a systematic review and meta-analysis.
Journal of robotic surgery · 2026 · PMID 42684651
Non-small cell lung cancer (NSCLC) represents 80-85% of lung cancer cases. Anatomical resection remains the cornerstone treatment for early-stage disease. Video-assisted (VATS) and robotic-assisted (RATS) thoracic surgery are alternatives to thoracotomy, though RATS's advantages over VATS remain controversial. We conducted this systematic review and meta-analysis to compare their perioperative and oncologic outcomes for anatomical resection in early-stage NSCLC. We searched PubMed, Cochrane Library, CINAHL, Web of …
Rank109.3
Long-term hormone therapy for perimenopausal and postmenopausal women.
The Cochrane database of systematic reviews · 2026 · PMID 42695385
BACKGROUND: Hormone therapy is widely provided to control menopausal symptoms and has been used for the management and prevention of cardiovascular disease, osteoporosis and dementia in older women. This is an updated version of a Cochrane review first published in 2005. OBJECTIVES: To assess the long-term effects of prolonged use (at least one year) of hormone therapy on mortality, cardiovascular outcomes, cancer, gallbladder disease, fractures and cognition in perimenopausal and postmenopausal women. SEARCH METHO…
Rank108.3
Efficacy and safety of immunotherapy in driver mutation-negative advanced non-small cell lung cancer: A systematic review and meta-analysis.
The Indian journal of medical research · 2026 · PMID 42555694
Background and objectives Despite substantial research on immunotherapy, its efficacy and safety in treating advanced non-small cell lung cancer (NSCLC) without identifiable driver mutations remain unclear. The objective of this review was to examine the efficacy and safety of immunotherapy, used as monotherapy or alongside chemotherapy, vs. chemotherapy alone in patients with advanced driver mutation-negative NSCLC. Methods A comprehensive literature search of PubMed, Embase, Scopus, and CENTRAL databases was cond…
Rank107.8
The clinical value of adding immune checkpoint inhibitors to radiotherapy for cancer: a systematic review and meta-analysis.
Annals of medicine · 2026 · PMID 42613912
BACKGROUND: While several randomized clinical trials (RCTs) have explored the addition of immune checkpoint inhibitor (ICI) treatment for patients undergoing radiotherapy, studies systematically assessing the clinical value of such interventions are lacking. METHODS: PubMed, Embase, and Cochrane Library databases were searched for relevant RCTs of cancers that received ICIs plus radiotherapy or radiotherapy. Eligible studies were those published in English as of 14 April 2024. Two independent reviewers screened the…
Rank107.8
First-line systemic treatment for people with extensive-stage small cell lung cancer: a network meta-analysis.
The Cochrane database of systematic reviews · 2026 · PMID 42578486
RATIONALE: Extensive-stage small cell lung cancer (SCLC) carries a poor prognosis and has limited therapeutic options. The addition of immune-checkpoint inhibitors (ICIs) to platinum-etoposide (PE) chemotherapy has become an important first-line treatment strategy. However, the comparative benefits and harms of different first-line chemotherapy-based regimens, including ICI-containing combinations, remain unclear. OBJECTIVES: To evaluate the comparative benefits and harms of immunotherapy (anti-PD-1, anti-PD-L1, or…
Rank107.6
Time-of-Day Immunotherapy Administration and Outcomes in Advanced Cancers: A Systematic Review and Meta-Analysis.
JAMA network open · 2026 · PMID 42084869
IMPORTANCE: Circadian rhythms affect immunity, which could affect the effectiveness of immune checkpoint inhibitor (ICI). Whether the time of ICI administration is associated with clinical outcomes in advanced cancers remains unclear. OBJECTIVE: To evaluate the association between time of day of ICI administration and oncologic outcomes in patients with advanced solid tumors. DATA SOURCES: MEDLINE (via PubMed), Embase, and Web of Science Core Collection were searched in February 2026 to identify eligible studies. S…
Rank107.5
A systematic review and network meta-analysis of first-line EGFR-TKI-based combination strategies for EGFR-mutant non-small cell lung cancer with brain metastases.
Scientific reports · 2026 · PMID 42686799
Brain metastases are common in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) and remain clinically challenging despite the improved central nervous system activity of third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs). Because direct comparisons between active first-line combination strategies are limited, this systematic review and network meta-analysis (NMA) evaluated the relative efficacy and safety of EGFR-TKI-based combinations in this population. PubMed, Embase, …
Rank107.2
Efficacy and safety of first-line immune checkpoint inhibitors combinations for extensive-stage small-cell lung cancer: A systematic review and network meta-analysis.
Medicine · 2026 · PMID 42566592
BACKGROUND: Combining immune checkpoint inhibitors (ICIs) with chemotherapy has become a major clinical research focus. Patients with extensive-stage small-cell lung cancer (ES-SCLC) have been treated with different first-line ICI combinations in randomized controlled trials (RCTs), but the optimal combination strategy has not yet been determined. Our aim was to evaluate this strategy through a systematic review and meta-analysis. METHODS: Articles published from inception to October 20, 2024 were systematically se…
Rank106.9
Efficacy and safety of durvalumab with or without tremelimumab in the treatment of metastatic non-small cell lung cancer: a meta-analysis of randomized controlled trials.
Proceedings (Baylor University. Medical Center) · 2026 · PMID 42658167
BACKGROUND: The therapeutic role of combining PD-L1 and CTLA-4 blockade in metastatic non-small cell lung cancer (NSCLC) remains unclear, with individual trials yielding discrepant results. METHODS: We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) to assess the efficacy and safety of durvalumab with or without tremelimumab in advanced NSCLC. The primary outcome was overall survival. Secondary outcomes included immune-related adverse events. Hazard ratios (HRs) and odds ratio…
Rank105.5
Single-fraction stereotactic radiosurgery vs. hypofractionated stereotactic radiotherapy for resected brain metastases: a systematic review and meta-analysis of comparative studies.
Neurosurgical review · 2026 · PMID 42700305
Postoperative stereotactic radiotherapy (SRT) is widely used after resection of limited brain metastases, but the optimal fractionation remains uncertain. Single-fraction stereotactic radiosurgery (SF-SRS) is convenient and well established, whereas hypofractionated stereotactic radiotherapy (HF-SRT) may improve dose delivery and normal tissue tolerance in larger or more complex cavities. This systematic review and meta-analysis compared these two postoperative approaches. PubMed, Scopus, and Embase were searched f…
Rank105.3
Efficacy and safety of neoadjuvant targeted therapy in non-small cell lung cancer: a systematic review and meta-analysis.
Systematic reviews · 2026 · PMID 41821091
INTRODUCTION: Epidermal growth factor receptor (EGFR) mutations are major oncogenic drivers in non-small cell lung cancer (NSCLC), occurring in 30-50% of Asian patients. Neoadjuvant EGFR-tyrosine kinase inhibitors (EGFR-TKIs) may improve surgical outcomes in resectable EGFR-mutant NSCLC, but evidence from small, heterogeneous trials is inconsistent and the overall efficacy and safety remain unclear. OBJECTIVES: To evaluate the efficacy and safety of neoadjuvant EGFR-TKI monotherapy in sensitizing EGFR-mutant NSCLC.…
Rank104.8
Perioperative antifibrotic therapy for patients with idiopathic pulmonary fibrosis undergoing lung cancer surgery: A systematic review and meta-analysis.
Heart & lung : the journal of critical care · 2025 · PMID 40789229
BACKGROUND: Patients with idiopathic pulmonary fibrosis (IPF) undergoing lung cancer surgery face a 4.4-20 % risk of acute exacerbation (AE-IPF) with mortality exceeding 50 %. The potential role of perioperative antifibrotic therapy in reducing surgical complications in this high-risk population remains unclear. OBJECTIVES: To evaluate whether perioperative antifibrotic therapy (pirfenidone/nintedanib) reduces complications, particularly acute exacerbations and mortality, in IPF patients undergoing lung cancer surg…
Rank103.0
Robotic-assisted transbronchial biopsy versus computed tomography-guided transthoracic needle biopsy for peripheral pulmonary lesions: a systematic review and meta-analysis of direct comparative studies.
Journal of robotic surgery · 2026 · PMID 42696224
Robotic-assisted bronchoscopy (RAB) and computed tomography-guided transthoracic biopsy (CTTB) are competing strategies for sampling peripheral pulmonary lesions (PPLs). Whether they differ in yield or safety is uncertain. To our knowledge, this is the first systematic review restricted to direct comparisons. We searched MEDLINE, Europe PMC, Scopus, Web of Science and ClinicalTrials.gov from inception to 7 July 2026 for studies directly comparing RAB with CTTB in adults with PPLs. The primary outcome was strict 202…
Rank102.4
Different Acupuncture Combined With Three-Step Analgesic Therapy in the Treatment of Bone Metastatic Cancer Pain: A Network Meta-Analysis Based on Randomized Controlled Trials.
Pain research & management · 2026 · PMID 42684261
BACKGROUND: Cancer pain (CP) is predominantly caused by bone metastases, imposing a significant burden on both patients and society. The limitations of the three-step analgesic (TSA) therapy in managing CP have become increasingly evident. Although acupuncture demonstrates promising therapeutic effects for this condition, there is currently limited research comparing the efficacy of different acupuncture modalities. RESULTS: A total of 20 studies were included, involving 1640 patients. The tumor types included lung…
Rank102.0
What is the incidence and clinical significance of dry eye disease in patients treated with immune checkpoint inhibitors? A systematic review and meta-analysis of ocular immune-related adverse events.
Acta ophthalmologica · 2026 · PMID 41800487
PURPOSE: Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but may cause immune-related adverse events (irAEs), including dry eye disease (DED). This study aimed to quantify the incidence of ICI-associated DED and to evaluate factors contributing to variability across studies. METHODS: A systematic review and meta-analysis was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and was registered in the International Prospective Register o…
Rank100.2
Surgical Outcomes of Perioperative Toripalimab in Stage III Resectable Non-Small Cell Lung Cancer: Post Hoc Analysis of the Neotorch Randomized Clinical Trial.
JAMA surgery · 2026 · PMID 42455561
IMPORTANCE: Perioperative immunotherapy has improved clinical outcomes for patients with early-stage non-small cell lung cancer (NSCLC). The influence of immune checkpoint inhibitor in combination with chemotherapy on surgical outcomes remains to be explored. OBJECTIVE: To evaluate perioperative toripalimab in combination with chemotherapy on surgical outcomes. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, double-blind, placebo-controlled phase 3 randomized clinical trial (Neotorch study) enrolled patients w…
Rank100.0
Non-Pharmacological Interventions for Cough in Patients With Lung Cancer: A Systematic Review and Meta-Analysis.
Journal of clinical nursing · 2026 · PMID 41834268
BACKGROUND: Cough, a prevalent and debilitating symptom of lung cancer, remains poorly managed. Accumulating evidence on non-pharmacological interventions for lung cancer cough necessitates systematic evaluation to assess their efficacy. AIM: To synthesise evidence on non-pharmacological interventions for managing cough in lung cancer patients. DESIGN: A systematic review and meta-analysis following the Preferred Reporting Items for Systematic reviews and Meta-Analyses reporting guideline. METHODS: Nine databases w…
Rank100.0
Pharmacological, psychosocial, and brain stimulation interventions in oncologic populations with mental disorders: An umbrella review.
Psychiatry research · 2026 · PMID 42184575
Mental health disorders frequently co-occur with oncological conditions, prompting an umbrella review(UR) to summarize meta-analytic evidence about the outcomes of pharmacological, psychosocial, and brain-stimulation interventions for psychiatric disorders in oncologic populations. We performed an UR of meta-analyses of randomized controlled trials(RCTs) documenting the efficacy of interventions for mental disorders in people with cancer(November 2, 2025). Re-calculated meta-analytic estimates employed the GRADE cr…
Rank100.0
Efficacy and safety of B7-H3-targeted antibody-drug conjugates in previously treated small cell lung cancer: a systematic review and meta-analysis with a contextual comparison to topotecan.
Frontiers in immunology · 2026 · PMID 42661867
OBJECTIVE: B7-H3-targeted antibody-drug conjugates (B7-H3-targeted ADCs) have shown promising antitumor effects in patients with previously treated small cell lung cancer (SCLC), yet the available evidence on their efficacy and safety has not been systematically synthesized. This study aimed to systematically evaluate the efficacy and safety of B7-H3-targeted ADCs and contextualize their clinical outcomes against standard-dose intravenous topotecan. METHODS: This systematic review and meta-analysis was conducted in…
Rank100.0
Programmed-death 1/programmed-death ligand 1 inhibitors plus chemotherapy versus chemotherapy for first-line treatment of advanced driver-gene negative non-squamous non-small cell lung cancer: An updated systematic review and meta-analysis.
Indian journal of cancer · 2026 · PMID 42301654
BACKGROUND: To assess the efficacy and safety of first-line programmed-death 1 (PD-1)/programmed-death ligand 1 (PD-L1) inhibitors + chemotherapy for driver-gene negative advanced non-squamous non-small cell lung cancer (NSCLC). METHODS: Eligible literature was identified following a systematic search of four electronic databases (PubMed, Embase, Ovid, and Cochrane library databases) from their inception to June, 2023. Unpublished research was searched from the American Society of Clinical Oncology (ASCO), European…
Rank100.0
Comparison of treatment efficacy of targeted therapies approved in China for non-small cell lung cancer before and after the introduction of accelerated drug marketing registration procedures.
International journal of clinical pharmacy · 2026 · PMID 41843046
INTRODUCTION: The introduction of Accelerated Drug Marketing Registration Procedures (ADMRPs) in China has improved patient access to innovative therapies, but concerns remain about the robustness and consistency of efficacy evidence. AIM: This study aimed to compare the treatment efficacy of approved targeted therapies for non-small cell lung cancer (NSCLC) before and after the implementation of ADMRPs. METHOD: In this retrospective study, we analyzed targeted therapies for NSCLC approved in China as of December 3…
Rank100.0
Economic evaluation comparing Endobronchial Ultrasound-guided Transbronchial Needle Aspiration (EBUS-TBNA) and surgical mediastinoscopy for mediastinal staging of lung cancer: a systematic review.
Journal of the Egyptian National Cancer Institute · 2026 · PMID 42579213
INTRODUCTION: Mediastinal sampling is essential for diagnosing and staging thoracic diseases, particularly non-small cell lung cancer (NSCLC). Traditional mediastinoscopy has been the gold standard; however, Endobronchial Ultrasound-guided Transbronchial Needle Aspiration (EBUS-TBNA) has emerged as a minimally invasive alternative. This systematic review compares the economic evaluations of EBUS-TBNA to determine their cost-effectiveness, healthcare resource use, and overall economic impact. METHODOLOGY: A systemat…
Rank100.0
Patient-Centered Physical Activity Intervention in Lung Cancer Patients: A Clinical Severity and Functional Capacity Systematic Review and Meta-analysis.
Cancer nursing · 2026 · PMID 39888667
BACKGROUND: Increasing physical activity levels is a significant unmet need in cancer survivors, and it can likely be enhanced through a better understanding of the interventions developed. Some studies on patient-centered physical activity interventions have shown promising results in increasing daily activity levels among lung cancer survivors. However, the programs present a high heterogeneity, and there is no consensus on the parameters and their effectiveness. OBJECTIVE: To examine the effectiveness of patient…
Safety And Adverse Effects197 records
Rank110.0
Risk of Liver Cancer From Major Causes Compared to Smoking and Lung Cancer: A Systematic Review and Meta-Analysis.
Journal of viral hepatitis · 2026 · PMID 42605247
Liver cancer is the second leading cause of premature cancer mortality globally, whose main causes-HBV, HCV, MASH and alcohol use-are preventable. Viral hepatitis' carcinogenicity is not as well-known as the risk of lung cancer from smoking, leading to rising rates of liver cancer worldwide. The aim of this study was to compare the risk of liver cancer in HBV, HCV, HDV, MASH and alcohol consumption with the better-known risk of lung cancer associated with smoking. We extracted the relative risk of liver cancer from…
Rank108.3
Efficacy and safety of immunotherapy in driver mutation-negative advanced non-small cell lung cancer: A systematic review and meta-analysis.
The Indian journal of medical research · 2026 · PMID 42555694
Background and objectives Despite substantial research on immunotherapy, its efficacy and safety in treating advanced non-small cell lung cancer (NSCLC) without identifiable driver mutations remain unclear. The objective of this review was to examine the efficacy and safety of immunotherapy, used as monotherapy or alongside chemotherapy, vs. chemotherapy alone in patients with advanced driver mutation-negative NSCLC. Methods A comprehensive literature search of PubMed, Embase, Scopus, and CENTRAL databases was cond…
Rank107.8
The clinical value of adding immune checkpoint inhibitors to radiotherapy for cancer: a systematic review and meta-analysis.
Annals of medicine · 2026 · PMID 42613912
BACKGROUND: While several randomized clinical trials (RCTs) have explored the addition of immune checkpoint inhibitor (ICI) treatment for patients undergoing radiotherapy, studies systematically assessing the clinical value of such interventions are lacking. METHODS: PubMed, Embase, and Cochrane Library databases were searched for relevant RCTs of cancers that received ICIs plus radiotherapy or radiotherapy. Eligible studies were those published in English as of 14 April 2024. Two independent reviewers screened the…
Rank107.8
First-line systemic treatment for people with extensive-stage small cell lung cancer: a network meta-analysis.
The Cochrane database of systematic reviews · 2026 · PMID 42578486
RATIONALE: Extensive-stage small cell lung cancer (SCLC) carries a poor prognosis and has limited therapeutic options. The addition of immune-checkpoint inhibitors (ICIs) to platinum-etoposide (PE) chemotherapy has become an important first-line treatment strategy. However, the comparative benefits and harms of different first-line chemotherapy-based regimens, including ICI-containing combinations, remain unclear. OBJECTIVES: To evaluate the comparative benefits and harms of immunotherapy (anti-PD-1, anti-PD-L1, or…
Rank106.9
Efficacy and safety of durvalumab with or without tremelimumab in the treatment of metastatic non-small cell lung cancer: a meta-analysis of randomized controlled trials.
Proceedings (Baylor University. Medical Center) · 2026 · PMID 42658167
BACKGROUND: The therapeutic role of combining PD-L1 and CTLA-4 blockade in metastatic non-small cell lung cancer (NSCLC) remains unclear, with individual trials yielding discrepant results. METHODS: We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) to assess the efficacy and safety of durvalumab with or without tremelimumab in advanced NSCLC. The primary outcome was overall survival. Secondary outcomes included immune-related adverse events. Hazard ratios (HRs) and odds ratio…
Rank106.0
Association between smoking and prognosis in idiopathic pulmonary fibrosis: A systematic review and meta-analysis.
Pulmonology · 2026 · PMID 42339520
BACKGROUND: Although smoking is a well-established risk factor for idiopathic pulmonary fibrosis (IPF) development, its impact on clinical outcomes remains unclear. RESEARCH QUESTION: Is smoking associated with clinical outcomes of IPF? METHODS: A systematic search of PubMed, Embase, and the Cochrane Library was conducted to identify studies reporting associations between smoking status and IPF outcomes, including mortality, acute exacerbation (AE), lung cancer development, and baseline lung function. Summary estim…
Rank105.7
Treatment Toxicity and Outcomes Following Definitive Radiation Therapy for Patients With Early-Stage Non-Small Cell Lung Cancers and Pre-Existing Interstitial Lung Disease-A Systematic Review and Dosimetric Analysis.
International journal of radiation oncology, biology, physics · 2025 · PMID 40581332
BACKGROUND: Patients with interstitial lung disease (ILD) who develop lung cancer represent a unique challenge, as they are at higher risk for serious toxicity from local and systemic therapies. The aim of this study is to provide an up-to-date analysis on toxicities and outcomes associated with definitive radiation therapy (RT) in patients with ILD and early-stage non-small cell lung cancer (ES-NSCLC). METHODS AND MATERIALS: We performed a systematic review in accordance with Preferred Reporting Items for Systemat…
Rank105.3
Efficacy and safety of neoadjuvant targeted therapy in non-small cell lung cancer: a systematic review and meta-analysis.
Systematic reviews · 2026 · PMID 41821091
INTRODUCTION: Epidermal growth factor receptor (EGFR) mutations are major oncogenic drivers in non-small cell lung cancer (NSCLC), occurring in 30-50% of Asian patients. Neoadjuvant EGFR-tyrosine kinase inhibitors (EGFR-TKIs) may improve surgical outcomes in resectable EGFR-mutant NSCLC, but evidence from small, heterogeneous trials is inconsistent and the overall efficacy and safety remain unclear. OBJECTIVES: To evaluate the efficacy and safety of neoadjuvant EGFR-TKI monotherapy in sensitizing EGFR-mutant NSCLC.…
Rank104.8
Necrotizing and Nonnecrotizing Granulomatous Reactions in Patients With Cancer Treated With Immune Checkpoint Inhibitors: A Systematic Literature Review.
The Journal of rheumatology · 2025 · PMID 40664481
OBJECTIVE: Immune checkpoint inhibitors (ICI) have improved cancer outcomes but often cause immune-related adverse events, including granulomatous reactions (GRs). We analyzed GRs in patients receiving anticytotoxic T-lymphocyte-associated protein 4 (anti-CTLA4), antiprogrammed cell death protein 1 (anti-PD1)/antiprogrammed death ligand 1 (anti-PDL1), and anti-CTLA4/anti-PD1 therapies. METHODS: We performed a literature review of GRs in patients receiving ICI. Data were extracted from 166 articles, including demogr…
Rank104.8
Perioperative antifibrotic therapy for patients with idiopathic pulmonary fibrosis undergoing lung cancer surgery: A systematic review and meta-analysis.
Heart & lung : the journal of critical care · 2025 · PMID 40789229
BACKGROUND: Patients with idiopathic pulmonary fibrosis (IPF) undergoing lung cancer surgery face a 4.4-20 % risk of acute exacerbation (AE-IPF) with mortality exceeding 50 %. The potential role of perioperative antifibrotic therapy in reducing surgical complications in this high-risk population remains unclear. OBJECTIVES: To evaluate whether perioperative antifibrotic therapy (pirfenidone/nintedanib) reduces complications, particularly acute exacerbations and mortality, in IPF patients undergoing lung cancer surg…
Rank103.4
Stevens-Johnson syndrome and toxic epidermal necrolysis associated with immune checkpoint inhibitors: a systematic review.
Frontiers in immunology · 2024 · PMID 39072330
INTRODUCTION: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare yet life-threatening adverse events associated with immune checkpoint inhibitors (ICIs). This systematic review synthesizes the current literature to elucidate the clinical characteristics and outcomes of patients with ICI-related SJS/TEN. METHODS: We conducted a thorough search across databases including Embase, Web of Science, Cochrane, MEDLINE, Scopus, and PubMed. Selection criteria focused on reports of SJS/TEN among canc…
Rank103.2
Pulmonary Toxicities of Antibody-Drug Conjugates in Small Cell and Non-Small Cell Lung Cancer: A Systematic Review and Meta-analysis.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2026 · PMID 42674256
BACKGROUND: Antibody-drug conjugates (ADCs) are increasingly used in the treatment of small cell (SCLC) and non-small cell lung cancer (NSCLC). Despite their targeted design, clinically significant pulmonary adverse events (AEs) have been reported, but the incidence and toxicity profile in lung cancer remain incompletely defined. We aimed to quantify the incidence and severity of pulmonary AEs associated with ADCs and to evaluate differences by tumor type and drug design features. METHODS: We performed a PRISMA-gui…
Rank103.0
Long-term oncologic outcomes after non-intubated versus intubated video-assisted thoracoscopic surgery for non-small cell lung cancer: a systematic review and meta-analysis.
Frontiers in oncology · 2026 · PMID 42666271
BACKGROUND: Non-intubated video-assisted thoracoscopic surgery (NIVATS) is increasingly used for selected non-small cell lung cancer (NSCLC) patients, but its long-term oncologic outcomes versus conventional VATS remain unclear. We therefore conducted this systematic review and meta-analysis to compare long-term oncologic outcomes between NIVATS and conventional intubated video-assisted thoracoscopic surgery (VATS). METHODS: We searched major databases and trial registries through June 30, 2026 for comparative stud…
Rank102.4
Different Acupuncture Combined With Three-Step Analgesic Therapy in the Treatment of Bone Metastatic Cancer Pain: A Network Meta-Analysis Based on Randomized Controlled Trials.
Pain research & management · 2026 · PMID 42684261
BACKGROUND: Cancer pain (CP) is predominantly caused by bone metastases, imposing a significant burden on both patients and society. The limitations of the three-step analgesic (TSA) therapy in managing CP have become increasingly evident. Although acupuncture demonstrates promising therapeutic effects for this condition, there is currently limited research comparing the efficacy of different acupuncture modalities. RESULTS: A total of 20 studies were included, involving 1640 patients. The tumor types included lung…
Rank102.2
Endobronchial ultrasound-guided mediastinal biopsies for the diagnosis of mediastinal diseases: A network meta-analysis.
Pulmonology · 2026 · PMID 41560513
BACKGROUND: Clinical guidelines recommend endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) as the initial diagnostic tool for lung cancer staging. However, despite the availability of mediastinal forceps biopsy and cryobiopsy, the optimal diagnostic approaches for other mediastinal conditions remain unclear. METHODS: We searched multiple databases and sources up to February 21, 2025, and employed single-arm, pairwise, and network meta-analytical approaches to comprehensively evaluate EBU…
Rank100.0
Financial toxicity among patients with lung cancer: a systematic review and meta-analysis.
Frontiers in public health · 2026 · PMID 42661720
BACKGROUND: Lung cancer imposes a substantial global health burden. Although advances in treatment have improved outcomes, increasingly prolonged and complex care may impose considerable financial pressure on patients and their families. We systematically synthesized evidence on financial toxicity (FT) and its associated factors among patients with lung cancer. METHODS: PubMed, Embase, the Cochrane Library, and Scopus were systematically searched through November 2025 for observational studies evaluating FT in pati…
Rank100.0
Efficacy and safety of B7-H3-targeted antibody-drug conjugates in previously treated small cell lung cancer: a systematic review and meta-analysis with a contextual comparison to topotecan.
Frontiers in immunology · 2026 · PMID 42661867
OBJECTIVE: B7-H3-targeted antibody-drug conjugates (B7-H3-targeted ADCs) have shown promising antitumor effects in patients with previously treated small cell lung cancer (SCLC), yet the available evidence on their efficacy and safety has not been systematically synthesized. This study aimed to systematically evaluate the efficacy and safety of B7-H3-targeted ADCs and contextualize their clinical outcomes against standard-dose intravenous topotecan. METHODS: This systematic review and meta-analysis was conducted in…
Rank100.0
SELECTIVE BRONCHIAL ARTERY CHEMOINFUSION IN NSCLC: CURRENT STATE OF REGIONAL THERAPY AND ITS ROLE IN MULTIMODAL APPROACHES.
Georgian medical news · 2026 · PMID 42603327
UNLABELLED: Regional intra-arterial delivery of cytotoxic drugs into bronchial arteries (bronchial artery infusion - BAI; bronchial arterial chemoembolization - BACE; drug-eluting bead BACE - DEB-BACE) aims to maximize local tumor exposure while minimizing systemic toxicity. Recent single-center series suggest potential for symptom control, local tumor downstaging and conversion to resectability in locally advanced NSCLC, but evidence remains heterogeneous. OBJECTIVE: To systematically review and critically apprais…
Rank100.0
Evidence-based indications for proton therapy in adults determined using the GRADE approach.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026 · PMID 41557143
PURPOSE: Proton therapy (PT) offers dosimetric advantages over conventional X-ray-based radiotherapy (XRT), aiming to reduce toxicity and better spare healthy tissues. The Agency for Health Quality and Assessment of Catalonia (AQuAS), commissioned by the Spanish Ministry of Health, conducted a Health Technology Assessment to evaluate the safety and clinical effectiveness of PT for cancer indications not yet approved for PT in Spain. This article summarizes the main findings regarding PT's safety and clinical perfor…
Rank100.0
Nanocarrier-Based Drug Delivery Systems for Lung Cancer: A Systematic Review and Meta-Analysis of Preclinical Studies.
Advances in respiratory medicine · 2026 · PMID 42644871
Drug delivery systems (DDS) may improve the therapeutic performance of chemotherapy in lung cancer, but their preclinical efficacy has not been quantitatively synthesized. We conducted a systematic review and meta-analysis of controlled in vivo mouse studies evaluating DDS-based chemotherapeutic formulations for lung cancer. Databases were searched from inception to 15 February 2025, and methodological quality was assessed using the SYRCLE risk-of-bias tool. Thirty studies comprising 47 experiments were included. C…
Rank100.0
The Cardiotoxicity Risk of Immune Checkpoint Inhibitors Compared with Chemotherapy: A Systematic Review and Meta-analysis of Observational Studies.
Cardiovascular toxicology · 2025 · PMID 40053271
Immune checkpoint inhibitors (ICIs) have demonstrated favorable outcomes in various cancers. However, it has been observed that ICIs may induce life-threatening cardiovascular toxicity. In this study, a meta-analysis was conducted to determine the risk of cardiovascular toxicities in patients exposed to ICIs or in combination with chemotherapy. PubMed, Cochrane Library, and Embase databases were searched from inception to September 24, 2023. This study was conducted in accordance with the PRISMA guidelines. A meta-…
Rank100.0
Health risk assessment of inorganic arsenic: an umbrella review.
Reviews on environmental health · 2026 · PMID 42494104
Inorganic arsenic (iAs) is a toxic environmental pollutant linked to serious health risks, prompting global regulatory efforts. This study identifies major health conditions associated with iAs exposure using text network analysis, and assesses health risk assessments through an umbrella review and dose-response analysis. It synthesizes previous systematic reviews to offer a broader perspective on iAs-related health effects. An optimized text network analysis-based search strategy was applied across multiple databa…
Rank97.2
Safety Evaluation of Tarlatamab in SCLC: A Systematic Review and Meta-Analysis.
JTO clinical and research reports · 2026 · PMID 42668666
INTRODUCTION: Tarlatamab, a bispecific T-cell engager targeting delta-like ligand 3 and CD3, demonstrated clinical activity both in previously treated SCLC and as intensification of maintenance immunotherapy. Owing to its action mechanism, tarlatamab exerts a new toxicity profile, needing careful management. Based on these premises, we performed a systematic review and meta-analysis to evaluate treatment-related adverse events (TRAEs) among available clinical trials enrolling patients with SCLC receiving tarlatamab…
Rank96.9
Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small-cell lung cancer: 7-year update from the phase III CROWN study.
Annals of oncology : official journal of the European Society for Medical Oncology · 2026 · PMID 42217582
BACKGROUND: Due to the unprecedented progression-free survival (PFS) benefit with lorlatinib after 5 years of follow-up in the phase III CROWN study, we aimed to quantify long-term outcomes at 7 years. PATIENTS AND METHODS: Treatment-naive patients (N = 296) with advanced anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) were randomly assigned 1:1 to receive lorlatinib 100 mg once a day (n = 149) or crizotinib 250 mg twice a day (n = 147). This post hoc analysis presents investigator-asse…
Rank96.8
SKYSCRAPER-01: Tiragolumab in Combination With Atezolizumab in Previously Untreated PD-L1-High, Locally Advanced, Unresectable or Metastatic Non-Small Cell Lung Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026 · PMID 42507968
PURPOSE: Tiragolumab plus atezolizumab has shown encouraging survival outcomes in metastatic non-small cell lung cancer (NSCLC), primarily in patients with PD-L1-high tumors. We further evaluated the combination of tiragolumab plus atezolizumab in the phase III SKYSCRAPER-01 study. METHODS: Patients with untreated, locally advanced unresectable/metastatic PD-L1-high (by central laboratory testing) NSCLC were randomly assigned 1:1 to receive either tiragolumab (600 mg) plus atezolizumab (1,200 mg) or placebo plus at…
Treatments That Failed Clinical Trials59 records
Rank99.3
Morning versus afternoon administration of immune checkpoint inhibitors in metastatic non-small-cell lung cancer.
Journal for immunotherapy of cancer · 2026 · PMID 42134900
BACKGROUND: Circadian biology suggests that synchronizing immune checkpoint inhibitor (ICI) dosing with morning peaks in immune activation could improve clinical outcomes, but well-powered studies using appropriate causal inference methodology are sparse. METHODS: We emulated a pragmatic randomized controlled trial of AM versus PM ICI infusions using Veterans Health Administration records from 2010 to 2024. In the emulated trial, stage IV non-small-cell lung cancer patients planned to undergo first-line or second-l…
Rank98.5
Preliminary Effects of Hydrogen-Oxygen Inhalation on Nodule Size, IL-6, and Neutrophils in Patients with Small Pulmonary Nodules.
Drug design, development and therapy · 2026 · PMID 42453934
OBJECTIVE: To evaluate the effects of hydrogen-oxygen inhalation on nodule diameter and peripheral blood inflammatory factors in patients with small pulmonary nodules (SPNs), and to further analyze its efficacy in the smoking subgroup. The primary endpoint was the change in pulmonary nodule diameter before and after intervention; secondary endpoints included alterations in serum IL-6, CRP, peripheral blood neutrophil count, and Mayo malignant transformation risk score. METHODS: A total of 59 patients with SPNs conf…
Rank97.9
Artificial Intelligence-Assisted Lung Nodule Evaluation on Low-Dose Chest CT in Asymptomatic Individuals: A Prospective Randomized Controlled Trial.
AJR. American journal of roentgenology · 2026 · PMID 41848489
BACKGROUND. The impact of artificial intelligence (AI) tools for lung nodule evaluation on low-dose CT (LDCT) has been evaluated primarily using experimental retrospective reader designs, outside of clinical practice. OBJECTIVE. The purpose of this study was to compare interpretation times and lung nodule detection rates between real-world interpretations conducted with versus without an AI-based lung nodule evaluation tool for LDCT examinations in asymptomatic individuals. METHODS. This prospective single-center, …
Rank97.6
First-line serplulimab plus chemotherapy with or without HLX04 versus chemotherapy in locally advanced or metastatic non-squamous non-small-cell lung cancer (ASTRUM-002): a randomised, double-blind, multicentre phase 3 trial.
The Lancet. Respiratory medicine · 2026 · PMID 41354044
BACKGROUND: Whether the addition of bevacizumab to a programmed cell death protein-1 (PD-1) inhibitor plus chemotherapy can provide further survival benefits as first-line treatment in non-squamous non-small-cell lung cancer (NSCLC) without EGFR sensitising mutations, or ALK/ROS1 rearrangements, is unknown. We evaluated serplulimab (an anti-PD-1 antibody) plus HLX04 (a bevacizumab biosimilar) and chemotherapy in non-squamous NSCLC. METHODS: ASTRUM-002 is a randomised, double-blind, multicentre, phase 3 trial with a…
Rank97.5
Benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3 trial.
The Lancet. Oncology · 2026 · PMID 41825453
BACKGROUND: PD-1 and PD-L1 inhibitors have been shown to synergise with anti-angiogenic agents in non-small-cell lung cancer (NSCLC). We aimed to compare benmelstobart plus anlotinib with pembrolizumab in patients with previously untreated, driver gene-negative, PD-L1-positive, advanced NSCLC. METHODS: The blinded, randomised, controlled, phase 3 CAMPASS trial was conducted in 79 centres across China. Patients aged 18-75 years with stage IIIB-IV squamous or non-squamous NSCLC, no previous systemic treatment for adv…
Rank97.4
Efficacy of alectinib for ALK-positive NSCLC according to tumor burden and body mass index: A pooled analysis of the randomized phase III trials ALEX and J-ALEX.
European journal of cancer (Oxford, England : 1990) · 2026 · PMID 42269244
BACKGROUND: Although first-line alectinib is highly effective, outcomes in ALK-positive NSCLC remain variable. METHODS: We conducted an individual patient-level pooled analysis of the phase III ALEX (NCT02075840) and J-ALEX (JapicCTI-132316) trials to explore new prognostic and predictive factors. The primary endpoint was PFS. Multivariate Cox and random effects models accounted for trials independence. Baseline characteristics analyzed included high vs. low tumor burden (sum of target lesions by RECIST v1.1 above/…
Rank97.3
Adjuvant Nivolumab vs Observation in Resected Non-Small Cell Lung Cancer: A Randomized Clinical Trial.
JAMA · 2026 · PMID 42224490
IMPORTANCE: Preoperative and perioperative nivolumab improve event-free survival in resectable non-small cell lung cancer. The role of adjuvant nivolumab after upfront surgery is unknown. OBJECTIVE: To determine whether adjuvant nivolumab improves disease-free survival and overall survival in patients with resected non-small cell lung cancer with any tumor programmed death-ligand 1 (PD-L1) expression and in those with at least 50% PD-L1 expression. DESIGN, SETTING, AND PARTICIPANTS: This open-label, randomized phas…
Rank97.2
Final overall survival analysis of the APPLE study: atezolizumab and platinum-pemetrexed with or without bevacizumab for metastatic nonsquamous non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) · 2026 · PMID 42127535
BACKGROUND: The phase III APPLE trial evaluated the efficacy of adding bevacizumab to atezolizumab with carboplatin plus pemetrexed (APP) for individuals with advanced nonsquamous non-small cell lung cancer (NSCLC). We here report the long-term outcomes of this trial with 3.5 years of follow-up. METHODS: Patients with advanced nonsquamous NSCLC were randomized 1:1 to receive APP or APP plus bevacizumab (APPB). Stratification factors were clinical stage, driver oncogenes, and PD-L1 expression. Endpoints included pro…
Rank97.0
Evaluating the prognostic impact of multiple 18FDG-PET imaging parameters in small-cell lung cancer: Insights from the long-term analysis of the CONVERT trial.
European journal of nuclear medicine and molecular imaging · 2026 · PMID 41801367
BACKGROUND: The prognostic value of baseline 18F-FDG PET/CT-derived metrics in limited-stage small-cell lung cancer (LS-SCLC) remains uncertain. We evaluated whether baseline PET-derived parameters provide prognostic information beyond tumour volume and clinical factors in patients treated with curative-intent chemoradiotherapy within the phase III CONVERT trial. METHODS: CONVERT was an international, multi-centre randomised controlled trial. This study is a post-hoc analysis of baseline 18F-FDG PET/CT from the mul…
Rank96.8
Ten-year overall survival in resectable stage-III NSCLC - Results of the randomized ESPATUE trial - Long-term survival and competing risk analysis.
European journal of cancer (Oxford, England : 1990) · 2026 · PMID 41702246
INTRODUCTION: More stage III non-small-cell lung cancer patients experience long-term survival (OS). ESPATUE-trial looked at surgery versus boost-radiochemotherapy following induction chemotherapy, consisting of three cycles of cisplatin 50 mg/m2 on days 1 and 8 and paclitaxel 175 mg/m2 on day 1 every 21 days, as well as concurrent chemoradiotherapy to 45 Gy given as 1.5 Gy twice daily, concurrent cisplatin 50 mg/m2 on days 2 and 9, and concurrent vinorelbine 20 mg/m2 on days 2 and 9 (Eberhardt et al, J Clin Oncol …
Rank96.8
Durvalumab Consolidation in Limited-Stage SCLC: Outcomes by Prior Concurrent Chemoradiotherapy and Prophylactic Cranial Irradiation in the Phase 3 ADRIATIC Trial.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2026 · PMID 41921748
INTRODUCTION: In ADRIATIC, consolidation durvalumab significantly improved overall survival (OS) and progression-free survival (PFS) versus placebo in patients with limited-stage SCLC without progression after concurrent chemoradiotherapy (cCRT). Exploratory analyses were conducted in prespecified subgroups per protocol-permitted cCRT components, prophylactic cranial irradiation (PCI) receipt, and time from end of cCRT to randomization. METHODS: Prior cCRT comprised cisplatin-etoposide or carboplatin-etoposide with…
Rank96.7
Adjuvant chemotherapy intensity and prognosis in completely resected high-grade neuroendocrine lung carcinoma: a post hoc analysis of JCOG1205/1206.
Lung cancer (Amsterdam, Netherlands) · 2026 · PMID 42425045
INTRODUCTION: We aimed to clarify the prognostic impact of adjuvant chemotherapy intensity in patients with high-grade neuroendocrine carcinoma (HGNEC) of the lung using a post hoc analysis of the phase III JCOG1205/1206 trial comparing irinotecan plus cisplatin (IP) with etoposide plus cisplatin (EP). MATERIAL AND METHODS: We included 217 patients (109 and 108 received EP and IP, respectively) with p-stage I-IIIA HGNEC. Prognosis was assessed based on treatment completion (four cycles) and relative dose intensity …
Rank96.7
Five-year overall survival in JCOG1205/1206: irinotecan or etoposide plus cisplatin for resected high-grade neuroendocrine carcinoma of the lung.
Lung cancer (Amsterdam, Netherlands) · 2026 · PMID 42000139
INTRODUCTION: We aimed to evaluate the long-term follow-up overall survival (OS) of irinotecan plus cisplatin (IP) versus etoposide plus cisplatin (EP) as postoperative adjuvant chemotherapy in patients with pathological Stage I-IIIA high-grade neuroendocrine carcinoma (HGNEC) of the lung. METHODS: The JCOG1205/1206 randomized, open-label, phase III study compared the efficacy of IP and EP as adjuvant chemotherapy. Patients with pathological Stage I-IIIA and completely resected HGNEC of the lung were randomized to …
Rank96.4
Three-dimensionally printed navigational template technology for lung biopsy: a noninferiority, randomized trial.
International journal of surgery (London, England) · 2026 · PMID 40928365
BACKGROUND: Percutaneous transthoracic needle biopsy (PTNB) guided by computed tomography (CT) greatly depends on the operators' skill for accuracy. This study aimed to evaluate whether three-dimensionally (3D)-printed navigational templates for PTNB achieve diagnostic yield comparable to conventional CT guidance. MATERIALS AND METHODS: Conducted from 1 November 2020 to 27 July 2023, this noninferiority randomized clinical trial included 159 patients with peripheral lung masses (≥30 mm). The analyses were performed…
Rank96.3
The influence of body mass index on Tumor Treating Fields therapy in patients with metastatic non-small cell lung cancer: A post-hoc and simulation analysis from the phase III LUNAR study.
Lung cancer (Amsterdam, Netherlands) · 2025 · PMID 41187466
INTRODUCTION: In the phase III LUNAR study, overall survival (OS) with PD-(L)1 inhibitor or docetaxel was improved by adding Tumor Treating Fields (TTFields) therapy in patients with metastatic non-small cell lung cancer progressing on/after platinum-based therapy. This post-hoc analysis evaluated the effects of body mass index (BMI) on TTFields delivery. METHODS: OS was assessed in LUNAR patients with BMI < 25 kg/m2 versus ≥ 25 kg/m2. TTFields intensity was evaluated via simulations using three array layouts in co…
Rank96.2
Effect of preoperative respiratory prehabilitation on cardiopulmonary function in patients undergoing lung resection for non-small cell lung cancer: a randomized controlled trial.
Journal of cardiothoracic surgery · 2026 · PMID 42010447
BACKGROUND: Preoperative respiratory prehabilitation has attracted increasing attention as a perioperative strategy in thoracic surgery, but evidence regarding its short-term effects on early postoperative functional recovery remains limited. This randomized controlled trial investigated the effect of a 7-day preoperative respiratory prehabilitation program on postoperative pulmonary function, cardiopulmonary exercise capacity, and postoperative complications in patients undergoing curative-intent lung resection fo…
Rank96.2
Intravenous lidocaine reduces systemic inflammation but not myocardial injury following thoracic surgery for lung cancer: a randomized controlled trial.
BMC anesthesiology · 2026 · PMID 41794665
BACKGROUND: Elevated high-sensitivity troponin T levels shortly after noncardiac surgery are closely linked to myocardial injury, a key factor in 30-day postoperative mortality. Intravenous lidocaine, known for its potent anti-inflammatory and membrane-stabilizing properties, has shown cardioprotective potential in other surgical settings, but its efficacy in noncardiac thoracic surgery remains unclear. OBJECTIVES: This study was a double-blind, placebo-controlled randomized trial. Participants were randomly alloca…
Rank96.1
[Huangqi Guizhi Wuwu Decoction in the Treatment of Pemetrexed Intrathecal Chemotherapy-induced Neurotoxicity in NSCLC Patients with Leptomeningeal Metastases: A Randomized Controlled Trial].
Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2026 · PMID 41975647
BACKGROUND: Leptomeningeal metastasis (LM) is a severe complication of non-small cell lung cancer (NSCLC). Although intrathecal Pemetrexed chemotherapy can effectively prolong patient survival, a high incidence of neurotoxicity has emerged as a critical factor limiting its clinical application. This study aims to investigate the efficacy and safety of Huangqi Guizhi Wuwu decoction (HGWD) in mitigating neurotoxicity induced by intrathecal Pemetrexed chemotherapy in NSCLC patients with LM. METHODS: In a prospective, …
Rank95.9
Impact of the Oncologist's Recommendation on Exercise Levels and Quality of Life in Patients With Lung Cancer: The ORE Randomized Controlled Trial.
Cancer medicine · 2026 · PMID 42036773
BACKGROUND: Although physical activity is associated with improved survival in lung cancer, most patients remain inactive. This study examined the impact of an oncologist's recommendation on exercise quantity, sedentary behavior, and quality of life (QoL) in patients with lung cancer. METHODS: In this single-blind, 3-arm randomized controlled trial, patients with lung cancer (stages I-IV) were assigned to: (1) usual care, (2) the oncologist's verbal and written exercise recommendation, or (3) the recommendation plu…
Rank95.8
Open-Label Randomized Controlled Study of a Disposable Dry Seal Chest Drainage System for Safety and Efficiency in Lobectomy Patients.
Thoracic cancer · 2026 · PMID 41622760
BACKGROUND: Lobectomy, a cornerstone in the treatment of various thoracic tumors, often requires postoperative chest drainage to prevent complications such as pneumothorax and pleural effusion. Traditional water-seal drainage systems have limitations, including inconvenience and restricted patient mobility. METHODS: This study investigated the safety and efficiency of a disposable dry seal chest drainage system compared to the traditional water-seal system in lobectomy patients. An open-label randomized controlled …
Rank95.7
Effect of evidence-based nursing intervention under quantitative evaluation strategy on psychological resilience and illness perception in lung cancer patients undergoing chemotherapy.
Applied nursing research : ANR · 2025 · PMID 41330645
OBJECTIVE: To investigate the effect of evidence-based nursing intervention guided by a quantitative evaluation strategy on psychological resilience and illness perception in lung cancer patients undergoing chemotherapy. METHODS: A total of 142 lung cancer patients receiving chemotherapy from March 2024 to March 2025 were enrolled and randomly divided into a study group (receiving evidence-based nursing intervention under a quantitative evaluation strategy, n = 71) and a control group (receiving routine nursing, n …
Rank95.6
Long-Term Effects of High-Intensity Training after Lung Cancer Surgery-A 5-Yr Follow-Up of a Randomized Controlled Trial.
Medicine and science in sports and exercise · 2026 · PMID 41851742
PURPOSE: To evaluate long-term extended effects of 20 wk of high-intensity training (HIT) performed shortly after lung cancer surgery on physical fitness, muscle mass, pulmonary function, quality of life (QoL), and survival. METHODS: All participants in the original HIT-trial were invited 5 yr after surgery. Original measures were repeated by the same technician and equipment. All-cause mortality was registered 5- and 10-yr postsurgery. RESULTS: Of 61 patients who completed the 20-wk intervention, 40 (66%) were ali…
Rank95.6
Feasibility and preliminary efficacy of an art-making program to manage fear of cancer recurrence (AM-I-FCR) in lung cancer patients: a randomized controlled pilot study.
BMC medicine · 2026 · PMID 41761252
BACKGROUND: Fear of cancer recurrence (FCR) imposes a significant psychological and physical burden on cancer patients. Art-making interventions may offer a novel approach to alleviating FCR. This study aimed to develop an art-making program (AM-I-FCR) and assess its feasibility and preliminary effects on FCR in lung cancer patients. METHODS: The AM7-I-FCR was developed and evaluated via intervention mapping from March to December 2023. Step 1 (needs assessment) involved qualitative interviews. Step 2 (setting obje…
Rank95.6
Minimal Residual Disease Enhances Prognostic Stratification beyond Pathologic Response in Resectable Non-Small Cell Lung Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research · 2026 · PMID 41537692
PURPOSE: Perioperative chemoimmunotherapy is the standard of care for resectable, locally advanced non-small cell lung cancer (NSCLC). Although pathologic complete response (pCR) correlates with excellent survival outcomes, some patients without pCR still exhibit long-term survival. In this study, we evaluate the added value of minimal residual disease (MRD). EXPERIMENTAL DESIGN: MRD was assessed in 60 patients from the NADIM II trial (NCT03838159) using the Guardant Reveal assay. In NADIM II, patients with NSCLC w…
Rank95.6
Gemcitabine as maintenance treatment of diffuse pleural mesothelioma: randomized phase II study.
BMC cancer · 2026 · PMID 41888696
BACKGROUND: Diffuse Pleural Mesothelioma (DPM) is an aggressive cancer with limited treatment options and a poor prognosis. Maintenance therapy has emerged as a potential strategy to delay disease progression following first-line chemotherapy. This study evaluates the efficacy and safety of gemcitabine maintenance therapy compared to best supportive care (BSC) in patients with unresectable DPM. METHODS: This single-center, randomized, phase II, open-label trial included 64 patients with unresectable DPM who achieve…
i
Research information notice
Alexandria organizes PubMed-indexed literature. PubMed inclusion does not establish accuracy, endorsement, clinical applicability, or treatment suitability. Automated extraction can contain errors or omissions. This page is not medical advice.